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SUMMARY 
Arenaviruses are a large and diverse family of viruses that merit significant attention as 
causative agents of severe hemorrhagic fevers in humans. Lassa virus (LASV) in Africa and 
the South American hemorrhagic fever viruses Junin (JUNV), Machupo (MACV), and 
Guanarito (GTOV) have emerged as important human pathogens and represent serious public 
health problems in their respective endemic areas.  
A hallmark of fatal arenaviruses hemorrhagic fevers is a marked immunosuppression of 
the infected patients. Antigen presenting cells (APCs) such as macrophages and in particular 
dendritic cells (DCs) are early and preferred targets of arenaviruses infection. Instead of being 
recognized and presented as foreign antigens by DCs, arenaviruses subvert the normal 
mechanisms of pathogen recognition, invade DCs and establish a productive infection. Viral 
replication perturbs the DCs’ ability to present antigens and to activate T and B cells, 
contributing to the marked virus-induced immunosuppression observed in fatal disease. 
Considering their crucial role in the development of an anti-viral immune response, the 
mechanisms by which arenaviruses, and in particular LASV, invade DCs are of particular 
interest. The C-type lectin DC-specific Intercellular adhesion molecule-3-grabbing 
nonintegrin (DC-SIGN) was recently identified as a potential entry receptor for LASV. The 
first project of my thesis focused therefore on the investigation of the role of DC-SIGN in 
LASV entry into primary human DCs. My data revealed that DC-SIGN serves as an 
attachment factor for LASV on human DCs and can facilitate capture of free virus and 
subsequent cell entry. However, in contrast to other emerging viruses, of the phlebovirus 
family, I found that DC-SIGN does likely not function as an authentic entry receptor for 
LASV. Moreover, I was able to show that LASV enters DCs via an unusually slow pathway 
that depends on actin, but is independent of clathrin and dynamin.  
Considering the lack of effective treatments and the limited public health infrastructure in 
endemic regions, the development of protective vaccines against arenaviruses is an urgent 
need. To address this issue, the second project of my thesis aimed at the development of a 
novel recombinant arenavirus vaccine based on a nanoparticle (NPs) platform and its 
evaluation in a small animal model. During the first phase of the project I designed, produced, 
and characterized suitable vaccine antigens. In the second phase of the project, I generated 
antigen-conjugated NPs, developed vaccine formulations, and tested the NPs for their ability 
to elicit anti-viral T cell responses as well as anti-viral antibodies. I demonstrated that the NPs 
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platform is able to activate both cellular and humoral branches of the adaptive anti-viral 
immunity, providing proof-of-principle.     
In sum, my first project will allow, in a long term perspective, a better understanding of 
the viral pathogenesis and contribute to the development of novel antiviral strategies. The 
second project will expectidly offer a new treatment option against arenaviruses. 
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RÉSUMÉ 
Les Arénavirus sont une vaste et diverse famille de virus dont certains membres sont à 
l’origine de nombreux cas de fièvre hémorragique sévère chez l’homme. Au cours des 
dernières années, le virus de Lassa (LASV, Afrique) et les arénavirus sud-américains Junin 
(JUNV), Machupo (MACV) et Guanarito (GTOV) ont émergé en tant qu’importants 
pathogènes pour l’homme et représentent un problème de santé publique majeur dans leurs 
zones d’endémie respectives.  
Les cas de fièvre hémorragique causés par des arénavirus sont caractérisés par une  
immunosuppression marquée chez les patients infectés. Les cellules présentatrices de 
l’antigène, telles que les macrophages et en particulier les cellules dendritiques (DCs), sont  
des cibles précoces et privilégiées du virus. Au lieu d'être reconnus et présentés comme des 
corps étrangers par les DCs, les arénavirus peuvent subvertir les voies normales de 
reconnaissance des agents pathogènes, envahir les DCs et y établir une infection productive. 
La réplication virale perturbe alors le fonctionnement normal des cellules, les rendant 
incapables de présenter correctement les antigènes et d’activer les cellules T et B, contribuant 
ainsi à l'immunosuppression induite par le virus dans les cas mortels de fièvre hémorragique. 
Compte tenu de leur rôle majeur dans le développement de la réponse immunitaire 
antivirale, l’investigation des mécanismes par lesquels les arénavirus, et en particulier le 
LASV, envahissient les DCs est un enjeu capital. La molécule DC-SIGN a récemment été 
identifiée comme un récepteur potentiel d'entrée pour le LASV. Mon premier projet de thèse 
s’est focalisé sur l'étude du rôle de DC-SIGN dans l’entrée du LASV dans les DCs primaires 
humaines. Les résultats ont révélé que le DC-SIGN fonctionne comme facteur d’attachement 
à la surface des DCs et peut faciliter la capture des virions libres, aidant ainsi leur pénétration 
dans la cellule. Cependant, contrairement à ce qui a pu être établi pour d’autres virus 
émergents de la famille des phlebovirus, DC-SIGN n’assume certainement pas la fonction de 
véritable récepteur entrée pour le LASV. De plus, j'ai démontré que celui-ci s’introduit dans 
les DCs via une voie anormalement lente qui dépend de l'actine, mais qui est indépendante de 
la clathrine et de la dynamine. 
Compte tenu de l'absence de traitement efficace contre les arénavirus et l'infrastructure de  
santé publique limitée dans les régions touchées, le développement de vaccins contre ces virus 
se révèle nécessaire. Mon second projet de thèse s’est concentré sur le développement d'un 
vaccin recombinant contre les arénavirus basé sur l’utilisation de nanoparticules (NPs), ainsi 
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que sur son évaluation dans un modèle murin. Au cours de la première phase du projet, j'ai 
conçu, produit et caractérisé les antigènes vaccinaux. Dans la deuxième phase du projet, j'ai 
généré des antigènes liés aux NPs, mis au point des formulations de vaccins et testé les NPs 
pour leur capacité à induire une réponse cellulaire antivirale ainsi que la production 
d’anticorps antiviraux. J'ai pu démontrer que les NPs sont capables d'activer les branches 
humorale et cellulaire de l'immunité adaptative anti-virale. 
En résumé, mon premier projet permettra, à long terme, une meilleure compréhension de 
la pathogénèse virale et contribuera au développement de nouvelles stratégies antivirales. 
Mon second projet offrira, nous l’espérons, un nouveau traitement contre les arénavirus. 
  
 
 
 
 
 
 
 
 
GENERAL INTRODUCTION 
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ARENAVIRUSES 
Arenaviradae family 
The Arenaviridae is a large and diverse family of viruses composed of the single 
Arenavirus genus (Fig.1), that merit significant attention as important emerging human 
pathogens and powerful models for experimental virology [6]. The Arenavirus genus includes 
around 30 known virus species, but only 25 are recognized by the International committee on 
Taxonomy (ICTV) (Fig.1). All known arenavirus species are carried by rodents, except 
Tacaribe virus, whose suspected host reservoir are fruitbats, and their geographical 
distribution maps to that of their natural hosts. Arenaviruses are classified into two major 
groups according to genetic and serologic characteristics, and geographic localization: the 1) 
Old World (OW) and 2) New World (NW) arenaviruses. The OW arenaviruses are endemic to 
Africa, whereas the NW arenaviruses are present in the Americas. While OW arenaviruses 
constitute a single lineage, NW arenaviruses are separated into four clades A/Rec, A, B, and 
C (Fig.1). [7] [8] 
 
Figure 1. The Arenaviridae family. OW
arenaviruses are found in Africa with
exception of lymphocytic choriomeningitis
virus (LCMV), which has a worldwide
distribution. The NW arenaviruses clade A/
Rec and A through C, are found in North
and South America, respectively. The OW
and the NW clade C viruses use mainly
alpha-dystroglycan as receptor whereas
NW Clade B viruses use transferrin
receptor 1 (TfR1) as a receptor. NW clade
A and A/Rec viruses use unknown
receptors. Confirmed human pathogens are
colored in blue (+ Chapare), red or green.
The schematic cladogram on the left
indicates the phylogenetic relationships
between the viral clades. 
(*) Not yet recognized by ICTV 
Picture modified from  [2]. 
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Viral particle structure and genome organisation 
Arenaviruses are enveloped viruses which contain a bi-segmented negative single-
stranded RNA genome (Fig.2A) comprised of a large (L) and a small (S) fragment (Fig.2B) 
[9]. Each RNA strand allows the synthesis of two different polypeptides in opposite direction. 
A non-coding hairpin structure serves as intergenic region (IGR) and separates the two open 
reading frames (ORF) in ambisense orientation (Fig.2B). The viral glycoprotein precursor 
(GPC), is post-translationally processed by the host pro-protein convertase (PC) subtilisin-
kexin-isozyme-1 (SKI-1), also known as site 1 protease (S1P), into the envelope glycoprotein 
(GP) 1 and the transmembrane GP2 implicated in viral fusion. GPC and the nucleoprotein 
(NP) are encoded by the S RNA (Fig.2B), whereas the L polymerase and Z matrix protein are 
encoded by the L RNA (Fig.2B). Viral replication is exclusively cytoplasmic and infectious 
progeny viruses assemble and bud from the plasma membrane (Fig.3).  
 
 
 
 
 
Figure 2. Representation of arenavirus particle and genome. A) Schematic representation of the arenavirus 
particle. The viral genome is completely encapsulated by the viral NP forming the ribonucleoprotein particle 
(RNP). The L protein, a RNA-dependent RNA polymerase, also associates with RNP and is essential for early 
viral transcription and replication. In association with the inner leaflet of the viral membrane envelope localizes 
the matrix protein Z, which interacts with the C-terminal part of the transmembrane GP2 moiety of the mature 
GP1/GP2 complex. The GP1 protein contains the host receptor binding site and constitutes the distal part of the 
GP1/GP2 complex, whereas GP2 corresponds to the membrane-proximal part and is necessary for viral fusion. 
Mature GP1/GP2 complexes presumably form trimers. B) Arenavirus coding strategy. Each of the two ssRNA 
segments, L and S, uses an ambisense coding strategy to direct the synthesis of two polypeptides in opposite 
orientations and is separated by an IGR predicted to have a stable hairpin structure. The 5’ ends of the genomic 
arenavirus RNA cannot serve as a template for translation and viral protein expression requires prior transcription, 
as in true negative-strand viruses. GP: Glycoprotein; GPC: Glycoprotein precursor; IGR: Intergenic region; L: 
RNA-dependent RNA polymerase; NP: Nucleoprotein. [4] 
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The arenavirus life-cycle 
The pathways  used by OW and NW arenaviruses for entry into host cells are distinct but 
both are receptor-dependent [10] (Fig.3). The use of the genetically conserved and 
ubiquitously expressed cell-surface proteins α-dystroglycan (α-DG) [11] and transferrin 
receptor 1 (TfR1) [12] as main receptors by the lymphocytic choriomeningitis virus (LCMV), 
Lassa virus (LASV), clade C NW arenaviruses, and clade B NW arenaviruses respectively, 
explains their wide host range and cell-type tropism. Recently, members of the Tyro3, Axl, 
Mer (TAM) receptor tyrosine kinases (Axl and Tyro3) and the C-type lectins Dendritic Cell-
Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), as well as 
Liver and lymph node Sinusoidal Endothelial cell C-type lectin (LSECtin) were found as 
candidate receptors for LASV that can mediate viral entry in absence of α-DG[13].  
Attachment of OW arenaviruses to cellular DG promotes virus-receptor internalization 
into smooth vesicles [14]. This endocytotic process is dependent on membrane cholesterol, 
but clathrin, dynamin, and caveolin-independent and does not depend on Rab5 or Rab7, 
indicating that the virus-receptor complex bypasses classical Early Endosome-Associated 
protein 1 (EEA1) positive endosomes. The virus is delivered to multivesicular bodies (MVB) 
of the late endosome, where the virus-receptor complex is sorted into intraluminal vesicles 
(ILV) by the endosomal sorting complexes required for transport (ESCRT) machinery [15]. In 
contrast to OW and NW clade C arenavirus, NW clade B virus cell entry involves clathrin-
mediated endocytosis (CME) and follows a classical Rab5 and Rab7-dependent endosomal 
entry pathway [16]. As for OW arenaviruses, NW arenavirus fusion requires a pH < 5.5, 
corresponding to late endosomal fusion.  
Viral RNA replication is initiated by the viral RNA-dependent RNA polymerase L upon 
the release of the viral genome into the infected cells’ cytoplasm (Fig.3). The first step of viral 
replication is the initiation of transcription by the viral L polymerase using promoters on each 
5’end of the genomic RNA segments, generating mRNAs coding for NP and L. Transcription 
termination is mediated by the IGR downstream of the 3’end of each ORF. Modest 
concentrations of NP early in infection prevent the polymerase from reading through the IGR, 
thus favoring transcription over replication. With time, NP accumulates, forcing the 
polymerase to shift to the “replication mode” reading across the IGR to produce the full-
length anti-genome (ag) RNAs which will serve as templates for the transcription of GPC and 
Z mRNAs [17]. Using agRNA as template, L produces large quantities of genomic L and S 
RNAs late in the infection cycle. Little is known about the molecular organization of the 
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arenavirus replication-transcription complexes (RTCs). Recent studies visualized arenavirus 
RTCs as discrete cytosolic clusters associated with NP, viral genomic and agRNA, but being 
largely devoid of viral mRNA [18]. Assembly and release of arenavirus infectious progeny 
occurs at the plasma membrane and requires that the viral RNPs associates with membrane 
domains enriched in mature viral GP and Z, so-called “budding zones”. The assembly of 
arenavirus particles and the budding process is driven mainly by the Z protein, which acts as a 
bona fide matrix protein and contains late domain motifs (PTAP and PPPY) [19,20,21]. 
Incorporation of mature GP into nascent virions requires a functional interaction with Z [22], 
which in turn recruits components of the ESCRT, in particular the ESCRT-I component 
Tsg101, that is crucial for arenavirus budding [19,20]. 
 
 
Arenavirus pathogenesis and clinical disease 
Humans are accidental hosts of arenaviruses and contract the virus via close contact with 
persistently infected rodents, contaminated food and drink, or through skin lesions or aerosols. 
OW arenaviruses such as LASV and NW arenaviruses as JUNV and MACV viruses are 
responsible for hemorrhagic fever (HF) syndromes, whose severity can vary from mild febrile 
disease to lethal hemorrhagic fever [23,24]. Human-to-human transmission is also possible 
via contaminated blood, body fluids, and organ transplants (particularly in the case of 
Figure 3. Life cycle of Arenavirus. LASV and JUNV use α-DG and TfR1, respectively, as primary receptors.
LASV can also use TAM receptor tyrosine kinases Axl and Tyro3 and C-type lectins (DC-SIGN and LSECtin)
as receptors. Please see the text for more details. Early endosome (EE), Multivesicular body (MVB). Late
endosome (LE). Uninvestigated or under investigation steps (?). Figure modified from [2]. 
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LCMV). LASV, the most prevalent OW arenavirus associated with human disease, is 
responsible for 300’000-500’000 infections per year with a mortality rate of 1-2% at the 
community level, raising to 15-30% among hospitalized patients [25]. This fatality rate can 
rise to >50% in nosocomial outbreaks, in particular in pregnant women and neonates. The per 
case mortality of JUNV and MACV, the most common disease-associated NW arenavirus, 
can reach 30-50% [26]. 
OW (LASV) and NW (JUNV and MACV) arenaviruses pathogenesis has been 
extensively covered by excellent recent reviews [4,27,28] thus I will only briefly summarize it 
in the next paragraphs. After an incubation period of 1-3 weeks, patients infected with 
arenaviruses develop unspecific “flu-like” symptoms as fever, asthenia and general malaise. A 
majority of infected patients recover while the others rapidly progress with increasing signs 
and symptoms of shock associated with hemorrhagic and/or neurological (particularly in 
JUNV infected patients) manifestations, which may be lethal. Permanent sensorineural 
deafness with lifelong hearing loss can arise as a Lassa fever complication late in disease’s 
course or in early convalescence. The patients who recover generally do so 2–3 weeks after 
disease onset and clear the virus from the blood.[4,27]  
Antigen-presenting cells (APCs), such as macrophages (MPs) and in particular dendritic 
cells (DCs) are major targets of OW (LASV and LCMV) and NW (JUNV) arenaviruses early 
during infection. As APCs, which are key cells for the induction and regulation of immune 
responses, they are widely spread among body tissues and can, for some subsets, circulate via 
the blood stream, and are thought to contribute to the spread of the virus in systemic infection. 
They are likely important sites of viral replication leading to release of viral particles, which 
then can infect and initiate viral replication in the liver, spleen, kidney, heart, vascular 
endothelium and adrenal cortex [4,27,28]. LASV-infected DCs are not activated, do not 
mature and do not produce inflammatory cytokines. MPs are also not activated but can 
produce small amounts of type I interferons (IFN). This absence of DCs activation and 
maturation may be linked to the immunosuppression observed in severe Lassa fever cases, as 
it leads to a major impairment of DCs function and modification of the cytokines/chemokines 
secretion profile [29]. Indeed, productive infection of human DCs with LASV perturbs their 
ability to activate T cells [30,31].  In contrast to LASV, the non-pathogenic OW Mopeia virus 
(MOPV) is able to fully activate DCs and MPs as well as stimulating type I IFN secretion and 
an efficient T cell response [32]. Type I IFNs are known to be important for control of the 
initial burst size of the virus, as well as the induction and maintenance of an efficient adaptive 
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immune response [33]. Thus, the absence of type I IFN secretion by the infected APCs 
probably plays a key role in the pathogenesis and the immunosuppression observed in severe 
Lassa  fever cases, as suggested by recent studies in non-human primate (NHP) models [34]. 
The viral entry pathway(s), the viral intracellular trafficking and the exact mechanisms 
leading to the functional impairment of human DCs in the context of LASV infection are 
largely unknown and represented a major focus of my thesis work. 
Tissue injury and systemic deregulations commonly associated with arenaviruses’ 
infection include characteristic lesions in spleen and liver, immunosuppression, as well as 
lymphopenia affecting T, B and natural killer (NK) cells. The characteristic “cytokine storm” 
observed in other viral hemorrhagic fevers (VHFs) characterized by elevated IFN and 
cytokines levels, hemorrhages, thrombocytopenia, and platelet dysfunction are largely absent 
in Lassa fever but seem more common in Junin and Machupo HFs. Disseminated 
intravascular coagulation, an important feature of Ebola and Marburg HFs,  is almost never 
observed in Lassa fever, and rare even in NW arenaviruses HFs. [4,35,36]. 
The limited bleeding from mucosal surfaces, little cellular damage, and modest 
infiltration of inflammatory cells observed in histological samples of severe Lassa fever cases 
do not explain the fatal disease outcome [35]. This is not the case in patients infected with 
NW arenaviruses, where lethal disease could at least be partially explained by the widespread 
organ damages and a rather classical hemorrhagic shock syndrome. One might classify NW 
arenaviruses as more typical hemorrhagic viruses whereas the pathogenesis of LASV seems 
rather atypical [4,37,38]. 
In contrast to LASV and the South American HF viruses, LCMV infection in adult 
immunocompetent humans manifests mainly as aseptic meningitis and encephalitis. However, 
in immunocompromised individuals, LCMV is a severe pathogen that causes a devastating 
systemic infection associated with multi-organ failure that shows striking parallels to fatal 
Lassa fever [39,40].   
Viremia is a highly predictive factor for the outcome of human arenavirus infection. 
Indeed high viral loads (≥ 1 x 106 tissue culture infectious dose (TCID) 50/ml) at time of 
hospitalization correlate with a fatal outcome [26,41]. This suggests that the virus is in tight 
competition with the immune system. Thus if we provide the immune system an advantage 
over the virus, as it would be the case by inducing neutralizing antibodies (nAbs), which 
would act as gatekeepers, we would tip the balance in favor of the immune system. 
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Immune responses to Arenaviruses 
The immune responses to LASV were recently extensively reviewed by Russier [42] and 
Hayes [43]. Several lines of evidence indicate that acute infection with the OW arenaviruses 
LASV and LCMV in immunocompetent hosts is mainly controlled by cellular immunity, in 
particular anti-viral CD8 T cells [44]. Despite the fact that high levels of antibodies (Abs), 
both IgM and IgG, are also produced early in disease, they are not protective and generally 
not neutralizing [41]. The individuals, which seroconvert have mainly GPC, NP, and Z 
protein specific Abs that are either strain-specific or broadly cross-reactive [45]. nAbs are also 
present but appear late in convalescence and are frequently of low titers. Attempts to use 
human convalescent plasma for post-exposure prophylaxis in Lassa fever patients had 
occasionally beneficial effects. However, due to the generally low nAbs amounts, therapy 
with convalescent plasma seems not a viable option [46]. Notably, in experimental animal 
studies in guinea pigs and primates infected with LASV, nAbs were efficacious, providing 
proof-of-concept for a beneficial role of nAbs as a potential immunological correlate of 
protection [47,48]. 
In the case of NW arenavirus infections, survivors develop a strong cellular immune 
response early in infection that controls the infection. nAbs tend to appear at 2-3 weeks of 
illness [26], but their exact role in clearing the virus is not known [36]. The significant drop of 
viral loads before appearance of nAbs suggests a major role of T cell responses in the 
protection against NW arenavirus. However, survivors generally show robust titers of nAbs in 
convalescence. After vaccination with the currently available anti-JUNV vaccine, Candid-1, 
virus specific T cell responses, as well as protective antibodies can be detected [49]. The 
reasons for the remarkable difference in the kinetics and quality of the antibody response 
between OW and NW arenaviruses are currently unknown. 
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C-TYPE LECTINS AS CANDIDATE LASV RECEPTORS ON HUMAN DENDRITIC CELLS  
As mentioned above, early and preferred targets of LASV are APCs of the patient’s 
immune system, in particular DCs. According to their nature as major sentinels for pathogen 
detection and antigen presentation, DCs express a set of specialized pathogen recognition 
receptors (PRRs) and have mechanisms of endocytosis, used for antigen internalization and 
processing, that are not present in other cells [50,51]. Interestingly, some PRRs present on 
DCs can function not only in pathogen recognition, but can also be abused by some viruses as 
receptors to mediate infection, in particular DC-SIGN and the mannose receptor [52,53]. The 
best-studied example, DC-SIGN, is a type II C-type lectin that contains a carbohydrate 
recognition domain that binds pathogen-derived carbohydrates in a calcium-dependent 
manner. DC-SIGN is present on many classes of DCs and is normally involved in endocytosis 
of antigens and delivery to late endosomes/lysosomes followed by processing and subsequent 
presentation in the context of the major hystocompatibility complex (MHC) II. DC-SIGN can 
facilitate infection or transmission of a variety of enveloped viruses, such as HIV-1 [54,55], 
the filoviruses Ebola and Marburg virus [56,57], SARS coronavirus [58], the flaviviruses 
Dengue virus [59,60] and West Nile virus [61]. Recently, DC-SIGN has been identified as the 
cell entry receptor for arthropod-borne bunyaviruses of the genus phlebovirus, including Rift 
Valley fever (RVFV) and Uukuniemi viruses (UUKV) in human DCs [62]. In a recent 
expression cloning approach, DC-SIGN has been identified as a candidate receptor for LASV. 
However, its actual role in LASV invasion of human DCs has not yet been addressed. Since 
early infection of DCs plays likely a crucial role in the virus-induced immunosuppression that 
underlies the pathogenesis of fatal Lassa fever in man, the characterization of the receptors 
and endocytotic pathways involved in this process are of great importance. The identification 
of novel LASV receptors involved in infection of human DCs may allow the targeting of the 
virus-receptor interaction. Moreover, the identification of the pathway of LASV entry into 
DCs may reveal essential cellular factors that will then be evaluated for their potential in anti-
viral therapy in our translational research program aiming at the development of novel 
therapeutics against LASV.    
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CURRENT THERAPY AGAINST ARENAVIRUSES  
The only licensed drug for treatment of human arenavirus infection is the nucleoside 
analogue ribavirin (Rib) (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) [63]. In vitro and 
in vivo studies have documented that Rib reduces both morbidity and mortality in humans 
associated with LASV infection [46], and experimentally in MACV [64] and JUNV [26] 
infections, if given early in the course of clinical disease. Over the past two decades efforts 
have been made to discover novel drug candidates to combat arenaviruses and only a short 
and by no means comprehensive overview can be given here: inhibitors of the inosine 5'-
monophosphate dehydrogenase [65], the S-adenosylhomocysteine hydrolase [66], 
phenotiazines compounds [67], brassinosteroids [68] and myristic acid [69] have been 
reported to have anti-arenaviral activity. Several zinc-finger-reactive compounds with 
antiretroviral potential showed activity against arenaviruses [70,71] and evidence has been 
provided for an involvement of the viral Z protein in their mechanism of action [72]. Studies 
from our laboratory identified amphipathic DNA polymers as potent inhibitors of arenavirus 
cell entry [73]. More recently, high throughput screens of small molecules by others and our 
group identified several potent small molecule inhibitors of arenavirus cell entry [74,75,76] 
that are currently being evaluated as anti-arenavirus drugs. Many enveloped viruses strictly 
require cleavage of their envelope glycoprotein precursors by host proteases of PC family. 
The PC SKI-1/S1P is crucial for productive infection by a number of highly pathogenic 
arenaviruses, including LASV [77], the South American hemorrhagic fever viruses JUNV, 
MACV, GTOV, and SABV [78]. Processing of the arenavirus GPC by SKI-1/S1P enables 
cell-to-cell spread of infection and the production of infectious progeny virus from infected 
cells [77,78,79,80]. In proof-of-concept studies, targeting GPC maturation with peptide- [81] 
or protein- [82] based SKI-1/S1P inhibitors was found to efficiently block arenavirus cell-to-
cell propagation. Importantly, these investigations showed that inhibition of GPC processing 
is sufficient to markedly limit infection. Recently, Pfizer Inc. identified a new small molecule 
inhibitor of SKI-1/S1P, PF-429242, which potently inhibits productive infection and spread of 
both NW and OW arenaviruses via interference with the SKI-1/S1P-mediated GPC priming 
[83,84]. To the best of my knowledge none of these drug candidates has undergone further 
evaluation in pre-clinical and clinical trials.  
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CURRENT STATUS OF ARENAVIRUSES VACCINE DEVELOPMENT  
Arenaviruses vaccine research started in the 1980s and initially focused on LASV. 
Several vaccine approaches were investigated since then: 1) inactivated viruses, 2) virus-like 
particles, 3) epitope-specific peptides, 4) DNA vaccines, 5) alphavirus vectors (Venezuelan 
equine encephalitis virus (VEEV)), and 6) recombinant/reassortant viruses (detailed in table 1,  
reviewed by Lukashevich [85]). Most of these vaccines have been evaluated in small animal 
model as well as NHP.  
The yellow fever 17D vector is already approved for human use (phaseIII ChimeriVax™-dengue and 
ChimeriVax-Japanese encephalitis (IMOJEV®) from Sanofi-Pasteur. [100]. 
Very promising candidate for clinical application 
 
Initial trials with killed LASV vaccines in NHP failed to elicit a protective immune 
response [87] and subsequent efforts focused on the development of live vaccines. In one 
attempt, LASV was attenuated by generating genetic reassortants with the less pathogenic 
MOPV [93]. This reassortant vaccine, called ML29 showed efficacy in guinea pigs [94] and 
small NHP [95]. However, despite the attenuation of ML29 in comparison to LASV, the use 
of this live vaccine faces severe limitations in populations living in endemic regions due to the 
high prevalence of infection with human immunodeficiency virus HIV-1 and other 
immunosuppressive conditions. Evaluation of recombinant viral platforms for antigen 
delivery, including vaccinia virus [88], alphavirus replicons [96], vesicular stomatitis virus 
[90], and the Yellow Fever virus vaccine strain 17D [92] revealed that expression of LASV 
Table 1. Non exhaustive summary of LASV vaccination strategies.  
Pathogen  Genes  Vector  Animal model  References 
LASV NP, GPC peptides Mouse [44,86] 
 all  
purified whole Lassa 
virus γ-irradiated  Rhesus monkeys  [87] 
NP, GPC  vaccinia virus  Strain 13 guinea pigs, rhesus monkeys  [88,89] 
GPC  VSV  Cynomolgus macaques  [90] 
 
GPC, 
GP1, 
GP2  
chimeric yellow fever 
17D  Mouse, strain 13 guinea pigs  [91,92] 
 NP, GPC  
Mopeia/Lassa 
reassortant ML29 
clone  
Mouse, strain 13 guinea pigs,  rhesus macaques 
and marmosets, immunocompromized rhesus 
macaques  
[93,94,95] 
 GPC, NP  VEEV replicon  Strain 13 guinea pigs  [96] 
 
NP, GPC, 
Z  virus-like-particle  Mouse  [97] 
NP  plasmid DNA  Mouse  [98] 
 NP  
aroA attenuated S. 
typhimurium  Mouse  [99] 
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GP was necessary and sufficient to confer protection in different animal models. However, the 
immunological correlate(s) of protection were not clearly defined. A limitation of 
recombinant viral platforms are host immunity to the vector backbone and unresolved 
biosafety issues of replicating agents like recombinant vesicular stomatis virus (VSV) 
expressing LASV GP. To my knowledge, none of these vaccine platforms has been further 
developed and so far no human vaccine trials have taken place. The only human vaccine 
available against arenavirus, and only in Argentina, is Candid-1 [101], which is currently only 
used in populations at risk, but has not been licensed elsewhere. To my knowledge no other 
vaccine targets than LASV and JUNV are currently under investigation in the arenavirus 
vaccine research field. 
 
POLYPROPYLENE SULFIDE NANOPARTICLE AS VACCINE PLATFORM  
To be used as viable vaccine options, synthetic alternatives to killed or live attenuated 
vaccines must fulfill several criteria. This includes delivery of antigen to APCs, especially 
DCs. Antigen-stimulated DCs have then to be able to present it in context of the MHC I and II 
and to be activated, thus triggering the subsequent activation of T and B cells. This induction 
of T and B lymphocytes has, in turn, to lead to the generation of a protective adaptive immune 
response.  
The laboratories of our collaborators Dr. Melody Swartz and Dr. Jeffrey Hubbell at the 
Ecole Polytechnique Fédérale Lausanne (EPFL), have recently developed Pluronic stabilized 
polypropylene sulfide (PPS) nanoparticles (NPs) that have promising characteristics as a 
vaccine platform [5]. These NPs are chemically synthesized via a reverse emulsion 
polymerization reaction as described in Figure 4. They are composed of a hydrophobic core of 
cross-linked PPS, which is degradable in oxidative conditions as it is the case within the 
lysosome, and an hydrophilic Pluronic F-127 surface consisting of a block copolymer of 
polyethylene glycol (PEG) and polypropylene glycol (PPG) [5,102] (Fig.4). The NPs size can 
be varied within a range from 20 to 250 nm by adjusting the PEG-Pluronic proportions.  
The efficacy and promise of the PPS NPs platform derive from three novel features: 1) 
their 25-30 nm size, which allows their efficient target to the draining lymph nodes (LN) 
where the density of immature DCs is high [3,103], 2) a chemical surface that could be 
engineered to activate the complement system, which can then give an additional adjuvant 
capacity to the NPs itself for DCs activation and B cell modulation [5] and 3) their easy 
production and stability in wet storage at room temperature (RT).  
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Both in draining LN and the spleen, NPs interact with APCs, T and B cells. Myeloid cells 
are capable of internalizing the NPs by macropinocytosis (Fig.5) and presenting the NPs-
conjugated antigens in both MHC I and II [104], whereas the modulation of T and B cells by 
NPs is exclusively extracellular. Indeed T and B cells do not internalize NPs (Fig.5) [3].  
 
 
 
 
 
 
  
Figure 4. Synthesis of Pluronic covered PPS NPs. PPS NPs are synthesized by reverse emulsion polymerization
of PPS. Pluronic F127 is used as a surfactant and a tetra-arm thiol is used as polymerization initiator. The resulting
NPs consist of a cross-linked rubbery PPS core stabilized by disulfide bonds and with PEG brushes at the surface.
Further functionalization of the Pluronic corona allows the production of biologically-functional NPs. [1]  
In green: PPS; in blue: PPG-block if Pluronic; in red: PEG-block of Pluronic.  
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CURRENT STATUS ON PPS NPS RESEARCH IN THE VACCINATION FIELD 
The PPS NPs platform has mainly been evaluated using ovalbumin (OVA) as a model 
antigen. In this context, NPs exhibited a high potential to trigger both humoral and cellular 
immunity (Fig.6B and C). This ability was dependent of the NPs size and complement activation 
(Fig.6A and C) [105,106]. Indeed, in animals lacking C3, the antibodies production was severely 
impaired (Fig.6B and C) [107,108]. The importance of the antigen conjugation to the NPs was 
assessed after intradermal, intranasal, and intrapulmonary administration [109] [110]. The 
presence of toll-like receptors (TLR) agonists, such as CpG [110], was shown to further improve 
the antibody and T cell responses [109,110]. Antibody isotype-switching, including class switch 
to IgA [109], could be observed in the bronchoalveolar lavage upon mucosal administration of 
antigen-conjugated NPs and different adjuvants. Furthermore, the subsequent recruitment of T 
cells in the pulmonary tissues conferred protection against Mycobacterium tuberculosis (Mtb) 
(Erdman strain) and influenza-ova [111] upon pulmonary delivery of antigen Ag85b, or OVA, 
respectively [110]. 
Figure 5. NPs are internalized by monocytes but only associate with lymphocytes. Biotinylated NPs (NP-
biotin) association with splenic (B, CD4, and CD8 cells) and bone marrow (CD11b+Ly6c+ and CD11b+Ly6g+) 
cells after 12 h incubation in vitro. NPs were surface stained with streptavidin-A488 and after permeabilization 
with streptavidin-A647. Modified from [3]. 
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A
B C
Figure 6. Immune responses upon NPs administration. A) NPs-induced complement activation. In the presence
of as poly hydroxlated NPs the C3a concentration in human serum increases considerably but few after the
incubation with polymethoxylated NPs (OH- and CH3O-NPs, respectively). B) CD8 T-cell memory could be
observed after treatment with OH-25-OVA-NPs but not CH3O-25-OVA-NPs. C) Anti-ovalbumin IgG titers were
observed only for OH-25-OVA-NPs, but not larger NPs or low-complement activating NPs. Injection of OH-25-
OVA-NPs to C3-/- mice (C3 defective), this response was abrogated (wild type, WT). [5]  
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PROJECT-I: LASV ENTRY IN HUMAN ANTIGEN PRESENTING CELLS 
A hallmark of fatal Lassa fever is a marked immunosuppression of the patient. Early and 
preferred targets of LASV infection are APCs, in particular DCs. Instead of being recognized 
and presented as a foreign antigen by DCs, LASV subverts the normal mechanisms of 
pathogen recognition, invades DCs and establishes a productive infection. Viral replication 
perturbs the DCs’ ability to present antigens and to activate T cells and B cells contributing to 
the marked virus-induced immunosuppression observed in fatal disease. Considering their 
crucial role in the development of an anti-viral immune response, the characterization of 
LASV entry receptor(s) and the mechanisms by which LASV invades DCs is of particular 
interest to understand viral pathogenesis and represents a promising target for the 
development of novel anti-viral strategies. The first project of my thesis aimed therefore in the 
investigation of LASV interaction with antigen presenting cells, more precisely at the first and 
decisive steps, host cell attachment and entry.   
 
PROJECT-II: EVALUATION OF A NOVEL NANOPARTICLE VACCINE PLATFORM 
AGAINST ARENAVIRUSES 
Limited therapeutic options are currently available to treat arenaviruses infections and all 
the prophylactic approaches (use of immune sera, vaccines) developed until now have either 
failed or have major limitations, making them likely not feasible for human administration. 
The laboratories of Jeffrey Hubell and Melody Swartz have developed novel vaccination 
platforms based on the immobilization of a wide variety of antigens on PPS NPs. According 
to the promising results they obtained in the context of the model antigen (OVA), as well as, 
Mycrobacterium Mtb and influenza virus, we decided to evaluate the NPs platform for the 
development of a safe and efficacious recombinant vaccine against human pathogenic 
arenaviruses. 
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ABSTRACT 
The arenavirus Lassa (LASV) causes a severe hemorrhagic fever with high mortality in 
humans. Antigen-presenting cells, in particular dendritic cells (DC), are early and preferred 
targets of LASV and their productive infection contributes to virus-induced 
immunosuppression observed in fatal disease. Here we characterized the role of the C-type 
lectin DC-specific ICAM-3-grabbing non-integrin (DC-SIGN) in LASV entry into primary 
human DCs using a chimera of the prototypic arenavirus lymphocytic choriomeningitis virus 
(LCMV) expressing the LASV glycoprotein (rLCMV-LASVGP).We found that 
differentiation of human primary monocytes into DCs enhanced virus attachment and entry, 
concomitant with the up-regulation of DC-SIGN. LASV and rLCMV-LASVGP bound to DC-
SIGN via mannose sugars located on the N-terminal GP1 subunit of LASVGP. We provide 
evidence that DC-SIGN serves as an attachment factor for rLCMV-LASVGP in MDDC and 
can accelerate capture of free virus. However, in contrast to the phlebovirus Uukuniemi virus 
(UUKV), which uses DC-SIGN as an authentic entry receptor, productive infection with 
rLCMV-LASVGP was less dependent on DC-SIGN. In contrast to DC-SIGN-mediated cell 
entry of UUKV, entry of rLCMV-LASVGP in MDDC was remarkably slow and depended on 
actin, indicating the use of different endocytotic pathways. In sum, our data reveal that DC-
SIGN can facilitate cell entry of LASV in human MDDCs, but that its role seems distinct 
from the function as an authentic entry receptor reported for phleboviruses.  
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INTRODUCTION 
The arenavirus Lassa (LASV) is endemic in Western Africa from Senegal to Cameroon 
and causes several hundred thousand infections per year with high mortality (1). There is 
currently no vaccine available and therapeutic intervention is limited to intensive care and the 
use of ribavirin, which shows some efficacy when given early in disease (2). Considering the 
number of people affected, the human suffering involved, and the unaddressed need for better 
therapeutics, LASV is arguably one of the most neglected tropical pathogens.  
A highly predictive factor for the outcome of LASV infection in humans is the extent of 
viremia (3). Patients with fatal Lassa fever have higher viral loads at time of hospitalization 
and are unable to limit viral spread, whereas survivors have lower viral load and control 
infection progressively. The inability of the host to control viral infection in fatal Lassa fever 
cases is due to a marked virus-induced immunosuppression (1). The virus-induced 
immunosuppression likely involves infection of antigen-presenting cells (APCs), in particular 
dendritic cells (DCs) that are crucial for the development of the adaptive anti-viral immune 
response in a primary LASV infection (4). Accordingly, infection of human DCs with LASV 
fails to activate the cells and results in an impairment of their ability to present antigens to T 
cells (5, 6). However, the virus induced-mechanisms leading to immunosupression remain 
largely unknown.  
Arenaviruses are enveloped negative-strand RNA viruses with a cell cycle restricted to 
the cytoplasm (7-9). The viral genome is comprised of two RNA segments. The S segment 
encodes the envelope glycoprotein precursor (GPC) and the nucleoprotein (NP), and the L 
segment the matrix protein (Z) as well as the viral polymerase (L). The viral GPC is 
synthesized as a single polypeptide and undergoes processing by cellular proteases yielding 
the N-terminal GP1, the transmembrane GP2, and a stable signal peptide (SSP) (10). The GP1 
binds to cellular receptors (11), whereas GP2 mediates viral fusion and structurally resembles 
other class I viral fusion proteins (12, 13). The first cellular receptor discovered for LASV 
was dystroglycan (DG), a ubiquitously expressed receptor for extracellular matrix (ECM) 
proteins (14, 15). Recent efforts to discover novel cellular receptors for LASV using an 
expression cloning approach identified the Tyro3/Axl/Mer (TAM) receptor tyrosine kinases 
Axl and Dtk (Tyro3), as well as the C-type lectins DC-specific ICAM-3-grabbing non-
integrin (DC-SIGN) and LSECtin as novel candidate receptors (16).  
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DC-SIGN is a type II C-type lectin that contains a carbohydrate recognition domain that 
binds pathogen-derived high-mannose carbohydrates in a calcium-dependent manner. DC-
SIGN is present on many classes of DCs and its expression can be subject to regulation by 
different factors (17, 18). In DCs, DC-SIGN is normally involved in endocytosis of antigens 
and delivery to late endosomes/lysosomes followed by processing and subsequent 
presentation in the context of MHC II (19). DC-SIGN can facilitate infection or transmission 
of a variety of enveloped viruses, such as HIV-1 (20, 21), the filoviruses Ebola and Marburg 
virus (22, 23), SARS coronavirus (24), the flaviviruses Dengue virus (25, 26) and West Nile 
virus (27). Recently, DC-SIGN has been identified as the cell entry receptor for arthropod-
borne bunyaviruses of the genus phlebovirus, including Rift Valley fever (RVFV) and 
Uukuniemi viruses (UUKV) in human DCs (28). DC-SIGN was found to directly bind to 
high-mannose glycans on phlebovirus GPs and to be crucial for attachment and subsequent 
internalization, leading to productive infection.  Considering the crucial role of human DCs in 
the development of an anti-viral immune response, the mechanisms by which LASV invades 
these cells are of particular interest to understand the viral pathogenesis. In our present study 
we investigated the role of known candidate receptors for LASV cell entry into human DCs.  
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MATERIALS AND METHODS 
Antibodies and reagents  
Monoclonal antibodies (mAbs) 113 (anti-LCMVNP) and 83.6 (anti-LCMVGP) have 
been described (29, 30). Mouse monoclonal antibodies (mAb) B-ly6 anti-CD11c conjugated 
to phycoerythrin (PE), mouse mAb 2331 anti-CD86-PE, mouse mAb DCN46 anti-CD209 
(DC-SIGN)-PE, and mouse mAb M5E2 anti-CD14-PE were from BD Pharmingen. Purified 
polyclonal goat IgG anti-hAxl, mAb 125518 ant-hMer-PE, mAb 96201 anti-hDtk-PE, mAb 
120507 anti-DC-SIGN and mAb DC28 anti-DC-SIGN/DC-SIGNR were from R&D Systems.  
Polyclonal guinea pig anti-LCMV NP serum was provided by Dr. Juan Carlos de la Torre 
(Scripps Research Institute, La Jolla).  The rabbit polyclonal antibody U2 is directed against 
all UUKV proteins and was generated as previously described (31). Mouse mAb B-5-1-2 anti-
α-tubulin, rabbit anti-goat IgG, goat anti-mouse IgG secondary antibodies conjugated to PE 
and biotinylated anti-guinea pig IgG were purchased from Sigma-Aldrich.  Horseradish 
peroxidase (HRP) conjugated polyclonal rabbit anti-mouse IgG was from Dako, Rhodamine 
Red-X-AffiniPure F(ab')2 Fragment Goat Anti-Rabbit IgG (H+L) from Jackson 
ImmunoResearch (EU), while Alexa Fluor® 594 goat anti-mouse IgM (µ chain), Alexa 
Fluor® 594 streptavidin and 4′,6-diamidino-2-phenylindole (DAPI) were purchased from 
Molecular Probes® (Invitrogen). Human FcR blocking reagent (MACS Miltenyi Biotec) was 
used during surface staining of immature dendritic cells with “whole” IgG primary antibodies. 
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
recombinant human interleukin-4 (IL-4) were obtained from Gibco. Recombinant human DC-
SIGN/CD209/Fc chimera was from R&D Systems, β1-2 N-Acetylglucosamine-mannose 
(GlcNAcβ1-2man) was from Dextra Inc. LIVE/DEAD® fixable dead cell stain kit was from 
Molecular probes®, Invitrogen. Recombinant DG fused to human IgG Fc (DG-Fc) was 
produced as described (32).   
 
Cells and viruses  
Peripheral blood mononuclear cells (PBMCs) were isolated from human blood obtained 
from healthy volunteers (protocol approved by the Commission cantonale d’éthique de la 
recherche sur l’être humain from de canton de Vaud, #106/10), from buffy coats (provided by 
the Service Régional Vaudois de Transfusion Sanguine, Epalinges, Switzerland), or purchased 
as frozen aliquots from Clonethics/Lonza (Walkersville, MD). Briefly, blood samples or buffy 
coats were diluted 2-4x volume in PBS supplemented with 2mM EDTA Utrapure™ (Gibco®) 
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and transferred in Leucosep® tubes (Greiner Bio-One GmbH, Huber) previously loaded with 
Biocoll Separating Solution 1.077g/ml density (Biochrom AG) according to the manufacturer 
instructions.  The Leucosep® tubes were then centrifuged at 1000xg for 10 minutes at 20°C in 
a swinging-bucket rotor without brake. The plasma layer was discarded and the PBMCs 
“ring” collected, washed once with PBS-EDTA and centrifuged 10 min. at 300xg. Red blood 
cells were lysed using sterile ACK Lysis buffer (1mM KHCO3, 0.15M NH4Cl, 0.1mM 
EDTA, HCl, pH 7.2-7.4) for 3-4 min. Cells were washed again with PBS-EDTA and 
centrifuged at 200 x g for 15 min at 4°C. CD14+ monocytes were isolated from PBMCs by 
CD14+ positive selection using a magnetic cell sorting (MACS®, Miltenyi Biotec) according 
manufacturer’s instructions. Monocytes derived immature dendritic cells (MDDCs) were 
obtained by culturing CD14+ monocytes in RPMI 1640 medium + GlutaMAX™ (Gibco®) 
supplemented with 10 % FCS, antibiotics (100 U/mL penicillin and 0.1 mg/mL 
streptomycin), 100 ng/ml GM-CSF and 50 ng/ml IL-4 for 3-5 days as described (33). A549 
and HEK293 cells were cultured in DMEM, 10 % (vol/vol) FBS, supplemented with 
glutamine, and penicillin/streptomycin. Jurkat cells were maintained in RPMI, 10 % (vol/vol) 
FBS, supplemented with glutamine, and penicillin/streptomycin. Raji cell lines expressing 
DC-SIGN WT, DC-SIGN wild-type and DC-SIGN-LL mutant were maintained in RPMI 
1640 medium + GlutaMAX™ supplemented with 10% FCS and 100 U/mL penicillin and 0.1 
mg/mL streptomycin as shown before (34). The Raji-derived B-THP-1 cells expressing 
LSECTin were a gift from the laboratory of Dr. Stefan Pöhlmann, Deutsches 
Primatenzentrum, Göttingen and were maintained as reported (35) 
The recombinant rLCMV-LASVGP and rLCMV-VSVG have been described 
elsewhere (36, 37). According to the institutional biosafety guidelines of the Lausanne 
University Hospital, the chimera rLCMV-LASVGP has been classified as a BSL2 pathogen 
for use in cell culture. The generation of recombinant VSVΔG* expressing GFP pseudotyped 
with VSV G (rVSVΔG*-VSVG) has been reported (38, 39). Viruses were produced and the 
titers determined as previously described (40). UUKV strain S23 was used in this study (41). 
UUKV production, purification and titration were performed in mammalian BHK-21 cells as 
described (28, 31). LASV (strain Josiah) was produced at the Special pathogens Branch of the 
Centers for Disease Control and Prevention (Atlanta, GA) and inactivated by gamma 
irradiation using a dose of 2 x 106 rads as described (42).   
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Flow cytometry analysis 
For cell surface staining, cells were detached, when adherent, with enzyme-free cell 
dissociation solution, resuspended in FACS buffer (1% (vol/vol) FCS, 0.1% (wt/vol) sodium 
azide, PBS), and plated in conical 96-well plates, followed by one hour on ice with FACS 
buffer diluted with corresponding primary antibody. Cells were then washed twice in FACS 
buffer and labeled with secondary antibodies (as needed) for 45 min on ice in the dark. After 
two wash-steps in 1% (vol/vol) FBS in PBS, cells were fixed with 1/10 CellFix® solution for 
10 min at room temperature in the dark. The cells were washed twice with PBS, and 
fluorescence intensity assessed using a FACSCalibur flow cytometer (Becton Dickinson) 
using the CellQuest Pro® acquisition and analysis software. Intracellular FACS staining of 
LCMV NP and UUKV antigens was performed as described (43).   
 
Solid phase binding assays 
For binding of virus to DC-SIGN-Fc and DG-Fc fusion proteins, 20 µg/ml purified 
proteins in PBS were immobilized in microtiter plates for 2 h and nonspecific binding blocked 
with 1% (wt/vol) bovine serum albumin (BSA) in PBS. Inactivated LASV or rLCMV-
LASVGP (107 PFU/ml) in 1% (wt/vol) BSA, PBS were applied for 12 h at 6°C. Bound 
viruses were detected with mAb 83.6 (20 µg/ml) in 1% (wt/vol) BSA, PBS using an HRP-
conjugated secondary antibody. For binding of DC-SIGN and DG-Fc fusion proteins to 
rLCMV-LASVGP, purified viruses (107 PFU/ml) were immobilized in microtiter plates and 
incubated with the Fc fusion proteins for 2 hours at 4 °C. Bound Fc-proteins were detected 
with a combination of mouse anti-human IgG Fc (1:500) and HRP-conjugated goat anti-
mouse IgG (1:500). Assays were developed with ABTS [2,2α-azinobis(3-
ethylbenzthiazolinesulfonic acid)] substrate and the optical density at 405 nm recorded in an 
enzyme-linked immunosorbent assay (ELISA) reader. Background binding to BSA was 
subtracted.  
 
Virus binding to monocytes and MDDC 
For biotinylation of rLCMV-LASVGP, we used a modified version of the protocol 
described (44). Briefly, purified virus was dialyzed against reaction buffer (0.1 M NaHCO3, 
100 mM NaCl, pH 8.0) and reacted twice with 1 mM NHS-X-biotin (Calbiochem) for 20 min 
on ice. The reaction was quenched by adding cold 50 mM glycine (final concentration) pH 8.0 
for 10 min, the virus dialyzed against PBS and infectivity checked by IFA on VeroE6 cells. 
Only biotinylated virus retaining >50% of infectivity was used in experiments. For virus 
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binding assay, single cell suspensions of monocytes and MDDC were prepared in 1% 
(vol/vol) FBS, 0.1% (wt/vol) sodium azide, PBS supplemented with 1 mM MgCl2 and 0.5 
mM CaCl2 (binding buffer) and blocked for 15 min on ice. Cells (5 x 104 per well) were 
transferred to M96 plates, centrifuged for 5 min at 1200 rpm, and resuspended in 50 µl 
binding buffer containing biotinylated rLCMV-LASVGP at the indicated particle/cell ratios in 
presence or absence of inhibitors. Incubation was for 1 hour on ice under shaking. After two 
wash-steps in binding buffer, cells were re-suspended in 4% (wt/vol) paraformaldehyde in 
PBS with 1 mM MgCl2 and 0.5 mM CaCl2 and fixed for 20 min on ice. After three washes in 
binding buffer, biotinylated virus was detected by adding FITC-conjugated streptavidin 
(1:100 in binding-buffer) for 45 min in the dark. After three wash-steps, cells were fixed with 
4% (wt/vol) paraformaldehyde, PBS for 10 min at room temperature, washed twice with PBS, 
and analyzed with a FACS Calibur flow cytometer (Becton Dickinson, San Jose CA) using 
Cell Quest software.  
 
Infection and inhibitor studies in Raji and B-THP-1 cells 
Raji cells were seeded in round bottom 96 well plates (Costar) pretreated for 30 min in 
the presence of mannan, anti-DC-SIGN antibodies (120507 or DC28), 5 mM EDTA/EGTA at 
the indicated concentrations at 37 °C followed by 1 hour infection at 37°C with rLCMV-
LASVGP or UUKV at the indicated multiplicity of infection (MOI) in the presence of the 
inhibitors at 37 °C.  Unbound virus was removed by washing the cells. At 4 hours post 
infection 20 mM ammonium chloride was added to prevent secondary infection. At 16 hours 
post-infection, cells were fixed (BD cellFix™). Infection with rLCMV-LASVGP was 
assessed by intracellular staining of LCMV NP with mAb 113 and a PE-conjugated secondary 
antibody, followed by analysis in flow cytometry as described (43). Infection with UUKV 
was assessed by flow cytometry at 7 hours post infection as described (28). B-THP-1 cells 
were seeded at 104 cells/well in round bottom 96 well plates and incubated with the indicated 
concentrations of inhibitors for 30 minutes. Cells were infected with rLCMV-LASVGP and 
rLCMV-VSVG at MOI = 10 as described above and infection assessed after 16 hours by flow 
cytometry.   
 
Determination of viral attachment and entry kinetics in MDDC 
To assess the kinetics of viral attachment, MDDCs were seeded in round bottom 96 well 
plates. After 16 hours, cells were chilled in ice and pre-treated with mAb DC28 or a control 
IgG at the indicated concentrations. After two washes in cold medium, fresh ice cold medium 
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containing rLCMV-LASVGP (MOI 10) in presence of antibodies was added and cells 
incubated on ice. At the indicated time points, unbound virus was removed by two rapid wash 
steps in cold medium, followed by addition of pre-warmed medium and incubation at 37 °C. 
At four hours after the temperature shift, 20 mM ammonium chloride was added to prevent 
secondary infection. At a total of 16 hours, cells were fixed and infection detected by 
intracellular staining of LCMV NP.  
For measurement of the viral entry kinetics, rLCMV-LASVGP and UUKV (MOI 3) were 
added to cells on ice for 1 hour. Unbound virus was removed by washing with cold medium. 
Pre-warmed complete medium was added and cells rapidly shifted to 37 °C at 5% CO2. 20 
mM ammonium chloride was added at 0, 5, 10, 20, 40, 60, 120 and 240 min. After 7 (UUKV) 
or 16 (rLCMV-LASVGP) hours infection were quantified by intracellular staining of the viral 
proteins by flow cytometry as described above. 
 
Immunoblotting 
Proteins were separated by SDS-PAGE and transferred to nitrocellulose. After blocking 
in 3% (wt/vol) skim milk in PBS, membranes were incubated with 1–10 µg/ml primary 
antibody in 3% (wt/vol) skim milk, PBS overnight at 4°C or 2 hours at RT. After several 
washes in PBS, 0.1% (wt/vol) Tween-20 (PBST), secondary antibodies coupled to HRP were 
applied 1:6000 in PBST for 1 h at room temperature. Blots were developed by enhanced 
chemiluminescence (ECL) using Super Signal West Pico ECL Substrate (Pierce). 
 
Inhibitor studies in MDDC  
MDDCs cells were seeded in round bottom 96 well plates (Costar) pretreated for 30 min 
in the presence of sugars (mannan, GlcNAcβ(1-2)Man), anti-DC-SIGN antibodies (mAb 
120507 or mAb DC28) on ice, or for 2 hours in the presence of chlorpromazine, or for 30 
minutes in presence of nocodazole , the actin inhibitors cytochalasin B, latrunculin A, and  
jasplakinoline,  dynasore, EIPA, and IPA-3 at the indicated concentrations at 37 °C. Cells 
were then infected in the presence of inhibitors for 1 hour with rLCMV-LASVGP, UUKV 
and rLCMV-VSVG at 37 °C. At 4 hours post infection 20 mM ammonium chloride was 
added to prevent secondary infection. Infection was detected after 7 (UUKV) or 16 (rLCMV-
LASVGP) hours by flow cytometry as mentioned above. The viability of drug-treated cells 
was determined by staining of single-cell preparations with Live and dead staining. 
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RESULTS 
Up-regulation of DC-SIGN in MDDC correlates with enhanced LASV entry  
Previous studies demonstrated that primary human monocyte-derived DCs (MDDC) are 
highly susceptible to infection with different LASV isolates and that productive infection 
caused virus-induced perturbation of their antigen presenting function (5, 6). To investigate 
LASV cell entry into human DCs, we therefore used primary human MDDCs as a model. 
Since LASV is a BSL4 pathogen, work with the live virus is restricted to laboratories with 
high security containment. To circumvent these biosafety concerns, we used a recombinant 
form of the genetically and structurally closely related prototypic arenavirus LCMV 
expressing the envelope GP of LASV (rLCMV-LASVGP) (36). The chimera rLCMV-
LASVGP does not show significant attenuation in vitro when compared to the parental 
LCMV strain and grows to robust titers. Since receptor binding and host cell entry of 
arenaviruses are mediated exclusively by the viral GP, rLCMV-LASVGP adopts the receptor 
binding characteristics of LASV. The rLCMV-LASVGP has been used extensively to study 
LASV cell entry and cell tropism in cultured cells in vitro (36, 45, 46) and recently in vivo 
using a small animal model (47). Notably, rLCMV-LASVGP showed a marked tropism for 
DCs in vitro and in vivo and showed a tissue distribution reminiscent of LASV in human 
patients (47, 48). The rLCMV-LASVGP chimera represents therefore a powerful BSL2 
surrogate for studies on LASV-receptor interaction and cell entry in the context of productive 
arenavirus infection.  
In a first step, we evaluated productive infection of our rLCMV-LASVGP chimera in 
human MDDCs. For this purpose, primary human monocytes were isolated from peripheral 
blood of healthy donors and differentiated in vitro in the presence of GM-CSF and IL-4 as 
described (5). Differentiation of monocytes into MDDCs resulted in up-regulation of DC-
SIGN, as detected by flow cytometry and Western-blot (Fig. 1A, B). To assess susceptibility 
to rLCMV-LASVGP, monocytes, and MDDCs were infected at different multiplicities. Cells 
were fixed and infection was detected by immunostaining for the intracellular viral 
nucleoprotein (NP) and quantification by flow cytometry. As a negative control, human CD4 
T cells (Jurkat), which are refractory to LASV infection, were included. When compared to 
monocytes, MDDCs showed increased susceptibility to rLCMV-LASVGP (Fig. 1C). In line 
with previous studies, CD4 T cells were highly resistant (Fig. 1C). Next, we determined virus 
production from infected monocytes and MDDC. Briefly, cells were infected with rLCMV-
LASVGP at high multiplicity (3) and virus production monitored by determination of 
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infectious viral titers in the cell supernatants over time using immunofocus assay (IFA). When 
compared to monocytes, MDDCs produced >10-fold higher amounts of infectious virus (Fig. 
1D).  
 
 
FIG. 1. Up-regulation of DC-SIGN in MDDC correlates with enhanced LASV entry. (A) Primary human 
monocytes were isolated from peripheral blood of healthy donors and differentiated in presence of GM-CSF and 
IL4 as described in Materials and Methods. The indicated markers were detected by immunostaining on live, 
non-permeabilized cells and analyzed by flow cytometry as described in Materials and Methods. Empty peaks: 
secondary antibody only, shaded peaks: primary and secondary antibody. One representative example is shown 
out of three experiments with different donors. (B) Detection of DC-SIGN in monocytes and MDDC. Monocytes 
(MC) and MDDC differentiated as in (A) were lysed, total proteins separated by SDS-PAGE, and blotted to 
nitrocellulose. Blots were probed with mAb 120507 to DC-SIGN and an HRP-conjugated secondary antibody 
using enhanced chemiluminescence (ECL) for development. As a loading control, α-tubulin was detected. The 
positions of DC-SIGN (DC) and α-tubulin (Tu) are indicated. One representative example is shown out of two 
experiments with different donors. (C) Infection of monocytes and MDDC with rLCMV-LASVGP. Primary 
human blood monocytes were either kept as monocytes (MC) or differentiated into MDDC. As a control, Jurkat 
cells (TC) were used. Cells were infected with rLCMV-LASVGP at the indicated multiplicities. After 24 hours, 
cells were fixed and infection detected by intracellular staining of LCMV NP in flow cytometry. Results are 
means + SD, n = 3. For monocytes and MDDCs, three different donors were used.  (D) Virus production. 
Monocytes (MC), and MDDC were infected with rLCMV-LASVGP at high multiplicity (3). After the indicated 
time points, supernatants were collected and infectious virus titers determined by immunofocus assay (IFA) on 
monolayers of VeroE6 cells. Data are means + SD of three experiments with different donors.  
 
The increased susceptibility to rLCMV-LASVGP of MDDC when compared to monocytes 
closely resembled previous observations made with live LASV isolates (5) and correlated 
with the strong up-regulation of DC-SIGN. Recent studies showed the absence of the TAM 
kinases Axl and Dtk from MDDC (33).  We confirmed these previous findings by probing 
TAM receptor expression in monocytes and MDDC by flow cytometry (Fig. 2) and Western 
blot (not shown). While primary human monocytes express low levels of Dtk, none of the 
TAM receptors was detected in MDDC. 
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FIG. 2. MDDC lack the TAM receptors Axl, Dtk, and Mer. Live, non-permeabilized monocytes and MDDC 
were stained for the TAM receptors Axl, Dtk, and Mer with specific antibodies, followed by fixation, detection 
with PE-conjugated secondary antibodies, and analysis by flow cytometry. As a positive control for Axl, A549 
cells were included. Empty peaks: secondary antibody only, shaded peaks: primary and secondary antibody. One 
representative example is shown out of three experiments with different donors. 
 
LASV GP binds DC-SIGN via mannose glycans on the receptor-binding GP1 
Considering the correlation between DC-SIGN expression and susceptibility to rLCMV-
LASVGP infection in monocytes vs. MDDC, DC-SIGN represented an interesting candidate 
LASV receptor in MDDC. To further characterize the molecular interaction between LASV 
GP and DC-SIGN, we used authentic inactivated LASV strain Josiah, provided by the Special 
Pathogens Branch of the Centers for Disease Control and Prevention. To define the LASVGP 
part involved in DC-SIGN binding, we first addressed the relative contributions of the N-
terminal GP1 and the transmembrane GP2. For this purpose, the virus was immobilized in 
microtiter plates and treated with 1M NaCl, which results in complete dissociation of GP1 
from virions, but does not affect GP2 (49). Virus stripped with high salt and untreated control 
virus were incubated with C-terminal fusion proteins of recombinant DG, known to bind GP1, 
and DC-SIGN with human IgG Fc (DG-Fc and DC-SIGN-Fc). Virus-bound DG-Fc and DC-
SIGN-Fc were then detected with an HRP-conjugated secondary antibody in a color reaction. 
The presence of mannose glycans in the viral glycoproteins was detected with the lectin 
Galanthus nivalis agglutinin (GNA) that specifically binds to α(1-3)-linked mannose. To 
monitor possible detachment of virus due to high salt treatment, the membrane-associated 
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GP2 was detected with mAb 83.6. High salt treatment of inactivated LASV markedly reduced 
binding of DG-Fc, DC-SIGN-Fc, and the mannose-specific lectin GNA, whereas the signal 
for GP2 was unaffected (Fig. 3A). The results indicate that DC-SIGN binds to LASV GP1, 
which bears mannose glycans. The very similar DC-SIGN binding characteristics observed 
with authentic LASV and rLCMV-LASVGP further confirmed that our chimera virus is an 
adequate model to study LASV-DC-SIGN interactions. 
The binding of DC-SIGN to mannose-rich glycans present on pathogens critically 
depends on divalent cations and can be blocked by the sugar polymer mannan and the mAb 
DC28 to DC-SIGN (20, 22, 23, 25, 28). To assess the effects of these inhibitors on the 
interaction between LASV GP1 and DC-SIGN, DG-SIGN-Fc was immobilized and pre-
treated with mannan, EDTA/EGTA and mAb DC28, followed by incubation with rLCMV-
LASVGP in the presence of inhibitors. Bound virus was then detected in ELISA using mAb 
83.6 to GP2 as described (32). As a control, the effect of inhibitors on virus binding to DG-Fc 
was examined. Binding of rLCMV-LASVGP to DC-SIGN-Fc, but not DG-Fc was 
specifically reduced by mannan, chelators, and mAb DC28 to DC-SIGN (Fig. 3B), suggesting 
a role of LASV GP1-derived mannose sugars in recognition of DC-SIGN. To corroborate a 
role of LASV GP1-linked mannose sugars in DC-SIGN binding, immobilized rLCMV-
LASVGP was treated with EndoH, which specifically removes high-mannose N-glycans, but 
not hybrid- and complex N-glycans. Subsequent probing with DC-SIGN-Fc and GNA 
revealed a significant reduction of binding, whereas attachment of DG-Fc and mAb 83.6 to 
GP2 was unaffected (Fig. 3C). Taken together, our data reveal that LASV GP binds to DC-
SIGN via mannose glycans on GP1.  
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FIG. 3. Characterization of the interaction of LASV GP with DC-SIGN. (A) DC-SIGN binds to LASV GP1. 
Inactivated LASV and rLCMV-LASVGP purified over a renografin gradient were immobilized in microtiter 
plates and treated with 1 M NaCl for one hour (NaCl) or left in PBS (Control). After several washes in PBS, 
recombinant DC-SIGN-Fc, DG-Fc, the mAb 83.6 to LASV GP2, and biotinylated GNA were added. Bound Fc-
fusion proteins were detected with HRP-conjugated anti-human IgG Fc, mAb 83.6 with an HRP-conjugated anti-
mouse IgG, and GNA with HRP-linked streptavidine in a color reaction. Data represent OD values with 
background subtraction, means + SD, n = 3. (B) Binding of DC-SIGN to rLCMV-LASVGP is blocked by 
mannan, EDTA/EGTA, and mAb DC28. DC-SIGN-Fc (left panel) and DG-Fc (right panel) were immobilized in 
microtiter plates and treated with mannan (25 g/ml) 5 mM EDTA/EGTA, 20 µg/ml mAb DC28, and IgG 
isotype control (IgG) at 20 µg/ml for one hour. Purified rLCMV-LASVGP was added at 107 PFU/ml in presence 
of inhibitors for 2 hours in the cold. Bound virus was detected with mAb 83.6 to LASV GP2, combined with an 
HRP-conjugated secondary antibody in a color reaction as in (A) (means + SD, n = 3). (C) Removal of mannose 
sugars from LASV GP reduces binding to DC-SIGN. Purified rLCMV-LASVGP was immobilized and subjected 
to treatment with EndoH glycosidase for 12 hours at room temperature (EndoH) or left untreated (Control). After 
several washes, binding to DC-SIGN-Fc, DG-Fc, GNA, and mAb 83.6 were assessed as in (A) (means + SD, n = 
3).  
 
DC-SIGN mediates attachment of rLCMV-LASVGP to MDDC 
In a next step, we addressed a possible role of DC-SIGN in attachment of LASV to 
human DCs. For this purpose, we performed a well-established virus-cell binding assay that 
had been previously used to characterize cellular receptors for LCMV (11, 44). Briefly, 
rLCMV-LASVGP was purified over a renografin gradient and labeled with biotin using the 
reagent NHS-X-biotin. Biotinylated virus was tested for infectivity and only preparation that 
retained >50% of infectious virus titers were used for further experimentation. Monocytes, 
MDDC, and CD4 T cells were incubated with biotinylated virus at increasing particle/cell 
ratios in the cold. Unbound virus was removed by washing and cells fixed.  Bound virions 
were detected with streptavidine conjugated to Alexa 488 in flow cytometry. The binding 
curves displayed in Fig. 4A revealed a marked increase in virus binding to MDDC when 
compared to monocytes, consistent with the enhanced susceptibility for productive infection 
(Fig. 1C). As expected, CD4T cells showed negligible virus binding. To address the role of 
DC-SIGN in virus attachment to MDDC, cells were pre-treated with mannan and mAb DC28, 
prior to exposure to biotin-labeled virus. Treatment with both mannan and mAb DC28 
46 
RESULTS OF PROJECT-I: LASV ENTRY IN HUMAN ANTIGEN PRESENTING CELLS 
resulted in a dose-dependent reduction of virus binding to MDDCs (Fig. 4B), implicating DC-
SIGN in virus attachment. To complement these studies, labeled virus was pre-treated with 
DC-SIGN-Fc, followed by binding to MDDC. Exposure of virus to DC-SIGN-Fc, but not an 
isotype Fc control resulted in a dose-dependent reduction of virus binding (Fig. 4C). 
Together, the data indicate a role for DC-SIGN in attachment of free virus to MDDC.  
 
 
FIG. 4. DC-SIGN is an attachment factor for rLCMV-LASVGP in MDDC. (A) Binding of rLCMV-
LASVGP to monocytes and MDDC. Biotinylated rLCMV-LASVGP was added to monocytes, MDDC, and 
Jurkat cells at the indicated particle/cell ratios for one hour at 4 °C. Unbound virus was removed, cells fixed and 
bound virus detected with streptavidin labeled with Alexa488. Virus-binding cells were detected in flow 
cytometry. Data are means + SD, of three experiments with different donors. (B) Blocking of virus binding to 
MDDC. MDDC were treated with the indicated concentrations of mannan, mAb DC28 to DC-SIGN, and control 
IgG for 2 hours on ice, followed by incubation with biotinylated rLCMV-LASVGP at 50 particles/cell for one 
hour in the cold. Bound virus was detected as in (A) and the percentage of virus-binding cells displayed. Data are 
means + SD, of three experiments with different donors. (C) Blocking of virus binding with DC-SIGN-Fc. 
Biotinylated rLCMV-LASVGP was incubated with the indicated concentrations of DC-SIGN-Fc and Fc control 
for 2 hours on ice and then added to MDDC for one hour in the cold. Virus-binding cells were assessed as in (A). 
Results are means + SD, of three experiments with different donors. 
 
DC-SIGN facilitates productive infection of rLCMV-LASVGP in MDDC  
The apparent role of DC-SIGN in attachment of rLCMV-LASVGP to MDDC (Fig. 4) 
opened the possibility that DC-SIGN could function as an entry receptor for LASV, similar to 
what has been observed for the phleboviruses UUKV and RVFV (28). In a next step, we 
therefore compared the role of DC-SIGN in productive infection of rLCMV-LASVGP and 
UUKV in MDDC. In a first step, cells were pre-treated with the DC-SIGN ligand mannan, 
followed by infection with rLCMV-LASVGP and UUKV in presence of the inhibitor. At four 
hours post infection, 20 mM ammonium chloride was added to avoid secondary infection. 
Infected cells were detected by intracellular staining for LCMV NP and UUKV antigen in 
flow cytometry after 16 and 7 hours, respectively. Blocking with mannan resulted in an only 
mild reduction (<30%) of infection with rLCMV-LASVGP, whereas UUKV infection was 
diminished by > 90% (Fig. 5A). To more specifically block DC-SIGN-mediated infection, 
MDDC were pre-treated with mAbs DC28 and 120507 to DC-SIGN, prior and during 
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infection with rLCMV-LASVGP and UUKV. Pre-treatment of MDDC with mAbs DC28 and 
120507 reduced infection with rLCMV-LASVGP by circa 60% and 40%, respectively. In 
contrast, infection with UUKV was consistently reduced by >90% (Fig. 5C). The only partial 
blocking of rLCMV-LASVGP infection in MDDC by anti-DC-SIGN antibodies suggested 
that DC-SIGN somehow facilitated viral entry and productive infection, but was not strictly 
required.  
Another candidate receptor identified for LASV is the C-type lectin LSECtin, identified 
in a recent expression cloning approach (16). Since LSECtin can be present on MDDC under 
some conditions (50), we addressed a potential role of LSECtin in LASV entry into MDDCs. 
For this purpose, cells were pre-treated with increasing concentrations of the LSECtin ligand 
GlcNacβ(1-2)Man, followed by infection with rLCMV-LASVGP and UUKV. Treatment of 
MDDCs with up to 100 μg/ml GlcNacβ(1-2)Man did not affect infection with the two viruses 
(Fig. 5A). To confirm the efficiency of our inhibitor treatment, we used B-THP-1 cells 
expressing recombinant LSECtin (35). In line with previous studies (16), pre-treatment with 
100 μg/ml GlcNacβ(1-2)Man, but not mannan significantly reduced infection with rLCMV-
LASVGP. As a negative control, we included a recombinant LCMV expressing the G protein 
of vesicular stomatitis virus (rLCMV-VSVG), which is not dependent on LSECtin and was 
not affected by the inhibitor treatment (Fig. 5B). Together, our data make a major contribution 
of LSECtin for cell entry of rLCMV-LASVGP in MDDC appear unlikely.  
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FIG. 5. DC-SIGN facilitates cell entry of rLCMV-LASVGP. (A) Blocking of virus infection in MDDC. 
MDDC were treated with 25 µg/ml mannan (Man 25), 100 µg/ml mannan (Man 100), 25 µg/ml GlcNacβ(1-
2)Man (GlcNAc 25), 100 µg/ml GlcNacβ(1-2)Man (GlcNAc 100), and PBS vehicle control (Control) for 30 
minutes at 37 °C. Cells were then infected with rLCMV-LASVGP (LASV) and UUKV at multiplicity of 3 for 
one hour in presence of inhibitors. Cells were washed and at four hours post infection, 20 mM ammonium 
chloride added to prevent secondary infection. Infection was assessed by FACS. Infection was normalized 
setting control specimens at 100%. Data are means + SD, of three experiments with different donors (6 donors in 
total). (B) B-THP-LSECtin cells were treated with inhibitors as in (A), followed by infection with rLCMV-
LASVGP (LASV) and rLCMV-VSVG (VSV) at MOI = 10. Infection was assessed by IFA after 16 hours and 
data normalized as in (A). (C) Blocking of virus infection in MDDC with mAb to DC-SIGN. MDDC were 
treated with 20 µg/ml of mAb DC28 (DC28), mAb 120507 (120507), isotype control IgG (IgG), or PBS 
(control) for 30 minutes at 37 °C, followed by infection with rLCMV-LASVGP and UUKV as in (A). Infection 
was normalized setting control specimens at 100%. Data are means + SD, of two experiments with different 
donors (4 donors in total). 
 
Different efficiency of DC-SIGN in mediating entry of rLCMV-LASVGP and UUKV 
The data at hand indicated that DC-SIGN can facilitate attachment and entry of rLCMV-
LASVGP in MDDC. In contrast, UUKV, RVFV, and other bunyaviruses can use DC-SIGN 
alone for binding and infectious uptake, suggesting different roles of DC-SIGN in entry. To 
assess the relative efficiency of DC-SIGN in mediating productive infection by rLCMV-
LASVGP and UUKV, we utilized Raji cells stable transfected with wild-type DC-SIGN and a 
DC-SIGN mutant containing a mutation in the cytoplasmic LL motif that is impaired in 
endocytosis (34). Parental Raji cells lacked TAM receptors (Fig. 6A), and expressed only 
negligible levels of DC-SIGN (Fig. 6B), making them refractory to rLCMV-LASVGP and 
UUKV. The Raji-DC-SIGN and Raji-DC-SIGN-LL stable transfectants expressed similar 
amounts of DC-SIGN at their surface (Fig. 6B). Parental Raji cells, Raji-DC-SIGN, and Raji-
DC-SIGN-LL were infected with rLCMV-LASVGP and UUKV. Productive infection was 
assessed after one round of replication and normalized to the untransfected parental line. In 
line with previous studies, expression of DC-SIGN increased infection with UUKV by >40-
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fold (28), whereas only circa 4-fold enhancement of rLCMV-LASVGP infection was 
observed (Fig. 6C). When compared to wild type DC-SIGN, DC-SIGN-LL was less efficient 
in mediating infection with rLCMV-LASVGP and UUKV (Fig. 6C). Infection of rLCMV-
LASVGP and UUKV in Raji-DC-SIGN cells was blocked upon treatment with mannan and 
the chelators EDTA/EGTA (Fig. 5C), confirming a role of DC-SIGN in enhancement of 
infection. The data obtained with Raji cells expressing recombinant DC-SIGN are in line with 
our findings in MDDC (Fig. 7). That rLCMV-LASVGP and UUKV present significant 
difference in their ability to infect DC-SIGN+ cells may reflect distinct roles of the lectin in 
mediating cell entry of these viruses. 
 
 
FIG. 6. Different efficiencies of DC-SIGN in cell entry of rLCMV-LASVGP and UUKV. (A) Detection 
TAM receptors in parental Raji cells by flow cytometry as in Fig 2. Empty peaks: secondary antibody only, 
shaded peaks: primary and secondary antibody. (B) Detection of DC-SIGN in Raji cell lines. Raji parental cells, 
Raji-DC-SIGN, and Raji-DC-SIGN-LL cells were stained with mAb 120507 to DC-SIGN combined with a PE-
conjugated secondary antibody and analyzed in flow cytometry. (C) Virus infection of Raji cell lines. Raji 
parental cells (C), Raji-DC-SIGN (wt), and Raji-DC-SIGN-LL (LL) were infected with rLCMV-LASVGP and 
UUKV at a multiplicity of 3. At 4 hours post infection, 20 mM ammonium chloride was added to avoid 
secondary infection. Infection was assessed by intracellular staining for LCMV NP and UUKV antigen after 18 
hours, respectively, and infected cells detected by flow cytometry (means + SEM, n = 2). (D) Inhibition of 
infection of Raji-DC-SIGN cells. Raji-DC-SIGN cells were treated with 50 µg/ml mannan (Man), 5 mM 
EDTA/EGTA, or PBS vehicle control (C) for 30 minutes, followed by infection with rLCMV-LASVGP and 
UUKV. Infection was assessed as in (B) and normalized setting control specimens at 100% (means + SEM, n = 
2).  
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DC-SIGN accelerates capturing of free rLCMV-LASVGP by MDDCs 
A hallmark of lectin-type carbohydrate-protein interactions are their relatively fast on-
rates, opening the possibility that DC-SIGN may be involved in capturing free rLCMV-
LASVGP by human DCs. To address this possibility, we investigated the role of DC-SIGN in 
the attachment kinetics of rLCMV-LASVGP in MDDCs. Cells were chilled on ice and pre-
incubated with mAb CD28 to DC-SIGN or a control IgG in the cold. rLCMV-LASVGP was 
then added at MOI 10 in presence of the antibodies. At the indicated time points, unbound 
virus was removed by washing and the cells rapidly shifted to 37°C. After 4 hours, 
ammonium chloride was added and infection detected after 16 hours by flow cytometry. In 
presence of control IgG, the virus rapidly attached to cells and reached saturation with half-
maximal binding after <15 minutes (Fig. 7A). Blocking of DC-SIGN with mAb DC28 
resulted in slower virus attachment that hardly reached saturation after 45 min. After < 45 min 
of attachment, we noticed reduced viral titers produced from cells treated with anti-DC-SIGN 
antibody (Fig. 7B). The data suggest that DC-SIGN can accelerate capture of free virus, 
facilitating productive infection. 
 
 
FIG. 7. Attachment and entry kinetics of rLCMV-LASVGP in MDDC. (A) DC-SIGN accelerates capture of 
free virus. MDDCs were pre-treated with mAb DC28 to DC-SIGN and control IgG (Control) for 1 hour in the 
cold, followed by binding of rLCMV-LASVGP at MOI of 10. At the indicated time points, unbound virus was 
removed by washing and cells shifted to 37°C. Productive infection was detected after a total of 16 hours by 
FACS (means + SEM, n = 3). (B) Conditioned cell culture supernatants from A were assessed for infectious 
virus titers by IFA as in Fig. 1D. Data are means + SD, of three experiments with different donors. 
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rLCMV-LASVGP enters MDDC via a slow actin-dependent pathway 
The apparently different role of DC-SIGN in productive infection of rLCMV-LASVGP 
and UUKV opened the posibility that the viruses may use distinct pathways for cell entry. In a 
first step, we compared the entry kinetics of rLCMV-LASVGP and UUKV in MDDC. Both 
viruses require a pH of < 6.0 for fusion indicating delivery to late endosomes for productive 
cell entry (28, 45). To assess how fast receptor-bound rLCMV-LASVGP and UUKV 
trafficked to late endosomes, we determined the time required for the viruses to become 
resistant to ammonium chloride. When added to cells, ammonium chloride raises the 
endosomal pH rapidly and blocks low pH-dependent membrane fusion without causing 
overall cytotoxicity (51, 52). The viruses were bound to MDDC in the cold, allowing receptor 
attachment without internalization. Unbound virus was removed and cells shifted to 37°C to 
restore membrane movements. Ammonium chloride was added at different time points post 
infection and kept throughout the experiment. Cells were fixed and infection assessed by flow 
cytometry. In line with published data, 50% of UUKV had escaped from the late endosome 
after circa 20 minutes (28). In contrast, cell entry of rLCMV-LASVGP was markedly slower 
with < 50% of the virus having escaped from the endosome after one hour (Fig. 8A).  
 To test the involvement of actin-dependent pathways, like macropinocytosis or phagocytosis 
that are present in MDDC, we treated cells with cytochalasin D or latrunculin A, which 
disrupt actin fibers, as well as jasplakinolide, an actin-polymer stabilizing drug that blocks the 
dynamics of actin filaments. When added to cells for 30 minutes prior to infection, 
cytochalasin D, latrunculin A, and jasplakinolide significantly reduced infection of rLCMV-
LASVGP, but not UUKV (Fig. 8B). Previous studies revealed that UUKV associates in 
MDDC with clathrin-coated pits (28). A possible role of clathrin-mediated endocytosis 
(CME) in cell entry of rLCMV-LASVGP into MDDC was therefore addressed using 
chlorpromazine (CPZ), a drug that perturbs the assembly of clathrin-coated pits at the plasma 
membrane. As a positive control, we included a recombinant VSV pseudotype that contains a 
GFP reporter and bears VSVG (rVSVΔG*-VSVG) in its envelope, which mediates cell entry 
in a clathrin- and dynamin-dependent manner (53). The VSV pseudotype lacks endogenous G 
and is limited to one round of replication, limiting viral spread. Treatment of MDDC with up 
to 8 μM CPZ did not significantly affect infection with rLCMV-LASVGP, but reduced 
infection of rVSVΔG*-VSVG in a dose-dependent manner (Fig. 8C). To address the 
involvement of dynamin in rLCMV-LASVGP cell entry, MDDC were treated with the 
dynamin inhibitor dynasore prior to infection. As control, we again included rVSVΔG*-
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VSVG. As shown in Fig. 8D, infection of MDDC with rLCMV-LASVGP was not affected by 
up to 100 μM dynasore, whereas infection of rVSVΔG*-VSVG was reduced.  
The actin-dependence and apparent clathrin- and dynamin-independence of rLCMV-
LASVGP cell entry into MDDC suggested a possible role of macropinocytosis in the process 
(54). Treatment of cells with the Na+/H+ exchanger inhibitor ethylisopropyl amiloride (EIPA) 
reduced infection with rLCMV-LASVGP, but only at relatively high concentrations (Fig. 8E). 
We further used the PAK1 inhibitor IPA-3, which plays a central role in macropinocytosis of 
some viruses, e.g. vaccinia (55). As shown in Fig. 8F, IPA-3 had no significant effect on 
infection of rLCMV-LASVGP in MDDC, but reduced infection of HeLa cells with vaccinia 
virus, in line with published data (55). Since vesicular transport to late endosomes in many 
cell types depends on microtubules (56), we tested the effect of nocodazole, a drug that 
dissociates microtubular structures on rLCMV-LASVGP entry into MDDCs. Pretreatment of 
cells with nocodazole to some extent reduced infection with rLCMV-LASVGP, indicating a 
role of microtubules in the process (Fig. 8G).   
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FIG. 8. Characterization of rLCMV-LASVGP entry into MDDC. (A) Entry kinetics of rLCMV-LASVGP 
and UUKV in MDDC. MDDC were incubated with rLCMV-LASVGP and UUKV at multiplicity of 3 for one 
hour in the cold. Unbound virus was removed and cells shifted to 37 °C. At the indicated time points, 20 mM 
ammonium chloride was added and left throughout the experiment. After 16 hours (rLCMV-LASVGP) and 7 
hours (UUKV), cells were fixed and infection detected as in Fig. 6. The percentage of infected cells was plotted 
against time, data are means + SEM of three experiments with three different donors. (B) Infection of rLCMV-
LASVGP in MDDC is actin-dependent. MDCC were treated with 20 µM cytochalasin D (Cyto), 5 µM 
latrunculin A (Lat), and 1 µM jasplakinolide (Jas), or solvent control (control) for 30 minutes, followed by 
infection with rLCMV-LASVGP and UUKV as in (A). Data are means + SD, of three experiments with three 
different donors. (C) Effect of CPZ on the infection of rLCMV-LASVGP. MDCC were treated with the 
indicated concentrations of CPZ or PBS only (0) for one hour, followed by infection with rLCMV-LASVGP or 
rVSVΔG*-VSVG (VSV) at a multiplicity of 10. After 4 hours, 20 mM ammonium chloride were added to 
prevent secondary infection, and rLCMV-LASVGP infected cells detected after 16 hours as in (A). Cells 
infected with rVSVΔG*-VSVG were fixed after 6 hours and GFP detected by direct fluorescence. At 6 hours 
post infection, MDDC infected with rVSVΔG*-VSVG, but not rLCMV-LASVGP started to show signs of 
activation. Infection was normalized setting untreated specimens at 100%. Data are means + SD, of three 
experiments with three different donors. (D) Blocking of infection of rLCMV-LASVGP with dynasore. MDDC 
were pre-treated with the indicated concentrations of dynasore or vehicle control (0), followed by infection with 
rLCMV-LASVGP or rVSVΔG*-VSVG (VSV) as in (C).  Data are means + SD, of three experiments with three 
different donors. (E) Inhibition of rLCMV-LASVGP infection in MDDC by EIPA. MDDC were pre-treated with 
the indicated concentrations of EIPA or vehicle control (0) for 30 minutes, prior to infection with rLCMV-
LASVGP as in (B). Data are means + SD, of three experiments with three different donors. (F) Effect of the 
PAK1 inhibitor IPA-3 on infection of rLCMV-LASVGP. MDDC and HeLa cells were pre-treated with the 
indicated concentration of IPA-3 or vehicle control (0) for 30 minutes, followed by infection with rLCMV-
LASVGP (LASV) or recombinant vaccinia virus expressing GPF (VV). Infection with rLCMV-LASVGP was 
assessed as in (B) and infection with VV by detection of the GFP reporter in direct fluorescence microscopy at 
12 hours post infection. Data are means + SD, of three experiments with three different donors. (G) The role of 
microtubules in rLCMV-LASVGP infection in MDDC. MDDC were pre-treated with nocodazole (10 μM) or 
solvent control (0) and infection with rLCMV-LASVGP performed as in (B). Data are means + SD, of three 
experiments with three different donors.   
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DISCUSSION 
Here we studied the role of the C-type lectin DC-SIGN in cell entry of LASV into human 
MDDC using a recombinant LCMV expressing LASV GP (rLCMV-LASVGP) as a BSL2 
surrogate for LASV. We found that differentiation of primary human monocytes into MDDC 
enhanced susceptibility to rLCMV-LASVGP infection, a situation similar to the one observed 
with live LASV isolates (5). The up-regulation of DC-SIGN in MDDC correlated with 
markedly stronger virus attachment and enhanced productive infection suggesting a role of 
DC-SIGN in attachment and/or infection of rLCMV-LASVGP, similar to its function in cell 
entry of the arthropod-borne phleboviruses UUKV and RVFV (28)  
Previous studies on the role of DC-SIGN in entry of UUKV and RVFV showed that these 
viruses bind to DC-SIGN via high mannose N-glycans present on their glycoproteins (28). 
Our present studies revealed a similar binding mechanism for LASV involving N-linked 
mannose sugars on GP1, in line with the previously reported observation that LASV GP1 
contains high proportion of mannose sugars (57), similar to the glycoproteins of arthropod-
borne viruses.   To investigate the role of DC-SIGN in different steps of LASV cell entry, we 
first performed virus-cell binding assays and found that DC-SIGN is involved in attachment 
of the virus to MDDCs. To address the function of DC-SIGN in productive infection, we 
compared rLCMV-LASVGP with UUKV that uses DC-SIGN as an authentic entry receptor 
(28). Blocking of DC-SIGN on MDDCs with mannan and antibodies almost completely 
abolished UUKV infection, but only partially reduced infection with rLCMV-LASVGP. 
Using Raji cells stable expressing DC-SIGN, we confirmed the different efficiency of DC-
SIGN in mediating infection of rLCMV-LASVGP and UUKV. While recombinant DC-SIGN 
greatly enhanced productive infection with UUKV, as shown previously (28), the effect on 
rLCMV-LASVG was more modest.  
The data at hand supported a role of DC-SIGN as an entry factor for rLCMV-LASVGP, 
raising the question about the possible physiological relevance of the LASV-DC-SIGN 
interaction. In early LASV infection, the virus infects DCs at the site of inoculation and the 
kinetics of free virus capture by DCs may thereby be an important determinant for efficient 
productive infection. To address the role of DC-SIGN in virus capture by MDDC, we 
determined the kinetics of virus-cell attachment in presence and absence of function-blocking 
anti-DC-SIGN antibodies. Using productive infection as readout, we provide first evidence 
that DC-SIGN can accelerate capture of free virus by MDDC.  
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The data at hand suggest that DC-SIGN can facilitate LASV infection of MDDC at the 
level of virus-cell attachment. However, its role in the subsequent cell entry process was 
unclear. UUKV and LASV require a similarly low pH for fusion, indicating that both viruses 
escape from a late endosomal compartments (31, 58, 59). Previous life cell microscopy 
studies performed with UUKV revealed that, upon virus attachment, the virus-DC-SIGN 
complex is rapidly internalized and delivered to early endosomes, followed by transport of the 
virus to the late endosome, where fusion occurs after only 9-15 minutes (28). Monitoring of 
viral entry kinetics in MDDC revealed that UUKV escaped from the endosome with a half-
time of less than 20 minutes, whereas < 50% of rLCMV-LASVGP had escaped after one 
hour. Using a combination of actin inhibitors, we found that entry of rLCMV-LASVGP, but 
not UUKV was actin-dependent. In contrast to UUKV that associated with clathrin-coated 
pits in MDDC (28), studies with inhibitors provided first evidence that entry of rLCMV-
LASVGP was independent of clathrin and dynamin. The strong actin-dependence of rLCMV-
LASVGP entry into MDDCs and its sensitivity to the amiloride EIPA, a potent inhibitor of 
the Na/H+ exchanger rather suggest an entry pathway related to macropinocytosis that is 
constitutively active in MDDCs. The distinct entry pathways used, together with the 
substantial DC-SIGN-independent infection of rLCMV-LASVGP, suggest rather different 
roles of DC-SIGN in cell entry of LASV compared to phleboviruses like UUKV and RVFV. 
In contrast to phleboviruses that use DC-SIGN as an entry receptor, DC-SIGN seems to serve 
primarily as an attachment factor for LASV in MDDC involved in virus capture. The partial 
independence of rLCMV-LASV entry from DC-SIGN suggests the existence of additional 
LASV entry factors in MDDCs. Of particular importance in this context is the role of DG, 
which represents a major LASV receptor. LASV binding to DG  critically depends on 
functional glycosylation of the receptor, in particular specific O-linked glycans present on α-
DG synthesized by the glycosyltransferase LARGE that are also crucial for recognition of 
DG’s ECM ligands (32, 60). While the core protein of DG is ubiquitously expressed, the 
functional glycosylation of the receptor is under tight tissue-specific control (61). In previous 
studies, we found that many human cell types targeted in vivo by LASV, such as epithelial 
cells, vascular endothelial cells, and hepatocytes express functionally glycosylated DG able to 
bind LASV with high affinity (62). However, the functional glycosylation of DG in human 
DCs, including MDDC, is currently unknown. Our initial attempts to detect functional DG in 
primary human MDDC in this study gave unclear results, suggesting possible differences in 
the extent or nature, or both, of functional glycosylation of DG compared to other cell types. 
In-depth characterization of the post-translational modification of DG in human DCs, and its 
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possible role as an entry factor for LASV, are currently under way in our laboratory and will 
contribute to a better understanding of LASV entry into this pivotal cell type 
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SUMMARY OF PROJECT-II 
Arenaviruses are the causative agents of severe viral HFs with high mortality in humans 
and represent a threat to public health. Considering the lack of effective treatment against 
these viruses and the limited public health infrastructure in affected regions, the development 
of protective vaccines against arenaviruses is an urgent need. To address this issue, we 
initiated the evaluation of a novel and promising recombinant vaccine platform based on NPs 
for the development of a safe recombinant vaccine against pathogenic arenaviruses.  
The first part of my second thesis project aimed at the engineering of a vaccine 
formulation capable to induce an antibody response against the highly pathogenic NW 
arenavirus MACV. Based on available structural data on the MACV envelope GP, in 
particular its receptor-binding GP1 moiety, we engineered suitable MACV GP1-derived 
immunogens with the potential to induce a protective humoral response. Specifically, we 
produced recombinant forms of MACV GP1 that comprise the binding site to the cellular 
receptor hTfR1. In a complementary approach, we designed a synthetic peptide immunogen 
mimicking MACV GP loop 10 (L10), which represents a key GP1 structure implicated in 
receptor binding. MACV GP1-derived immunogens were produced in mammalian cells, 
conjugated to PPS NPs and evaluated in vivo in a mouse model. Vaccination of mice with 
NPs conjugated to MACV GP1 fragments induced strong and specific Abs responses, 
demonstrating efficient delivery and presentation of the antigens. However, based on the 
available neutralization assays only weak and transient nAbs titers were detected in the first 
attempt.  
Since recombinant subunit vaccines may not be able to elicit nAbs titers that can confer 
protective immunity per se, we undertook a complementary approach and evaluated our NPs 
platform for its ability to induce cellular anti-viral immunity. In a proof-of-concept study, we 
employed the infection of LCMV in its natural host, the mouse. Well-defined peptides derived 
from defined MHC class I restricted CD8 T cell epitopes derived from LCMV were 
conjugated to NPs. First assessment of anti-viral T cell responses indicated that NPs are able 
to elicit a potent CD8 T cell response to immunodominant epitopes with a markedly weaker 
response to sub-dominant epitopes. Viral challenge experiments are currently performed to 
assess the protective potential of the anti-viral memory CD8 T cell response elicited by NPs.   
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INTRODUCTION 
Arenaviruses have emerged as a growing public health problem in many countries of 
Africa and South America [37]. Considering the number of people affected and the current 
lack of efficacious treatments and licensed vaccines, arenaviruses like LASV, JUNV, and 
MACV belong arguably to the most neglected tropical pathogens. Taking into account the 
limited public health infrastructure in the affected regions and the limited resources at hand, 
the development of a protective vaccine that is safe, easy to administer and does not require a 
continued cold chain is of highest priority. Extensive work over the past decades resulted in 
the development of a live attenuated vaccine against JUNV, Candid-1 [49] that is currently 
administered in high-risk populations in Argentina, but has not been approved for broader use. 
A LASV/MOPV reassortant vaccine (ML29) showed promising characteristics when tested in 
NHP, but has not yet been tested in man [112]. Despite being promising, the use of such live-
attenuated vaccines will be severely restricted in the affected regions of the world due to the 
high prevalence of immunocompromising conditions and biosafety concerns. The 
development of a safe recombinant vaccine that can be produced at low costs remains 
therefore the major goal of current arenavirus vaccine development.  
Several lines of evidence indicate that neutralizing antibodies (nAbs) represent an 
important correlate of protection for a number of anti-viral vaccines [113,114]. By 
neutralizing free virus, nAbs can act as “gatekeepers” either providing sterilizing immunity or 
at least limiting the initial burst of viral replication, providing a window of opportunity for the 
host’s cellular immunity to control infection and eliminate the virus. In the case of 
arenaviruses, clinical and experimental evidence revealed important differences in the quality 
of the antibody response in primo-infection with pathogenic OW (LASV) and NW (JUNV 
and MACV) arenaviruses. Human primary LASV infection seems mainly controlled by the 
anti-viral CD8 T-cell response, whereas nAbs appear late during convalescence and are 
frequently of low titers [34,41]. However, if provided at sufficient titers, nAbs to LASV 
proved to be protective in post-exposure prophylaxis in animals [47,48], and in some human 
cases [115,116]. In contrast, nAbs appear earlier after infection with JUNV and MACV[117], 
and the development of nAbs in the second week of disease correlates with positive clinical 
outcome [118]. The robust nAbs titers in JUNV and MACV convalescent plasma provide the 
basis for the current immune plasma therapy of human JUNV and MACV infection that 
markedly reduces mortality from > 30 to < 0.1% [119]. The strong nAbs responses against 
NW arenaviruses indicates that the viral GP1 is immunogenic and a recombinant vaccine 
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capable of inducing sufficient nAbs titers seems in principle feasible. Moreover, in contrast to 
other viral HFs, there is currently no evidence for enhancement of human arenavirus disease 
by sub-neutralizing antibodies [23,26]. The reasons for the striking difference in quality of the 
antibody response against OW and NW arenaviruses are currently unknown. Although NW 
arenavirus HFs are widespread in endemic regions, there is no evidence for repeated infection 
in survivors [120]. This suggests that a vaccine would likely be protective.  
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PART 1: INDUCTION OF A PROTECTIVE ANTIBODY RESPONSE 
1.1. Design and production of the vaccine antigen 
A large body of evidence supports the notion that antibodies targeting viral attachment 
proteins are of particular importance for protection as they prevent host cell attachment and 
entry [114,121,122]. The arenavirus envelope GP is initially synthesized as a single 
polypeptide that is processed into the N-terminal GP1 and the membrane-associated GP2 (Fig. 
1A, B), which forms trimers, similar to other class I fusion-active viral GPs [123] (Fig. 1C). 
Structural studies on MACV GP1 showed that arenavirus GP1 represents an independent 
folding unit with a globular structure [124,125] (Fig. 1D). Examination of the complex 
between MACV GP1 and its receptor revealed that trimerization of MACV GP1 is not 
required for receptor binding (Fig. 1E) [12,125]. The MACV GP1 monomer thus represents 
the “functional unit” of receptor recognition, which involves conserved peptide loops 
protruding from its surface (Fig.1F). 
 
 
Figure 1. Structure of arenavirus glycoproteins. A) Schematic representation of arenavirus GPC: The N-
terminal receptor-binding GP1 subunit, the C-terminal GP2 subunit, the transmembrane domain and the signal 
peptide SSP are indicated. The S1P processing site is depicted with a black arrow. B) In the virion membrane, 
mature arenavirus GP forms a trimer. C) X-ray crystallographic structure of the trimeric GP2 of LCMV taken 
from [123]. D) Structure of MACV GP1 with two receptor-binding loops (L3 and L10) highlighted in yellow. E) 
Structure of the complex of MACV GP1 (blue) with its cellular receptor TfR1. Only one monomer of the TfR1 
dimer is shown with the individual domains indicated. F) Details on the molecular contact between loops L3 and 
L10 of MACV GP1 (blue) with the apical domain of TfR1 (green).(D-F taken from [125]). 
  
In line with these structural data, nAb were found to be directed exclusively against GP1 
[126,127], and GP1 purified from JUNV virions was able to elicit a nAb response [128]. 
Based on these data we designed soluble recombinant “GP1 only” fragments. Considering the 
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wealth of structural data available and its similarity to JUNV, we initially chose MACV GP1 
for our studies on NW arenaviruses.  
The studies by Bowden and colleagues revealed that the GP1 of MACV consists of a 
novel α/β fold (Fig.1D) and that deletion of the first 87 amino acids from the full-length GP1 
protein greatly enhances protein expression in HEK293 cells [124]. Using a PCR cloning 
approach (see material and methods for details), we constructed an analogous truncated form 
of MACV GP1 containing an N-terminal HA-tag and a C-terminal FLAG-tag, HA-
MACVGP1-88-262-FLAG (MACV∆GP1) shown in Fig. 2A. The construct was cloned in a 
pcDNA 3.1(+) expression vector containing the cytomegalovirus major immediate early 
promoter, followed by an intron (intron A) sequence and expressed in HEK293T cells by 
transient transfection.  Protein expression and secretion was assessed by SDS-PAGE and 
Western blot (Fig. 2B). 
  
 
 
Affinity purification using an anti-HA column followed by HA-peptide competitive 
elution yielded around 0.5-1 mg of protein of >95% purity per liter of supernatant. Sequential 
anti-HA purifications of the same supernatant batch were performed in order to increase the 
protein recovery.   
 
1.2. Conjugation of the vaccine antigen MACV∆GP1 onto PPS NPs 
In a first approach to conjugate our MACV∆GP1 immunogen to PPS NPs, we tried to 
generate NPs bearing anti-FLAG Fab fragments at their surface, allowing immobilization of 
our immunogen via its C-treminal FLAG-tag.  The advantage of this conjugation scheme was 
the defined orientation of the immunogen on the NPs and the coupling without prior 
modification. Nevertheless, this approach turned out to be not feasible due to technical and 
cost restrictions.   
The modular chemistry for conjugating antigens onto the surface of pyridyl disulfide 
activated PPS NPs via a disulfide link between the NPs surface and the thiol (SH) functional 
Figure 2. The MACV GP1 fragment: A) 
Recombinant MACV GP1 variant HA-
MACVGP1-FLAG, containing a deletion 
of amino acids 1-87, an N-terminal HA-tag 
and a C-terminal FLAG-tag B) Purified 
HA-MACVGP1-FLAG detected with an 
anti-HA antibody in Western blot (left) and 
by Coomassie blue staining (right). 
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group of cysteine residue(s) on the antigen has been recently described [129]. MACV∆GP1 
has 8 cysteines, organized in four intra-molecular disulfide bonds that stabilize the overall 
conformation of the protein, but no free sulfhydryl (S-S) groups (Fig.1D) [130].  In order to 
accomplish conjugation via thiol groups, an unpaired cysteine residue was inserted into 
MACV∆GP1 by PCR cloning resulting in the form MACV∆CGP1. Although MACV∆CGP1 
was efficiently expressed in HEK293T cells, the purified protein spontaneously formed high 
molecular weight aggregates, perturbing the protein conjugation. The aggregates could only 
be partially dissociated in the presence of strong reducing agents resulting in a loss of protein 
conformation (data not shown).  
In a second approach, a partial reduction scheme of the wild type MACV∆GP1 was 
considered, where the solvent accessible disulfide bonds would be reduced preferentially. For 
this purpose, we tested two different reducing agents: β-mercaptoethylamine (2-MEA) and 
Tris(2-carboxyethyl) phosphine (TCEP) covalently linked to 4% crosslinked beaded agarose. 
The latter having the advantage of being easily removable from the initial reduction reaction 
by centrifugation without any additional purification steps. To assess MACV∆GP1 
conformation preservation we performed an in vitro binding assay to its receptor hTfR1. 
MACV∆GP1 reduced with 2-MEA was not retained for further conjugation on the NPs as 
more than 80% of the protein was lost during the pre-conjugation purification step. The partial 
reduction of MACV∆GP1 with TCEP was carried out in two ways, using TCEP beads with or 
without guanidinium hydrochloride (GuHCl). At low concentrations, the chaotropic agent 
GuHCl allows the protein to “swell” without actual denaturation of its tertiary structure, thus 
enhancing accessibility of disulfide bonds to TCEP. Although GuHCl treatment enhanced 
conjugation efficiency (Fig. 3A), it also impaired the binding of the protein to hTfR1, whereas 
treatment with TCEP alone retained > 50% of receptor bind capacity (Fig. 3B). Since our 
objective was the production of nAbs, the TCEP/ without GuHCl formulation was chosen as 
reduction method for MACV∆GP1 prior to conjugation on the NPs. 
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 Figure 3. MACV∆GP1 partial reduction and conjugation. A) Comparison of TCEP+GuHCl and TCEP 
agarose reduced proteins conjugation efficiency to PPS NPs. MACV GP1 was partially reduced by TCEP + 1M 
guanidium hydrochloride, conjugated to PPS NPs and purified by gel filtration. Peaks corresponding to NP-
conjugated and free protein are indicated. B) hTfr1 binding assay. GP1 binding at various concentrations to 
CHO.K1 cells transiently transfected with hTfr1 was assessed by flow cytometry on a CyAn™ ADP Analyzer 
(Beckman Coulter). MACV∆GP1 was detected by a polyclonal rabbit anti-FLAG antibody against its C-terminal 
FLAG tag, followed by a secondary anti-rabbit antibody conjugated with Alexafluor 647. Only live (Live/Dead 
violet, Invitrogen), hTfr1+ (PE-anti hTfr1 clone M-A712) cells are depicted for the normalized geometric mean 
of the FL8 channel, which reflects the AF647 fluorescence intensity. Analysis was done using FlowJo (version 
7.5.5, Tree Star) software. C) MACV∆GP1 NPs’conjugation profile. MACVΔGP1 was reduced with TCEP 
beads at 37°C (1h). Reduced MACV GP1 was mixed with NPs in a 1:1 reaction (v/v) and reacted over night at 
RT, purified by size exclusion chromatography and eluted with H2O. NPs and protein presence was assessed in 
each elution fraction by iodine staining (absorbance at 342nm upper graph) and fluorescamine reactivity (lower 
graph) respectively. 
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1.3. Evaluation of MACV∆GP1 NPs in vivo  
To evaluate the ability of our GP1-conjugated NPs to elicit an anti-viral antibody 
response in vivo, we performed a proof-of-principle study using the MACV∆GP1-NPs 
produced above. For this purpose, groups of five age and sex-matched C57Bl/6 mice were 
vaccinated with our MACV∆GP1-NPs. For comparison, we applied purified MACV∆GP1 
protein alone. As a negative control, unconjugated NPs were used. Since previous studies had 
shown a positive effect of stimulators of Toll-like receptors (TLRs) on the quality and 
magnitude of immune responses in the context of the NP platform [104], we added the TLR9 
agonist CpG to our vaccine formulations. Mice were injected following the vaccination 
schedule shown in Fig. 4A. At the indicated time points, mice were bled and serum obtained. 
Detection of specific antibodies (IgG) against MACV GP1 in ELISA revealed a strong and 
specific antibody response against MACV GP1 in mice immunized with MACVΔGP1-
conjugated NPs (Fig. 4B). Notably, the IgG titers obtained with the NP platform were 
significantly higher than those obtained with the purified protein. As expected, pre-immune 
sera and sera from mice vaccinated with unconjugated NPs showed no detectable titers of 
anti-MACV GP1 antibodies. To assess the presence of nAbs, we employed a  neutralization 
test, as described in materials and methods [131].  In animals vaccinated with MACVΔGP1-
conjugated NPs, we were able to detect nAbs (Fig. 4C). However, the neutralizing activity of 
the antibodies was low and the extent of neutralization would likely provide insufficient 
protection. 
Until now our data have shown that the NPs platform could induce a strong humoral 
immune response, which was specific for the antigen used for vaccination. However, the 
weak and transient nAbs titers detected suggested that the majority of the antibodies detected 
in figure 4 were directed to non-neutralizing epitopes displayed by our immunogen. During 
natural infection, MACV GP1 is displayed in its native conformation on virion surfaces and 
on infected cells. In contrast, our MACV GP1 immunogen displays peptide structures that are 
either not present or inaccessible in the native GP, such as the peptide tags (HA, FLAG) and 
structures of GP1 that are normally hidden within the mature GP trimer.   
To detect antibodies directed against the accessible surface of MACV GP1 in the native 
protein, we expressed full-length MACV GP in human HEK293 cells. At 48 hours post-
transfection, live, non-permeabilized cells were incubated with sera and bound antibodies 
detected in flow cytometry. Notably, no significant binding of serum antibodies to native 
MACV GP1 was detectable in NPs-MACV∆GP1 immunized animals (data not shown). This 
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suggests, that the antibodies generated by our vaccine were either unable to recognize MACV 
GP1 in its native form or had low affinity. The absence of high affinity antibodies to native 
MACV GP1 is in line with the lack of a robust neutralizing activity in mice sera shown in 
Fig.4. 
 
 
Figure 4. NPs conjugated to MACVGP1 elicit strong antibody responses. A) Groups of five age- and sex-
matched C57BL/6 mice were immunized with MACVGP1 conjugated NPs (NPs-MACVGP1, 1.6 μg of 
protein/mouse), unconjugated NPs (NP), or MACVGP1 protein (MACVGP1), all in combination with 10 µg of 
CpG-B. At days 14 and 28, mice were given vaccine boosts. Blood draws were performed at the indicated time 
points (red drops). B) Antibody titers (IgG) in vaccinated mice over time. Titers of specific anti-MACV GP1 IgG 
were determined by ELISA using purified MACVGP1 immobilized in microtiter plates and IgG specific 
secondary antibodies. Note that the specific IgG titers after vaccination with the NPs conjugated antigen were 
consistently higher than those obtained with the soluble protein. Data shown are means + SD, n = 5.  C) 
Neutralization assay.  Preimmune sera and immune sera from d35 and d93 (40 x dilution) were mixed with 
MACV pseudotypes virus carrying the reporter gene luciferase.  The inoculums were added to susceptible 
human cells (A549) and infection detected by luciferase assay. Signals were normalized to preimmune sera. Data 
shown are means + SEM, n = 2. 
In order to further characterize the antibody responses induced by our vaccine, we sought 
to identify MACV GP1 peptide structures recognized by the antibodies present in the sera of 
vaccinated mice. To this end, we employed the peptide array technology described in Fig.5A. 
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This technique allowed us to identify peptides of MACV∆GP1 that are bound by antibodies 
and thus to obtain information about structures on the immunogen that are recognized. The 
results of a study are shown in Fig.5B. We observed that the major peptides recognized by 
sera from both mice immunized with NPs-MACV∆GP1 and MACV∆GP1 located to the N-
terminal part of the protein, in particular to a region encompassing the HA-tag 
(DYPYDVPDYAGAQPARSPGL, HA epitope in bold) (Fig.5).  
 
 
 The preferential recognition of the HA-tag by antibodies from sera of vaccinated mice 
was confirmed by flow cytometry and ELISA (data not shown).  
 
1.4. A “Second generation” of MACV∆GP1 constructs  
The strong antibody response obtained against the HA-tag indicates efficient antigen 
delivery and presentation upon vaccination with NPs conjugated to PPS NPs. The lack of 
nAbs may be due, at least in part, to the loss of conformational epitopes on MACV GP1 
Figure 5. A) CelluSpots™ technology. CelluSpots™ are array of cellulose-bound peptide spotted on glass
slides. The cellulose support can be dissolved after peptide synthesis. The solutions of individual peptides
covalently linked to macro molecular cellulose are then spotted onto a surface of choice. After evaporation of
the solvent a three-dimensional layer is formed which is not dissolved in aqueous reagents used for standard
assays. B) Epitope mapping array. The whole sequence of MACV∆GP1 protein was displayed on a peptide
slide array (201 x 20-mer peptides with one amino acid overlap, in duplicate). The peptide slides were then
incubated with the sera of one mouse of each vaccination group: 1) nanoparticles; 2) NPs-MACV∆GP1; 3)
MACV∆GP1 only. Bound antibodies were detected with a HRP-conjugated goat anti-mouse secondary
antibody with enhanced chemiluminescence. Red squares: linear B-cell epitopes detected in both MACVGP1-
NPs and MACVGP1 only immunized mice.  
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caused by the conjugation chemistry and the associated treatments of the immunogen with 
reducing agents. In order to circumvent these problems, we evaluated an alternative 
conjugation strategy. The recently developed aldehyde-tag strategy allows single site 
modification of native bioactive proteins for further conjugation to fluorochromes, antibodies, 
etc [132,133]. In our context, “aldehyde tags” would allow coupling of the immunogen via a 
specific chemical functional group without affecting the MACV GP1-derived part under mild 
conditions that allow retention of the native conformation. This technique requires the 
insertion of a formylglycine generating enzyme (FGE) recognition site (LCTPSRAALLTGR, 
minimal sequence recognized by the FGE in bold) either at the N- or C-terminus of the target 
protein (Fig.6A). The FGE post-translationally converts the cystein within recognition site 
into a formylglycine containing a reactive aldehyde group (Fig.6A and B). As the FGE is 
naturally present and active in the endoplasmic reticulum (ER) of mammalian cells, the 
engineered protein can be directly produced in mammalian cells. Nevertheless, the addition of 
exogenous FGE (by co-transfection with the target protein) generally increases the cystein-
formylglycine conversion yield. From our previous studies, we have learned that the HA-tag 
was recognized as major epitope and we were concerned that the strong antibody response to 
these apparently highly immunogenic sequences could interfere with a potential weak MACV 
GP1 response. Therefore we decided to include a thrombin (TH) cleavage site between the 
GP1 and the HA sequence (Fig.6A). This would allow us to remove the HA-tag after 
purification and prior to conjugation. The aldehyde-tag should then allow the conjugation of 
the antigen to hydrazide/aminooxy functionalized NPs under mild conditions (room 
temperature, pH 6-7.5) allowing retention of the native conformation of MACV GP1. 
 
Figure 6. Site-specific modification using the genetically endoded aldehyde-tag. A) Schematic representation 
of Ald-tagged MACVΔGP1and the FGE recognition sequence. After recognition of a specific sequence inserted 
in the antigen sequence, FGE oxidizes the Cys in the tag to formylGlycine leading to the site specific labeling of 
the functionalized protein (ald-tagged protein). B) Schematic representation of the Ald-tagged MACVΔGP1. 
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The aldehyde (Ald)-tagged MACV∆GP1 constructs were successfully produced in 
HEK293T cells (Fig.7A) and purified using an anti-HA affinity matrix (Fig.7B) in analogy to 
the first generation of MACV∆GP1 constructs. After purification, the HA tag was removed by 
treating the protein with agarose-bound thrombin as described in the material and methods 
section, allowing cleavage of >90% of the HA tag (Fig.7C). The extent of cystein to 
formylglycine conversion was determined by reaction of the Ald-tagged MACV∆GP1 with 
aminooxy biotin (see material and methods). Based on the results obtained, we estimate 80-
90% Cys-formylglycine conversion efficiency for the N-terminal Ald-tagged protein (Ald-
MACV∆GP1) (Fig.7D, AldΔGP1) and 50-70% for the C-terminal Ald-tagged protein 
(MACV∆GP1-Ald). As the conversion efficiency was higher for the Ald-MACV∆GP1 than 
for the MACV∆GP1-Ald, we decided to use the N-terminal Ald-tagged construct for further 
conjugation on the NPs and in vivo testing. 
 
Figure 7. Ald-tagged MACV∆GP1 expression in mammalian cells. A) Total protein extraction from 
HEK293T cells supernatant and cell lysates. Total cell supernatants and cell lysates (intracellular)  proteins 
(secreted) were recovered by methanol/chloroform extraction, resuspended in SDS sample buffer and detected 
using anti-HA Ab in western blot. ΔGP1FLAG: non Ald-tagged protein used as control. AldΔGP1 and ΔGP1Ald 
correspond to the N and C terminal Aldehyde tagged proteins respectively. B) Anti-HA affinity matrix purified 
Ald-MACV∆GP1 protein. Supernatant from a large scale (1-3 liters) protein’s production was loaded on an anti-
HA affinity matrix (0.5ml/min), the column was eluted for 15 min at 37°C (3 sequential elutions) and a sample 
of each eluate (E1-E3) was mixed with SDS sample buffer. The purification efficiency was assessed by 
coomassie staining (left) and specific protein detection was achieved using an anti-HA Ab (right). C) HA 
cleavage efficiency. Buffer exchanged Ald-MACV∆GP1 was mixed with 3U/mg of protein of thrombin-agarose 
and incubated over night at R.T. (23-25°C) on a wheel. Agarose-bound thrombin was removed using a spin 
column. The cleavage efficiency was determined by coomassie staining (left) and anti-HA detection (right). C 
stands for cleaved protein. D) Aldehyde reactivity assessment. Ald-MACV∆GP1 was reacted with aminooxy-
biotin for 2h at RT. The Ald-MACV∆GP-aminooxy-biotin binding was determined using and a streptavidin - 
HRP coupled. KDa: kilo Dalton. 
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Two different conjugation strategies were simultaneously tested for the coupling of the 
Ald-tagged protein on PPS NPs. 1) NPs containing reactive amines were functionalized with a 
hydrazino-nicotinamide (HyNIC) linker and then reacted with the Ald-tagged protein 
(Fig.8A). Succinimidyl-6-hydrazino-nicotinamide (S-HyNIC), an aromatic hydrazine and 4-
succinimidyl-formylbenzamide (S-4FB), an aromatic aldehyde allow the linking of diverse 
molecule types (proteins, oligos and peptides) through primary amines, thiols or maleimides 
to a variety of compounds resulting in an UV-traceable, stable bis-arylhydrazone bond. 2) 
Oxyamine-pluronic (aminooxy) NPs were synthesized and directly reacted with the Ald-
tagged protein (Fig.8B). The conjugation data with Ald-tagged OVA showed almost 100% 
coupling efficiency to the NPs (data not shown). In contrast to Ald-OVA, only 16% of the 
Ald-MACV∆GP1 was coupled to the NPs in both conjugation startegies (Fig.8C). The Ald-
MACV∆GP1-NPs conjugation procedure needs further optimization and is currently ongoing 
in the laboratory of our collaborator at the EPFL. 
 
Figure 8. Schematic representation of Ald-MACVΔGP1 conjugation to NPs. A) Conjugation via hydrazine. 
B) Conjugation via oxyamine. C) Ald-MACV∆GP1 NPs’ conjugation profile. Ald-MACVΔGP1was mixed 
either with hydrazine or oxyamine functionalized NPs in a 1:1 reaction (v/v) and reacted over night at RT, 
purified by size exclusion chromatography and eluted with H2O. NPs and protein presence was assessed in each 
elution fraction by iodine staining (not shown) and fluorescamine reactivity respectively. For more details about 
the conjugation conditions see materials and methods section. 
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1.5. The receptor-binding MACVGP1 loop 10 as antigen   
In our first approach to generate nAbs against MACV, we adopted a rather conventional 
protein-based vaccine strategy using the major part of the viral envelope GP targeted by nAbs 
in vivo. Protein-based vaccines have proved to be efficient and are routinely used in clinics. 
Nevertheless, they are not always cost-effective and straightforward to produce due to the fact 
that many viral proteins are toxic for mammalian cells and thus difficult to produce in high 
amounts. The use of bacterial or insect expression systems is not always feasible as they are 
devoid of some enzymes crucial for the correct post-translational modifications of mammalian 
proteins. A cost-effective alternative to protein-based vaccines is the use of peptide-based 
antigens. Peptides can be easily produced by liquid or solid phase synthesis. Moreover, they 
can display single, multiple and/or combined T or B cells epitopes allowing targeting the 
immune response towards a specific region of interest within a previously identified on the 
native protein.  
“First generation” peptide-based vaccines are frequently potent inducers of T cell 
immune responses. Indeed, most of the T cells epitopes are composed of linear continuous 
amino acid (aa) sequences with an average length of circa 10 aa for MHC I and 13-20 aa for 
MHC II epitopes. In contrast, B cell epitopes required for the induction of nAbs are frequently 
discontinuous sequences, which in some cases adopt secondary and/or tertiary structures, thus 
limiting the use of linear peptides for the induction of nAbs. However, a “new generation” of 
peptides, which were engineered to adopt a tertiary conformation allowed overcoming some 
of these limitations. Several strategies for the generation of conformational peptides are now 
available. Another concern regarding peptide-based vaccines is their lack of immunogenicity. 
However, this can, at least in part, be compensated by appropriate vaccine formulations, 
including the addition of adjuvants.  
In a complementary strategy, we sought to identify MACV GP1-derived peptide 
structures that would be suitable for the design of immunogenic peptides with the potential to 
elicit nAbs. As shown in Fig. 1D and E, structural studies revealed that MACV GP1 binds to 
its receptor hTfR1 via distinct peptide loops that protrude from the surface of the GP1 and 
virtually “grab” the receptor surface in a finger-like fashion. Subsequent structure-function 
analysis and mutagenesis pinpointed in particular the peptide loops L3 and L10 as crucial 
structures implicated in receptor recognition [12]. We hypothesize that binding of an IgG 
molecule with sufficient affinity to any of these loops would drastically perturb the 
attachment of MACV GP1 to hTfR1 obstructing host cell attachment of the virus. First, we 
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employed molecular modeling to predict the structure of the peptides derived from L3 and 
L10 in solution, when separated from their protein core. These studies performed with the 
help of Prof. Matteo Dal Peraro from the laboratory of Biomolecular Modeling of EPFL, 
revealed that a peptide derived from L3 adopted with a high probability a linear undefined and 
non-conformational structure. In contrast, the peptide sequence corresponding to L10 
spontaneously adopted a loop-like structure similar to that observed in the crystal structure of 
the MACV GP1-hTfR1 complex. Thus only L10 was selected as a candidate immunogen. The 
binding efficiency of the S-4FB linker to L10 is currently ongoing. Once obtained 4FB 
functionalized L10 will be conjugated to HyNIC functionalized NPs as described in Figure 9. 
Then we will proceed with the in vivo testing in mice as described for MACVΔGP1-NPs 
immunization. 
 
 
Figure 9.  Loop 10 conjugation to NPs’ schema. 
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PART 2: INDUCTION OF A PROTECTIVE T CELL RESPONSE 
While nAbs would significantly contribute to protection against virus challenge, we are 
aware that nAbs titers conferring sterile immunity against virulent arenaviruses may be 
difficult if not impossible to achieve. As a complementary strategy, we therefore evaluated the 
NPs platform for its capacity to induce anti-viral T cells. The focus on receptor-binding GP1 
fragments for the development of a NPs vaccine able to elicit a protective Abs response 
resulted in removal of major CD8 T cell epitopes. For this reason, we wanted to complement 
the GP1-conjugated NPs with NPs displaying MHC I-restricted CD8 T cell epitopes with the 
goal to elicit an anti-viral CD8 T cell response. To this end, we used the infection of the 
prototypic arenavirus LCMV in the mouse, which is one of the best experimental models to 
study anti-viral CD8 T cell responses [134,135]. The major dominant and subdominant MHC 
I-restricted CD8 T cell epitopes of LCMV are well-defined and are derived for the structural 
proteins NP and GPC. 
Infection of mice with LCMV results in a strong CD8 T cell response that has been 
extensively characterized, including the identification of CD8 T cell epitopes, as well as their 
functional hierarchy. For our studies we used C57/Bl6 mice and selected H2-Db-restricted 
CD8 T cell epitopes. We chose two dominant CD8 T cell epitopes, LCMV GP33-41 and 
NucP396-404, and a less dominant one LCMV GP276-286, in order to check if the hierarchy 
between the CD8 T cell epitopes was conserved upon immunization with NPs-conjugated 
peptides. The peptides were synthesized by solid phase synthesis. For conjugation, we used a 
peptide design known to allow the targeting of peptides to MHC I cross-presentation by 
antigen presenting cells [104]. This new strategy ensures efficient uptake of the NPs, and 
intra-endoplasmic reticulum processing to reveal the immunogenic epitope, excluding non-
specific attachment to surface MHC I. The GP33-41 and GP276-286 peptide epitopes were 
successfully conjugated to NPs, whereas conjugation of NucP396-404 requires further 
optimization. As proof-of-principle, LCMV GP33-41 and LCMV GP276-286-conjugated NPs 
were evaluated and compared to the well-characterized H2-Kb restricted OVA peptide 
SIINFEKL for their efficacy to trigger a cellular immune response.  
 
2.1. Conjugation of MHC I LCMV peptides onto PPS NPs 
As described in a previous publication, peptide epitopes can be readily conjugated to the 
core sulfhydryls of the Pluronic stabilized PPS NPs via disulfide bonds [104]. Briefly, the 
native cysteines of the peptides LCMV GP33-41, LCMV GP276-286 and OVA250-264 (used as a 
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control) were activated with a 2-pyridylthiol group (Fig.10). Conjugation was verified by 
analytical HPLC/MS. 
 
Figure 10. Peptide conjugation. LCMV peptides epitopes can be readily conjugated to the core sulfhydryls of 
the pluronic stabilized PPS NPs via disulfide bonds. The native cysteines LCMV peptides were activated with a 
2-pyridylthiol group. Extent of peptide conjugation was monitored by absorbance of pyridine-2-thione at 340nm, 
and free peptide removed by size exclusion. 
 
2.2. Evaluation of NPs bearing CD8 T cell epitope peptides in vivo  
To evaluate the ability of the peptide-conjugated NPs to elicit a cellular anti-viral immune 
response in vivo, groups of three age- and sex-matched C57Bl/6 mice were vaccinated with 
NPs conjugated to the peptides LCMV GP33-41 and LCMV GP276-286, either individually or in 
combination (Mix), or NPs bearing the peptide OVA250-264, which includes the 
immunodominant SIINFEKL, as shown in Figure 11A. The induction of a specific MHC I-
restricted CD8 T cell response to the different epitopes was assessed on days 14 (data not 
shown)  and 21 by detection of interferon (IFN)-γ producing CD8 T cells in enzyme-linked 
immunospot (ELISPOT) assay (Fig.11B) and by intracellular cytokine staining of CD8 T cells 
producing IFN- γ and TNF-α (Fig. 11C). As shown in Figure 11B and C, a robust CD8 T cell 
response to the immunodominant epitope GP33-41 could be measured, which was comparable 
in magnitude to the OVA peptide SIINFEKL. However, we were unable to detect a 
significant response to the less dominant epitope GP276-286. When applied in combination, the 
epitopes GP33-41 and GP276-286 resulted in CD8 T cells response comparable to the GP33-41 
alone, indicating lack of a synergistic effect between the two peptides. This gave first hints 
that the NP platform maintains the functional epitope hierarchy between GP33-41 and GP276-286. 
As expected, responses measured at day 14, after single immunization were weaker that those 
measured at day 21, after a boost. Examination by intracellular cytokine staining in flow 
cytometry (Fig.11C) revealed 1-2% of GP33-41 epitope specific IFN-γ producing CD8 T cells, 
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which is in the order of magnitude of the GP33-41 epitope-specific CD8 T cell frequencies 
observed in natural infection  (6-8%) [136].   
 
 
Figure 11.  CD8 T cell responses after vaccination A) Vaccination schematic. Six age- and sex-matched 
C57Bl/6 mice were vaccinated intradermally on their hind legs on day 0, followed by a boost vaccination on day 
14. Mice were vaccinated with 10 µg of CpG-B and with the following formulations at 2.2 nmol total 
immunodominant peptide per mouse: NPs conjugated to the C-OVA250-264; NPs conjugated to LCMV GP33-41; 
LCMV GP276-286; or a mix of LCMV GP33-41 and LCMV GP276-286 (Mix). CD8 T cell responses were assessed on 
days 14 (n=3) (data not shown) and 21 (n=3). B) Detection of IFN-γ producing CD8 T cells at day 21 by 
ELISPOT. 105 splenocytes were plated and restimulated with corresponding peptides, and developed according 
to the manufacturer’s instructions (eBioscience ELISPOT READY-SET-GO!). Note that the numbers of IFN-γ 
producing cells for the mouse groups immunized with LCMV GP33-41 and the OVA250-264 are likely 
underestimated due to the high number of spots in the assay. C) Fequencies of epitope-specific CD8 T cells 
producing IFN-γ at day 21, analysis by flow cytometry. d21 splenocytes were restimulated in vitro with 
respective peptides for 6 h and Brefeldin A was added for the last 3 h of incubation for intracellular cytokine 
staining. Splenocytes were surface stained for CD8 T cells with CD3ε and CD8α, and intracellular stained for 
IFN-γ by analysis by flow cytometry. ICS: intracellular staining. 
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1. PROJECT-I 
In the first project of this thesis, we focused on the role of the recently identified 
candidate receptors DC-SIGN and LSECtin, as well as the TAM receptor tyrosine kinases, 
Axl and Tyro3, combined with the rLCMV-LASV chimera entry into DCs, using human 
primary MDDC as a model. We identified DC-SIGN as an attachment factor for LASV in 
human MDDC. DC-SIGN enhanced the binding of free virions to this crucial immune cell 
type in vitro. This binding was mediated by high mannose N-glycans present on the LASV 
GP1 and facilitated capture of free virus by MDDC. However, we observed significant 
residual infection in MDDC after treatment with mannan and function-blocking anti-DC-
SIGN antibodies, indicating that other factors, in addition to DC-SIGN, contribute to LASV 
entry.  In follow-up studies to this work, I propose to address the following questions/points:  
1) What is the exact role of DC-SIGN in the LASV entry process in MDDC? 
2) What is the role of the LASV receptor DG in LASV infection in MDDC? 
3) What is the intracellular trafficking route of LASV in MDDC? 
1.1. What is the exact role of DC-SIGN in the LASV entry process in MDDC? 
The studies during my thesis revealed that DC-SIGN can facilitate LASV entry, but the 
underlying mechanisms are unknown. I propose to use a microscopic approach to further 
investigate the role of DC-SIGN in LASV entry using rLCMV-LASVGP as a model. In 
human DCs, DC-SIGN forms dynamic clusters at the plasma membrane that are associated 
with signaling molecules and seem to represent the functional units of pathogen recognition 
and endocytosis [137]. In a first step, confocal microscopy could be used to visualize the 
interaction of rLCMV-LASVGP with DC-SIGN clusters at the level of the plasma membrane 
and subsequent steps of viral entry into MDDC. Briefly, MDDCs cultured on coverslips will 
be incubated with fluorescence-labeled rLCMV-LASVGP at a high particle/cell ratio (100 
particles/cell) in the cold. Unbound virus will be removed and the temperature shifted to 
37°C. At different time points (e.g. 0, 5, 15, 30 min, 1, 2, and 4 h), cells will be fixed and 
permeabilized. Virus will be detected by direct fluorescence and DC-SIGN with an antibody 
[62]. Co-localization will be performed by combination with antibodies to markers for the 
plasma membrane and different intracellular compartments, including Rab5 (transport 
vesicles to early endosomes), EEA1 (early endosome), CD63/LBPA (MVB), Rab7 (transport 
vesicles to late endosomes), and LAMP1 (late endosome). Images will be acquired and 
reconstructed by Z-stack analysis. These studies will reveal if the virus attaches to pre-formed 
DC-SIGN clusters located at the plasma membrane, prior to uptake into the cell. Co-
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localization studies with markers for intracellular compartments will reveal if DC-SIGN is 
internalized together with the virus or if the virus dissociates from DC-SIGN prior to or after 
internalization. These microscopic studies may help to understand if the slow LASV entry 
kinetics observed in MDDC is due to slow internalization of the virus-receptor complex or 
based on delayed intracellular transport with possible “temporary” sequestration of the virus 
in an intracellular compartment. Co-localization with Rab5/EEA1 and Rab7/LAMP-1 will 
reveal if LASV traffics through the classical endosomal pathway or uses a Rab5/EEA1-
independent route, as previously shown for DG-mediated LASV entry in other cell types 
[14,138]. These studies will help to distinguish if DC-SIGN acts only as an attachment factor 
that concentrates virion particles at the cell surface prior to binding to the true entry receptor 
or if DC-SIGN is also involved in the internalization step. Based on previous studies on DC-
SIGN-mediated entry of phleboviruses, we would expect that the virus separates from DC-
SIGN at the level of the early endosome due to the low pH-induced dissociation of the DC-
SIGN tetramers [62].    
1.2. What is the role of the LASV receptor DG in LASV infection in MDDC? 
We demonstrated that TAM receptor tyrosine kinases and the C-type lectin LSECtin are 
unlikely candidates for LASV receptors in MDDC. Neither of the TAM receptors was found 
on MDDC, in line with published studies [139]. Blocking of LSECtin with its carbohydrate 
ligands had no significant effect on MDDC infection with rLCMV-LASVGP and UUKV, but 
blocked LSECtin-mediated cell entry in a heterologous expression system, validating the 
inhibitor treatment.  
A major receptor for LASV in many human cell types is DG. Functional DG is expressed 
in many cell types that are infected by LASV in humans in vivo, including, but not limited to 
epithelial cells, endothelial cells, and hepatocytes [140]. In the host cell, α-DG is subject to 
complex post-translational modifications that are crucial for its function as an ECM receptor 
[141,142]. Of particular importance are specific O-mannosyl-glycans found at the N-terminus 
of α-DG’s mucin-type domain produced by the glycosyltransferase LARGE that are crucial 
for binding to ECM proteins [143] and arenaviruses [140,144,145]. While the core protein of 
DG is ubiquitously expressed, the functional glycosylation of the receptor is under tight 
tissue-specific control [142]. Since the functional glycosylation of DG in human immune cells 
and in particular in human DCs is largely unknown, we started to characterize the expression 
of functional DG in human monocytes and MDDC. To detect functional DG in MDDC, cells 
were lysed and DG core protein enriched by affinity purification with the lectin wheat germ 
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agglutinin (WGA) as described [146]. As controls, we used the human lung epithelial cell line 
A549 rich in functional DG and the CD4 T cell line Jurkat that lacks functional receptor 
[145]. Lectin-bound proteins were separated by SDS-PAGE and probed with monoclonal 
antibody (mAb) IIH6 that recognizes the functional O-glycans on α-DG required for virus and 
ECM binding [143]. High amounts of glycosylated α-DG were present in A549 cells, whereas 
the expression levels in monocytes, MDDC, and Jurkat cells were below the detection limit of 
our assay (Fig.12A). Detection of glycosylated α-DG at the surface A549 cells, monocytes, 
and MDDC by flow cytometry gave similar results (Fig.12B). The lack of detection with the 
glycosylation-specific anti-α-DG antibody IIH6 in MDDC was unexpected and suggested 
either low levels of functional α-DG glycosylation or enhanced shedding of α-DG from β-DG. 
Previous studies demonstrated that over-expression of LARGE can rescue functional α-DG in 
cells bearing various genetic defects in DG glycosylation [147]. Using adenoviral (AdV) 
vectors, we over-expressed LARGE in MDDC, which resulted in detection of a band of 120-
125 kDa by mAb IIH6, possibly functional α-DG (Fig.12C). No significant signals were 
detected in MDDC transduced with a control AdV expressing GFP. The appearance of a 
defined IIH6 reactive protein upon LARGE over-expression suggests the presence of α-DG 
core protein in MDDC, albeit with low endogenous levels of functional glycans. In a 
complementary approach, we tried to block infection of rLCMV-LASVGP in MDDC and 
A549 cells with mAb IIH6. Cells were pre-treated with increasing concentrations of mAb 
IIH6 and an isotype control, prior to addition of virus. After 16 hours, infection was assessed 
by flow cytometry. As expected, DG-mediated infection in A549 cells was blocked by IIH6 in 
a dose-dependent manner (Fig.12D). In contrast, no significant inhibition was observed in 
MDDC (Fig.12D). In sum, the data at hand suggest that human monocytes and MDDC 
express a form of DG that is only weakly recognized by the glycosylation-dependent mAb 
IIH6.  
The expression of an underglycosylated DG form in MDDC with low virus-binding 
affinity seems to be in line with the significant contribution of DC-SIGN in virus attachment. 
However, our assays used so far are limited in their sensitivity and we cannot rule out that 
underglycosylated DG can still function as an entry receptor in MDDC, e.g. in concert with 
DC-SIGN. To address this possibility, I propose to perform depletion of the DG core protein 
in MDDC using RNA interference (RNAi). To this end, human monocytes will be transduced 
with lentiviral vectors expressing a validated shRNA targeting DG that is available in our 
group. Upon differentiation into MDDC, the absence of DG core protein can be validated by 
Western blot and RT-qPCR for DG mRNA. In case we are able to achieve > 95% depletion of 
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DG core protein, this RNAi approach would allow addressing a possible role of DG as a low 
affinity LASV receptor in MDDC.  
Our finding that MDDC apparently express an underglycosylated form of α-DG is per se 
novel and interesting. I therefore propose to further study the glycosylation state of the α-DG 
form present on monocytes and MDDCs. In a first step, we could investigate, by real time 
PCR, the expression profile of the different enzymes responsible for the post-translational 
modifications of this protein, specifically LARGE (1 and 2) the proteins O-
mannosyltransferases POMT1 and POMT2 [148], protein O-mannose β1,2-N-GlcNAc 
transferase 1 (POMGnT1) [149], fukutin, and fukutin-related protein (FKRP) [150].  
 
 
 
Figure 12. Detection of functional DG in human monocytes and MDDC. A) Monocytes, MDDC, A549 cells, 
and Jurkat cells (5 x 106 cells) were lysed and subjected to WGA affinity purification as described in Materials 
and Methods. Lectin-bound proteins were eluated by boiling in SDS-PAGE sample buffer.  The whole eluates 
for monocytes, MDDC, and Jurkat cells and 1/10 of the eluate from A549 cells were analyzed in Western blot 
using mAb IIH6 to α-DG (upper blot) and mAb 8D5 to β-DG (lower blot). The position of β-DG and apparent 
molecular masses are indicated. B) Detection of functional DG at the cell surface.  Monocytes, MDDC, and 
A549 cells were subjected to staining with mAb IIH6 on live, non-permeabilized cells. Cells were fixed and 
bound mAb IIH6 detected with a PE-conjugated secondary antibody in flow cytometry. Empty peaks: secondary 
antibody only, shaded peaks: primary and secondary antibody. C) Over-expression of LARGE rescues functional 
DG in MDDC. MDDC were infected with AdV-LARGE and AdV-GFP at MOI = 100. After 48 hours, total cell 
lysates were prepared and probed with mAb IIH6 as in (A). D) Blocking of infection of rLCMV-LASVGP with 
mAb IIH6. MDDC and A549 cells were blocked with mAb IIH6 or a control mouse IgM (Control IgM) at the 
indicated concentrations for 2 h at 4°C. Next, rLCMV-LASVGP (multiplicity of 1) was added for 45 min. 
Infection was assessed after 16 hours by flow cytometry for LCMV NP (means + SD, n = 3). 
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Moreover, we should exclude the possibility that the α-DG glycosylation profile observed 
in MDDCs was due to the in vitro procedure we uses for differentiation. I propose to examine 
the functional α-DG expression on DCs directly isolated from human blood using negative or 
positive selection of blood cells with specific DCs markers coupled to magnetic beads. The 
investigation of additional DCs subtypes, in particular plasmacytoid DCs (pDCs) that are also 
targets for LCMV and LASV [151] would also be of great interest. From these experiments 
we could acquire a better knowledge about the expression of functional DG in human primary 
DCs and further validate MDDCs as an experimental model. Preliminary data from studies I 
performed on PBMC, which include T (45-70%), B (15%) and NK (15%) lymphocytes, 
monocytes (10-30%) and several types of DCs (1-2%) directly isolated from human blood, 
tended to confirm the absence of functional α-DG on primary human DCs (data not shown), 
but need to be confirmed.  
 
1.3. What is the intracellular trafficking route of LASV in MDDC? 
We have observed that the entry kinetics and characteristics of LASV in MDDC were 
remarkably different from those of DG-mediated LASV entry in other cell types as well a 
DC-SIGN-mediated cell entry of phleboviruses. This unusual entry pathway may be related to 
the ability of LASV to evade innate detection in MDDC and the ability of the virus to perturb 
antigen presentation by MHC I and II. The examination of the intracellular trafficking route 
used by LASV in MDDC is therefore of great importance. The microscopic studies on the 
role of DC-SIGN in LASV attachment and/or internalization mentioned above will give first 
hints about the events taking place at the plasma membrane and during internalization. In a 
next step, we will try to identify the initial compartment that is reached by the virus upon 
internalization. To detect the virus in putative early endosomal structures, we will perform 
19°C trapping experiments. At 19°C, uptake of cargo takes place to some extent, whereas 
membrane maturation and vesicular sorting from early endosomal compartments are 
markedly slowed down [152]. Fluorescence-labeled virus (rLCMV-LASVGP) will be added 
to cells on ice followed by a temperature shift to 19°C for 30 min, 1, 2, and 4 h. Cells will be 
virus co-localized with Rab5, EEA1, Rab7, LBPA, CD63, LAMP1, and DAPI (nuclei). In 
case we observe accumulation of virus at intracellular sites distinct from classical early 
Rab5/EEA1 positive endosomes or the MVB/late endosome, I propose to assess the size, 
shape and lumenal pH of the compartment. For this, one could use LysoSensor™ probes 
(Invitrogen) that exhibit a pH-dependent increase in fluorescence in acidic environments and 
allow measuring the intralumenal pH of a given compartment. These studies will reveal if the 
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virus-receptor complex passes through an early acidified compartment in which it is retained 
for some time, or if it is directly transported to the MVB/late endosome.  Apart from classical 
Rab5/EEA1 positive early endosomes, other early endosomal compartments have more 
recently been identified, such as clathrin-independent carrier compartments (CLIC) or GPI-
protein enriched early endosomal pathway (GEECs), which may be involved in the process 
[153]. Interestingly, entry via CLIC and GEECs critically depends on actin, but is clathrin- 
and dynamin independent [154]. To further address a possible role of CLIC/GEECs, one 
could study the role of regulatory proteins implicated in the pathway, including the small 
GTPases Cdc42 and Arf1 using a combination of RNAi and dominant negative (DN) mutants. 
Co-localization with microtubules will visualize possible microtubular transport of virus-
containing vesicles form early to late endosomes, suggested by the sensitivity of LASV entry 
to nocodazole.  
 
1.4. Identification of novel LASV entry factors in human DCs  
The significant residual infection of rLCMV-LASVGP upon blocking of DG and DC-
SIGN in my studies suggests the existence of yet unknown LASV entry factors in MDDC. 
The expression cloning approaches performed by the laboratory of Prof. Kawaoka to identify 
LASV entry factors [13] were carried out in a sophisticated manner and I do not propose to 
repeat or to duplicate this work. Instead, I would like to suggest a complementary strategy, 
based on quantitative proteomics. This approach may allow the discovery of LASV entry 
factors in MDDC, whose identification may not be feasible by expression cloning. For the 
proteomic analysis, I propose to use stable isotope labeling of amino acids in culture 
(SILAC). This method is based on the in vivo incorporation of a non-radioactive isotope label 
into proteins in cultured cells to allow analysis by mass spectrometry (MS). SILAC allows the 
discrimination of two experimental conditions by the relative mass of proteins labeled with 
different isotopes present in the samples. This can be achieved by labeling cellular proteins by 
adding isotope-labeled amino acids, typically Lys and Arg, containing 15N and 13C isotopes 
(Lys-8 and Arg-10) to the cell culture medium during several passages. A key feature and 
advantage of SILAC is the possibility to detect specific changes in protein interactions by 
subtractive analysis, greatly reducing non-specific background and increasing the signal/noise 
ratio [155]. To assess feasibility of a SILAC proteomic approach in the follow-up of my 
project, I have performed a first set of preliminary studies that will be briefly summarized.  
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The putative LASV entry factors on human DCs are proteins or protein-bound entities: 
A major restriction of SILAC for the identification of viral entry factors is that the method 
works only with proteins, but not sugars or lipids. In a first step, we sought to validate the 
protein nature of LASV entry factors in MDDCs. Cells were treated with a series of proteases, 
lipases, or glycosidases, and the effect of treatment on subsequent infection assessed. 
Treatment with the proteases trypsin and proteinase K resulted in >98% reduction of rLCMV-
LASVGP infection, but hardly affected infection with rLCMV-VSVG, which uses a non-
protein receptor. Treatment of cells with different phospholipases, PNGaseA, which remove 
all types of N-glycans and O-glycosidase, which hydrolyzes most O-linked sugars, had no 
significant effect on infection. These data suggest that the putative LASV entry factor(s) on 
MDDC are likely proteins or protein-linked entities, supporting a SILAC-based proteomic 
approach. 
 
THP-1-derived MDDC are a suitable DC model: SILAC requires labeling of cells with 
heavy amino acids during several passages, limiting the use of primary cells. The human 
monocyte-derived cell line THP-1 can be differentiated in presence of PMA and IL-4 into a 
DC-like phenotype that shows key features of MDDC, including up-regulation of DC-SIGN 
[156]. Comparing receptor use and entry of rLCMV-LASVGP in THP-1-derived MDDC with 
primary cells revealed that the virus enters both cell types in a DG-independent manner 
facilitated by DC-SIGN. Blocking of DC-SIGN with antibodies reduced productive infection 
of rLCMV-LASVGP by <50%, suggesting the presence of alternative receptor(s) in THP-1-
derived MDDC. However, I am aware of the limitations of the model and recommend 
validating candidate entry factors in primary MDDC.    
  
The bait: recombinant LASVGP1 immunoadhesins: Fusion proteins that combine the 
receptor-binding region of a viral GP with the Fc region of an IgG, so-called 
“immunoadhesins”, have been successfully used as baits to identify virus receptors by 
proteomics [157,158]. The laboratory of Dr. Erica Ollman Saphire (Scripps, La Jolla) 
provided us with a fusion protein of LASV GP1 with the Fc part of rabbit IgG. The 
LASVGP1-Fc immunoadhesin was produced in HEK293T cells with good yields (>1 mg/l) 
and purified by protein A affinity chromatography. The purified protein formed dimers, 
showed the expected molecular mass, and bound to α-DG with high affinity, proving 
biological activity.  
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To identify candidate LASV entry factors, THP-1 cells will be cultured for 10 passages in 
medium supplemented with Lys-8/Arg-10 resulting in labeling of > 95% of cellular proteins, 
or normal medium. Cells will then be differentiated into MDDC-like cells for 3-4 days. 
Membrane lysates of cells labeled with heavy amino acids will be incubated with LASVGP1-
Fc and cells kept in normal medium with a control IgG. Co-IP will be performed with protein 
A matrix and proteins will be analyzed by MS. In case the binding affinity of LASV GP1 for 
candidate cellular receptors is too low to allow co-IP, the GP1-receptor complexes could be 
stabilized by chemical cross-linking. To this end, hydrophilic, membrane-impermeable cross-
linkers with short spacers (0.5-1.5 nm) between their reactive groups may be applied. The use 
of cleavable reagents allows the recovery of cross-linked proteins after their isolation. Upon 
cross-linking, the resulting GP-receptor complexes will be immunoprecipitated prior to 
further processing. In case we are unable to detect any candidate proteins upon co-IP 
combined with cross-linking with S-DST or Sulfo-SADP, we will evaluate the new tripartite 
cross-linker TRICEPS, which has longer spacer arms and combines amino reactive functions 
with a carbohydrate-reactive moiety and a biotin tag [159].  
For functional validation, candidate receptor proteins will be expressed in resistant Jurkat 
cells by electroporation of plasmids encoding the corresponding cDNAs. Transduction with a 
functional receptor will render cells more susceptible to infection with rLCMV-LASVGP, but 
not rLCMV-VSVG. Possible cooperation of candidate receptors with DC-SIGN will be 
addressed by co-expression with DC-SIGN.  In a complementary approach, primary MDDC 
will be transfected with siRNA against candidates and control siRNAs using electroporation 
and the knock-down verified by Western blot or RT-PCR. Depletion of a functional receptor 
will increase resistance of transfected cells to rLCMV-LASVGP, but not rLCMV-VSVG. 
Validated receptors in MDDC could then be examined for their expression/role in LASV cell 
entry into other immune cells that are targeted by LASV in vivo, including pDCs and 
macrophages. Considering the pivotal role of DCs in LASV pathogenesis the identification of 
such entry factors is of great importance. 
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2. PROJECT-II 
2.1. Induction of an efficient humoral immune response against MACV GP1 
An initial evaluation of our MACV GP1-NPs vaccine revealed that the immunogen 
conjugated to the surface of the PPS NPs elicited a specific antibody response that was 
significantly stronger than the response obtained after delivery of the non-conjugated 
immunogen. The enhanced magnitude of the antigen-specific antibody response was in line 
with previous reports that demonstrated a strong adjuvant effect of the NPs platform. [5,160]. 
Monitoring of IgG titers as well as determination of the prevalence of IgG subtypes (data not 
shown) over time indicated that the total IgG titers were stable over 6 months. Initially IgG2c 
represented a major IgG subtype and IgG1gradually decreased. However, despite the 
detection of robust IgG titers in ELISA, neutralization assays using a well-characterized 
pseudotype platform showed only low nAbs in sera of mice vaccinated with either NPs-
conjugated or free immunogen. The nAbs titers were not only low, but also faded away over 
time, indicating an only weak and transient nAbs response. This was in contrast to the 
situation in the context of the natural MACV infection that is characterized by robust nAbs 
titers in convalescent serum [118,161]. The low nAbs titers observed in our system were also 
very different from the serological evidence obtained from studies on the live attenuated 
JUNV vaccine Candid 1, in which solid and long-lasting nAbs are detected in vaccinated 
individuals after one immunization [49]. The obvious discrepancy between the nAbs response 
observed in our NPs vaccine when compared to the natural infection or live vaccine raised 
serious concerns about the antigenic nature of our immunogen. In a next step, we therefore 
further investigated the nature of the antibodies present in the sera of vaccinated animals, in 
particular the question what parts of our immunogen are indeed recognized. For this purpose, 
we employed the technology of peptide arrays that have been widely used for epitope 
mapping. Display of the entire immunogen sequence in an array of 20 peptides with an off-set 
of only one aa allowed a comprehensive screen for antigenic peptides. The array data 
pinpointed sequences surrounding the N-terminal HA tag as major antigenic sites. The 
preferential recognition of the HA-tag and in particular the flanking sequences by the 
antibodies present in the sera of vaccinate mice was further confirmed by flow cytometry. 
Since nAbs frequently recognize conformational epitopes [122,162], a possible restriction of 
the peptide array format used in my studies is the presentation of the immunogen in the form 
of linear peptides. To close this gap we sought to test the ability of antibodies in sera of 
vaccinated animals to recognize MACV GP1 in its native conformation present at the virion 
91 
DISCUSSION AND OUTLOOK 
surface. To this end, we expressed recombinant full-length MACV GP in human HEK293 
cells. Previous studies from our group showed that recombinant MACV GP is displayed at the 
surface of HEK293 cells in its native conformation and retains it biological activity [78]. Flow 
cytometry analysis revealed weak but consistent binding of antibodies derived from mice 
vaccinated with the non-conjugated protein to native MACV GP, but no detectable attachment 
of antibodies from mice vaccinated with the NPs-conjugated protein. Together, the data at 
hand suggest that the antibody response elicited by our NPs-conjugated MACV GP1 
immunogen was mainly directed against sequences surrounding the HA-tag, but not the 
MACV GP1 part.   
Together, our results indicated two major flaws in the design of our immunogen. First, 
the introduction of the N-terminal HA-tag generated highly immunogenic sequences at the 
junction between the tag sequence and the surrounding protein. We hypothesize that these 
artificial immunogenic sites present in our vaccine antigen may somehow divert the antibody 
response and may be, at least in part, responsible for the very weak response against the 
MACV GP1-derived structures. This problem has already been solved by the introduction of 
thrombin cleavable HA-tag into MACVΔGP1. After efficient cleavage of thrombin, only a 
stub of two amino acids is retained, which is not expected to give raise to an aberrant antibody 
response.   
Second, the initial procedure used to conjugate the MACV∆GP1 immunogen to NPs 
likely resulted in the disruption of crucial antigenic sites of the protein. As pointed out in the 
results section, the MACV∆GP1antigen produced in HEK293 T cells does not contain free 
cysteine residues. In order to conjugate the protein to the NP surface with the classical thiol-
based coupling chemistry, we performed partial reduction with TCEP in the cold. Assessment 
of receptor binding capacity of the protein after TCEP treatment indicated retention of circa 
50% of its binding activity, suggesting that about half of the protein may have undergone 
irreversible denaturation. Since the coupling efficiency to NPs occurs with < 10% efficiency, 
we cannot exclude a preferential conjugation of the denatured protein that may display a 
higher number of free cysteine side chains. During the in vivo evaluation of our NPs vaccine a 
study was published that identified specific structures of MACV GP1 crucial for receptor 
binding. According to this work, the major interaction of MACV GP1 with TfR1 is mediated 
by two peptide loops that protrude from the MACV GP1 surface, L3 and L10 highlighted in 
Fig.13. Notably, L10 is stabilized by the disulfide bond C220-C229 that is essential for the 
correct orientation of the crucial contact residue F226 of MACV GP1 with TfR1 [12,125]. 
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Since the disulfide bond C220-C229 is located closely to the water-accessible surface of 
MACV GP1, it may react preferentially with TCEP and be cleaved efficiently even under 
mild conditions, disrupting the conformation of L10, which represents a key structural 
element of the receptor binding site. Moreover, the free thiol groups liberated after cleavage 
of the disulfide-bridge C220-C229 may result in conjugation of MACV GP1 in an orientation 
that renders the receptor-binding face and thus putative “neutralizing surface” inaccessible 
(Fig.13).  
 
 
Figure 13. Structure of MACV GP1 with receptor-binding structures highlighted in yellow. The major 
receptor-binding L3 and 10 are highlighted. Note that L10 is stabilized by a disulfide bond formed by the Cys 
residues C220 and C229 (modified from [12]. Below: partial reduction of the disulfide bond C220-C229 and 
subsequent conjugation of MACV GP1 to the NPs surface (for details, please see text).  
 
Considering the problem encountered with the partial reduction and subsequent thiol-
conjugation of our vaccine antigen, we developed a novel strategy NPs coupling employing 
the recently developed “aldehyde (Ald)-tag” that allows site-specific conjugation of 
recombinant proteins under mild non-reducing conditions compatible with the retention of the 
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native conformation of MACV GP1. As outlined in the results section, we successfully 
engineered two new MACV∆GP1 constructs containing Ald-tags either at their N- or C-
terminus. Both constructs could be produced with similar efficiencies, however, the construct 
containing the C-term Ald-tag showed lower reactivity with oxyamines. We therefore decided 
to only use the N-terminally tagged protein for further studies. Ald-tagged MACV∆GP1 
readily reacted with oxyamine-biotin, indicating accessibility and reactivity of the aldehyde 
function. Initial attempts to conjugate the Ald-tagged MACV∆GP1 to NPs resulted in around 
16% conjugation efficiency. Although a good starting point, we are currently optimizing the 
individual conjugation steps to increase efficiency.  
Taking into account the crucial role of the MACV GP1 L3 and L10 for receptor binding, 
we are currently evaluation these peptide sequences as possible vaccine antigens. Molecular 
modeling reveled that a synthetic peptide derived from loop 3 will unlikely adopt the correct 
conformation seen in the MACV GP1-TfR1 co-crystal structure. We therefore focus on L10. 
After successful synthesis of L10, preliminary data suggest sufficient conjugation efficiency 
and we anticipate no problems in the production of the NPs. In a next step, immunization will 
be performed analogous to our studies with MACV∆GP1-NPs. Using the serological assays 
established during my thesis, vaccinated mice will be examined for the development of 
specific antibodies to the L10 sequence and possible nAbs will be tested in our neutralization 
assay with MACV GP pseudotypes. These studies could serve as proof-of-principle for the 
use of conformational peptides linked to NPs in the context of arenaviruses and other human 
pathogenic viruses. Upcoming crystal structures of other arenavirus GPs, in particular LASV 
and JUNV, could be used for the design of analogous peptides.  
   
2.2. Towards a multivalent vaccine against the major pathogenic NW arenaviruses 
Among the South American hemorrhagic fever viruses, JUNV represents the largest 
threat for human health. The rodent Calomys musculinus and several other rodent species 
represent the natural reservoir of the virus. The exact mechanism of rodent to human 
transmission is not known, but there is strong experimental evidence that these viruses are 
infectious as aerosols [163]. While former endemic hot spots are currently cooling off, the 
disease area increases progressively, placing larger populations at risk [118]. Argentine 
hemorrhagic fever (AHF) is a severe illness with hemorrhagic and neurological 
manifestations and a case fatality of 15-30% [26,36,118]. With over 50,000 reported cases so 
far and considering the number of people at risk, JUNV currently represents one of the top 
priority BSL4 pathogens by the National Institute of Health (NIAID/NIH) and the Centers for 
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Disease Control and Protection (CDC). A major goal of the follow-up of my thesis project is 
therefore the development of a bivalent vaccine against MACV and JUNV, which combines 
the two most relevant pathogenic NW arenaviruses. JUNV and MACV are phylogenetically 
and antigenetically closely related. The study of receptor use by pathogenic and non-
pathogenic Clade B arenaviruses showed that all viruses of this Clade use TfR1 orthologues, 
albeit with different species-specificities. The ability of a Clade B New World arenavirus to 
use human TfR1 is absolutely predictive for its potential to cause hemorrhagic fevers in man 
[164]. Virus binding was mapped to a specific region of the apical domain of hTfR1 that 
contained a conserved tyrosine in position 211 in humans, and the reservoir rodents, but not 
other species like rat and mouse [165]. The remarkable conservation of the receptor site 
recognized by MACV and JUNV suggests a similar conservation in the complementary 
receptor-binding site. In line with these recent findings, earlier serological studies indeed 
indicated cross-neutralization of MACV by anti-JUNV nAbs [166]. Together, the classical 
serological evidence and more recent structural data at hand suggest that the development of a 
bivalent JUNV/MACV vaccine is feasible. In a first step we will test our MACV NPs vaccine 
for its potential to generate nAbs that are cross-neutralizing between MACV and JUNV, as 
observed in the natural infection. If this is not the case, we will engineer and produce JUNV 
GP1-derived antigens analogous to our MACV GP1 antigen and produce NPs that display 
both antigens at their surface.  
 
2.3. The challenge of generating a protective NPs vaccine against LASV 
Although the South American hemorrhagic arenaviruses JUNV and MACV represent 
important public health problems, they are virtually dwarfed by the humanitarian impact of 
LASV that causes several hundred thousand infections annually in Western Africa [167]. The 
impact of LASV on public health in Western Africa is perhaps best illustrated by the fact that 
in some regions, >50% of the adult population are seropositive for LASV [168], making 
LASV likely a major cause of death in this part of the world [23]. However, as we have seen 
earlier, there are important differences in the quality of the antibody response between LASV 
and the NW arenaviruses JUNV and MACV [23,118]. While natural infections with JUNV 
and MACV result in robust nAbs titers that are fully protective against re-infection [118], the 
nAbs response against LASV in humans is normally delayed and rather weak [23]. Surveys in 
endemic regions revealed a high prevalence of non-neutralizing serum antibodies against 
LASV NP in survivors of LASV infection, but only low nAbs titers against GP that even 
seem to fade away over time [168]. Despite the only weak nAbs response observed in humans 
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after LASV infection, proof-of-concept studies in animal models demonstrated that nAbs are 
protective against LASV challenge, when given at sufficient titers [47,48,169]. The lack of a 
potent nAbs response against LASV seems reminiscent to the infection with the prototypic 
OW arenavirus LCMV in its natural host, the mouse [134]. Humans are not natural hosts of 
LASV and any extrapolation between the LCMV infection in the mouse and human Lassa 
fever appears therefore questionable. However, the lack of nAbs in both infection paradigms 
is intriguing and suggests that LASV and LCMV GP1 either lack inherent antigenicity or that 
the envelope GP1 of LASV and LCMV are presented to the host’s immune system in the 
context of the natural primo infection in a way that prevents the production of potent nAbs.  
Potential lower antigenicity of LASV GP1 could be due to different reasons. On many 
viral envelope GPs, N-glycans shield potential antigenic sites against the humoral immune 
response [162]. Indeed, when compared to the NW viruses JUNV and MACV, LASV GP1 
contains more actual N-glycosylation sites, suggesting the presence of a more extensive 
“glycan shield” [170]. Another important difference between the GP1 of JUNV and MACV 
on the one hand and LASV on the other hand is receptor use. JUNV and MACV attach to the 
apical surface of hTfR1 via an extended molecular protein-protein interaction surface [125]. 
In contrast, LASV and LCMV recognize their receptor via conserved xylose/glucuronic acid 
co-polymer sugars attached to the N-terminal domain of DG by the glycosyltranserase 
LARGE [140,145,171] in a lectin-type binding. One might speculate that the extended 
molecular surface of MACV and JUNV GP1 interacting with hTfR1 could be easily 
recognized by antibodies, whereas this may be less the case for the sugar binding pocket of 
LASV GP1. To experimentally address these issues, I propose to use our PPS NPs in a 
comparative study testing the antigenicity of MACV GP1 and LASV GP1 in the context of a 
normalized vaccine platform. For this purpose, LASV GP1 analogues to our newest-
generation MACVΔGP1 are currently produced in the laboratory. The corresponding 
MACVΔGP1 and LASVΔGP1 containing Ald-tags and cleavable HA-tags will be conjugated 
to PPS NPs and evaluated side-by-side for their ability to elicit a nAbs response. We expect to 
see at least some nAbs development upon vaccination with MACVΔGP1-NPs. Significantly 
lower nAbs titers in response to LASVΔGP1-NPs would indicate an inherent difference in the 
antigenicity of MACV and LASV GP1. Comparable levels of nAbs generated upon 
vaccination with MACVΔGP1-NPs and LASVΔGP1-NPs would indicate that the apparent 
lack of nAbs in LASV primo infection is not an inherent property of the GP1, but likely due 
to important differences in antigen presentation and/or immunoregulation in the context of the 
two infections. In case we would observe marked differences between LASV and MACV 
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with LASV GP1 being less antigenic, we could try to improve the NPs platform and the 
LASV GP1 immunogen in an iterative way to achieve induction of nAbs. In a first step, we 
could perform peptide array analysis of the sera obtained from immunization with 
LASVΔGP1-NPs. The goal would be to identify potential neutralizing and in particular 
possible immunodominant non-neutralizing epitopes on LASVGP1. In case we would observe 
a predominantly non-neutralizing antibody response, we would try to define the dominant 
non-neutralizing epitopes, as they may act as “decoys” to divert the humoral immune 
response. Such “decoy” epitopes could be subjected to “silencing” by site-directed 
mutagenesis and introduction of novel N-glycosylation sites that will “shield” such epitopes 
allowing a more focused response to putative neutralizing epitopes.  
 
2.4. Induction of an efficient T cell response 
Our studies demonstrated that our PPS NPs conjugated to LCMV-derived MHC class I 
peptides were able to trigger a strong and specific anti-viral CD8 T cell response in mice. This 
response was much higher after a prime-boost vaccination strategy than after a unique 
immunization, which was somehow expected from the available literature. In addition, the 
functional hierarchy of the CD8 T cell epitopes seemed maintained upon vaccination with the 
conjugated NPs. However, more epitopes need to be tested to confirm this observation. To 
this end we will generate a complete set of NPs displaying known H2-Db restricted CD8 T 
epitopes of LCMV in C57BL/6 mice. Specifically, we will study the epitopes GP33-41, NP396-
404, and GP276-286, as well as the subdominant epitope GP92-101. This will allow us to monitor 
the frequencies of epitope-specific cells and conservation of CTL epitope hierarchy.   
A crucial next step will be the systematic analysis of the CTL response to our NPs in 
comparison with a non-infectious vaccine paradigm (DNA vaccination) and the LCMV primo 
infection. The comparison with these systems will allow benchmarking the NPs platform’s T 
cell response against those of the DNA vaccine and natural infection. DNA immunization has 
been studied extensively in the LCMV model and, in general, plasmid DNA encoding LCMV 
proteins induced better CD8 T cell responses than antibody responses. Depending on the 
antigen, mouse strain, and route of inoculation, DNA vaccination using minigenes coding for 
immunodominant CTL epitopes conferred insufficient protection [172,173], whereas plasmid 
DNA encoding full-length NP or GP resulted in at least partial protection against LCMV 
infection [174,175,176]. I propose to use defined expression plasmids for full-length LCMV 
NP and GP that will be administered by intramuscular injections [175].  
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For benchmarking relative to the natural infection, mice will be infected with a low dose 
(105 PFU) of the low virulence LCMV ARM53b strain. In this classical paradigm, the CTL 
response peaks around day 8 post infection, following by a contraction period and memory 
formation. Mice clear virus after 15 days. Primo infection with LCMV ARM53b in C57BL/6 
mice results in a CD8 T cell response with the following hierarchy of epitopes: NP396-404 > 
GP33-41 > GP276-286 >> GP92-101. Upon viral re-challenge, memory CD8 T cells rapidly activate 
and proliferate leading to a potent secondary anti-viral CTL response that confers life-long 
protection of the animal. 
In a next step, our MHC I peptide NPs will be tested in a well-established challenge 
model in vivo at 8 weeks after vaccination. Specifically, vaccinated mice will be infected with 
high doses of the more virulent LCMV strain clone-13 (cl-13). When given at a dose of 2x106 
PFU i.v. in naïve C57BL/6 mice, LCMV cl-13 induces a transient immunosuppression due to 
CTL exhaustion and establishes a persistent infection that lasts for 60-90 days. The quantity 
and quality of memory T cells will be monitored by MHC I tetramer staining. After 48 hours 
of challenge, splenocytes will be isolated and analyzed after peptide stimulation by 
intracellular cytokine staining (IFN- and TNF-α), and in a CTL killing assay. In naïve mice, 
upon primary infection, anti-viral CD8 T cells are undetectable at 48 hours of infection and 
any significant anti-viral CD8 T cell activity at this time point must stem from memory T 
cells induced by our vaccine.  Kinetics of serum viral load will be monitored in blood of mice 
to assess protection against the viremia normally observed in the LCMV cl-13 paradigm.   
This evaluation of the PPS NPs vaccine in the context of the LCMV model will represent 
the first extensive characterization of this platform with an infection of a pathogen in its 
natural host and close an important gap in our current knowledge about its possibilities. The 
extensive body of data available on the LCMV model, either in the natural infection or other 
vaccine systems, e.g. DNA vaccines, will allow a valid comparison of its future potential.   
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PCR generation of MACV∆GP1 and LASV∆GP1 constructs DNA 
MACV∆GP1 and MACV∆CGP1 (Carvallo NC_005078) fragments were produced by PCR 
using as template the respective full length glycoprotein precursors (GPC) subcloned in 
pCAGGS vector. All constructs were further subcloned in the the pcDNA 3.1 int A 
expression vector, kindly provided by Dr. Branco (Tulane University Health Sciences Center, 
New Orleans, LA, USA). 
Amplification primers:  
MACV∆GP1: 
Forward:  5’-ATTCCCGGGCTCCCATCTCTCTGCATGCTT-3’  
Reverse:  5’-CGATCTCGAGTCAGTCAGCCCTTGTCGTCGTCGTCCTTGTAGTCGGCAGCA 
GACCTCTCAAAGTTGAGATG-3’ 
MACV∆CGP1: 
Forward: 5’-ATTCCCGGGTGTCTCCCATCTCTCTGCATGCTT-3’,  
Reverse: 5’- CGATCTCGAGTCAGTCAGCCCTTGTCGTCGTCGTCCTTGTAGTCGGCAGC 
AGACCTCTCAAAGTTGAGATG-3’ 
Ald-MACV∆GP1 construct sequence: 
5’ -AAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGG 
    AATTCGGCTTGGGGATATCCACCATGGAGACAGACACACTCCTGCTATGG 
    GTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACCTGTGCACCCCCAG 
    CCGGGCCGCCCTGCTGACCGGCCGGCCCGGGCTCCCATCTCTCTGCATGC 
    TTAACAATAGTTTTTATTATATGAGGGGAGGTGTGAACACCTTCCTGATT 
    CGTGTTTCTGATATTTCAGTCCTCATGAAGGAGTATGATGTATCAATCTA 
    TGAACCAGAAGACCTTGGAAATTGTCTTAACAAGTCTGACTCAAGCTGGG 
    CTATTCATTGGTTCTCAAATGCTTTGGGACATGACTGGCTTATGGATCCT 
    CCAATGCTATGTAGAAACAAGACAAAGAAGGAGGGATCTAACATTCAATT 
    CAACATCAGCAAAGCTGATGATGCCAGAGTGTATGGAAAGAAGATAAGAA 
    ATGGTATGAGGCATCTCTTCAGGGGCTTCCATGACCCGTGTGAGGAAGGG 
    AAAGTGTGCTACCTGACCATCAATCAGTGTGGTGACCCCAGTTCCTTTGA 
    CTACTGTGGCGTGAATCATCTTTCCAAATGTCAGTTTGACCATGTGAACA 
    CCCTTCATTTCCTTGTGAGAAGTAAGACACATCTCAACTTTGAGAGGTCT 
    GCTGCCCTTGTCCCACGTGGTTCTTATCCATATGATGTTCCAGATTATGC 
    TTGACTGACTCGAGATCG-3’ 
 
Restriction sites HindIII, XmaI and XhoI are underlined. The red highlighted region 
corresponds to IgK sequence from pDisplay vector and is fused to the FGE full length 
recognition region in yellow (HindIII-XmaI). This sequence was synthesized by GeneArt® 
Gene Synthesis (Life technologies™). The rest of the construct (grey, green and violet 
highlight) was generated by PCR (XmaI-XhoI) using the following primers: 
Forward: 5’-TTACCCGGGCTCCCATCTCTCTGCATGCTT-3’,  
Reverse: 5’CGATCTCGAGTCAGTCAAGCATAATCTGGAACATCATATGGATAAGAACCA 
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CGTGGGACAAGGGCAGCAGACCTCTCAAAGTTGAG-3’ 
MACV∆GP1-Ald construct sequence: 
5’-AAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAGTGTGCTGG 
   AATTCGGCTTGGGGATATCCACCATGGAGACAGACACACTCCTGCTATGG 
   GTACTGCTGCTCTGGGTTCCAGGTTCCACTGGTGACTATCCATATGATGT 
   TCCAGATTATGCTCTTGTCCCACGTGGTTCTCCCGGGCTCCCATCTCTCT 
   GCATGCTTAACAATAGTTTTTATTATATGAGGGGAGGTGTGAACACCTTC 
   CTGATTCGTGTTTCTGATATTTCAGTCCTCATGAAGGAGTATGATGTATC 
   AATCTATGAACCAGAAGACCTTGGAAATTGTCTTAACAAGTCTGACTCAA 
   GCTGGGCTATTCATTGGTTCTCAAATGCTTTGGGACATGACTGGCTTATG 
   GATCCTCCAATGCTATGTAGAAACAAGACAAAGAAGGAGGGATCTAACAT 
   TCAATTCAACATCAGCAAAGCTGATGATGCCAGAGTGTATGGAAAGAAGA 
   TAAGAAATGGTATGAGGCATCTCTTCAGGGGCTTCCATGACCCGTGTGAG 
   GAAGGGAAAGTGTGCTACCTGACCATCAATCAGTGTGGTGACCCCAGTTC 
   CTTTGACTACTGTGGCGTGAATCATCTTTCCAAATGTCAGTTTGACCATG 
   TGAACACCCTTCATTTCCTTGTGAGAAGTAAGACACATCTCAACTTTGAG 
   AGGTCTGCTGCCCTGTGCACCCCCAGCCGGGCCGCCCTGCTGACCGGCCG 
   GTGACTGACTCGAGATCG-3’ 
 
Restriction sites HindIII, XmaI and XhoI are underlined. The red highlighted region 
corresponds to IgK sequence from pDisplay vector and is fused to the HA tag (violet) 
followed by the thrombin cleavage site (green) (HindIII-XmaI). This sequence was 
synthesized by GeneArt® Gene Synthesis (Life technologies™).  The rest of the construct 
(grey and yellow highlight) was generated by PCR (XmaI-XhoI) using the following primers: 
Forward:  5’-TTACCCGGGCTCCCATCTCTCTGCATGCTT-3’ 
Reverse:  5’-CGATCTCGAGTCAGTCACCGGCCGGTCAGCAGGGCGGCCCGGCTGGGGGT 
GCACAGGGCAGCAGACCTCTCAAAGTTGAGATGTGTCTTACT-3’ 
Peptides and loops 
LCMV glycoprotein derived peptides, LCMVGP33-41 (KAVYNFATC), LCMVGP276-286 
(SGVENPGGYCL), and LCMVNP396-404 (CAIFQPQNGQFI), the cysteine residue was 
artificially added to this peptide to allow further conjugation) and the ovalbumine peptide 
(CSIINFEKL, the cysteine residue was artificially added to this peptide to allow further 
conjugation) were obtained from PolyPeptide group (France). 
The MACV GP1 loops 3 and 10 were synthesized by the Laboratory of Therapeutic Proteins 
and Peptides-LPPT at the EPFL. 
Cell culture 
HEK 293 T cells were grown and maintained in culture in complete Dulbecco's Modified 
Eagle Medium (DMEM) medium (DMEM-GlutaMAX™, 10 % fetal calf serum (FCS), 1% 
penicillin/streptomycin). 
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Antigen production 
In house production: 
HEK 293 T cells were grown in T75 flasks to 80-90 % confluence. One day before 
transfection 15 cm cell culture dishes were pre-treated with poly-lysine (~ 5 ml/ plate, 100 
μg/ml in distilled water, (Poly-L-lysine hydrobromide, 50m/ml)) for 30 minutes. Plates were 
washed at least 3 times with distilled water. Cells were trypinized (around 300 μl of 
TRIPLEX) briefly, plated in a 15 cm dish (30 ml/well) and then incubated for 16-20 hours at 
37 °C with 5% CO2. Cells were transfected by calcium phosphate with the appropriated 
constructs and incubated at 37 °C with 5% CO2 for 6-12h. Then the transfection mix was 
removed and cells washed once with a serum free medium (293 SFM II). Complete serum 
free medium (293 SFM II, 2 mM glutamine, 10 mM HEPES) was added (20 ml/15 cm dish) 
and cells were incubated at 37°C, 5 % CO2. After 48h, the supernatants were harvested. The 
proteins were either extracted by methanol/chloroform precipitation (expression level 
checking) or directly purified from 0.22μm or 0.45μm filtered cell supernatants by affinity 
chromatography using an anti-HA column. 
Out-source production: 
As a high amount of purified proteins were required for our experiments. The in house 
produced plasmids containing the constructs of interest were further amplified by a local 
company (Fasteris SA, Geneva, Switzerland). The plasmid DNA coding for each generated 
construct was then provided to the EPFL protein expression core facility managed by Dr. 
David Hacker for high scale protein production  [177]. 
Affinity chromatography purification 
All antigens were purified using an anti-HA affinity matrix (Clone 3F10, Roche). Briefly, the 
affinity matrix was washed with wash buffer (20 mM Tris pH 7.5, 0.1 M NaCl, 0.1 mM 
EDTA, 0.05% of Tween 20 (Applichem)), centrifuged 4 min at 2000 rpm and loaded into a 
column (0.5-1.0 ml final volume). Then 10 column bed volumes of equilibration buffer were 
added (20 mM Tris pH 7.5, 0.1 M NaCl, 0.1 mM EDTA). The previously prepared protein 
supernatants (0.22 or 0.45 μm filtered) were loaded into the affinity matrix column. The 
matrix was washed with a minimum of 20 column bed-volumes of wash buffer at +15 to 
+25°C to remove nonspecifically bound protein. Affinity matrix column elution was 
performed by adding 3 times 1 bed-volume of Elution buffer (1mg/ml of HA peptide in 
equilibration buffer) and incubating it for 15 min at 37°C.  
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Immunobloting 
Protein expression levels and purification yields were checked by Western blotting. Briefly, 
proteins were mixed with either non-reducing or reducing (100 mM Dithiothreitol) SDS-
PAGE sample buffer (31.1mM Tris-HCl pH 6.8, 10% glycerol, 1% sodium dodecyl sulphate, 
2.5 %) and loaded into 7.5% or 12% polyacrylamide gels respectively, followed by either 
Coomassie blue staining or transfer of the proteins onto a nitrocellulose membrane 
(Whatman®). All proteins were detected with anti-HA (3F10) or anti-FLAG (M2) primary 
antibodies followed by polyclonal anti-rat or anti-mouse horseradish peroxidase (HRP) 
conjugated, respectively. Proteins were revealed by further incubation with HRP LiteAblot® 
chemiluminescent substrate (Euroclone) and transferred on an X-ray film. 
Thrombin cleavage of the HA-tag 
After affinity matrix purification the HA-tagged constructs were buffer exchanged by over-
night (O/N) dialysis to thrombin cleavage buffer (20 mM Tris-HCl pH 8.4, 150mM NaCl, 2.5 
mM CaCl2). Thrombin-agarose (Novagen®), 3 units/mg of protein, was added to the buffer 
exchanged protein and incubated O/N ant RT (23-25°) under mild shaking. The thrombin-
agarose was then removed by centrifugation using a spin column (Novagen®) provided by the 
manufacturer. 
Assessing the aldehyde tag reactivity 
The aldehyde-tagged protein was reacted with 300μM aminooxy-biotin for 2h at RT in 100 
μM Mes (pH 5.5) [132]. Protein loading was determined by Coomassie blue staining. Western 
blots were probed with streptavidin-HRP (1:1000 dilution; Millipore). Proteins were revealed 
by further incubation with HRP LiteAblot® chemiluminescent substrate (Euroclone) and 
transferred on an X-ray film. 
Conjugation via reactive thiol residues 
Conjugation of MACV∆GP1 onto the nanoparticles was carried by reducing the protein with 
TCEP beads in a 5:1 ratio (v/v) at 37°C for 1h in 50 mM HEPES, 50mM NaCl pH 7.4. The 
reduced protein was purified and mixed immediately with pyridyl disulfide functionalized 
nanoparticles, and left to react for 2 hours at RT. Conjugated nanoparticles were purified by 
size exclusion chromatography using a Sepharose CL6B resin and 50 mM HEPES, 50 mM 
NaCl pH7.4 as eluent. The conjugation efficiency was analyzed by taking the area under the 
curve of an elution profile detected by fluorescamine. Protein in the particle fraction was 
confirmed by Western blotting using the anti-HA antibody. 
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Conjugation via reactive hydrazine or oxyamine 
A solution of 500μL containing 35mg/ml of NPs holding NH2 terminal groups in 0.1M 
sodium phosphate buffer, 50mM NaCl, pH 8.0 was mixed with 2mg of HyNIC reagent 
(Solulink™) in 50μL of DMF.  After 16h, the HyNIC activated NPs were transferred into a 
dialysis membrane of 5KDa MW and dialyzed extensively against 0.1 sodium phosphate 
buffer pH 6.0. (conjugation buffer).  Finally, NPs were mixed with a 500μL of solution of 
Ald-MACV-GP1 (1mg/ml) in conjugation buffer, and let to react during 2 days at 4°C. The 
protein-NPs conjugates were purified by size exclusion chromatography on 
a Sepharose CL6B resin using a solution of 0.9% NaCl as eluent. The conjugation efficiency 
was analyzed by taking the area under the curve of an elution profile detected by 
fluorescamine. 
Receptor binding assay 
MACV∆GP1 binding to hTfr1 was verified by adding the protein at various concentrations to 
Chinese hamster ovary subclone K1 (CHO-K1) cells transiently transfected with hTfr1. 
Binding was measured by flow cytometry on a CyAn™ ADP Analyzer (Beckman Coulter). 
MACV∆GP1was detected by a polyclonal rabbit anti-FLAG antibody, followed by a 
secondary anti-rabbit antibody conjugated with Alexafluor 647. Only live (Live/Dead violet, 
Invitrogen), hTfr1+ (PE-anti hTfr1 clone M-A712) cells were analyzed by taking the 
normalized geometric mean of the FL8 channel, which reflects the AF647 fluorescence 
intensity. Analysis was done using FlowJo (version 7.5.5, Tree Star) software. 
Humoral responses 
Groups of five age- and sex-matched C57/Bl6 mice were immunized intradermally on their 
hind legs as described previously in the part 1 of project 2 results section. Blood draws were 
performed at defined time points. IgG antibody titers were measured by ELISA using purified 
MACV∆GP1 immobilized in microtiter plates (Greiner bio-one) and IgG class specific 
secondary antibodies HRP coupled.  
T cell responses   
Six age- and sex-matched C57/Bl6 mice were vaccinated intradermally on their hind legs as 
described previously in the part 2 of project 2 results section. At day 21 mice were sacrificed 
and spleens collected. T cell responses were measure by detecting IFN-γ production by 
splenic epitope-specific CD8 T cells by ELISpot and intracellular staining followed by flow 
cytometry. In brief, 105 splenocytes were plated in 96 well microplates and restimulated with 
104 
MATERIALS AND METHODS 
the corresponding peptide. The ELISpot was developed according to the manufacturer’s 
instructions (ELISPOT READY-SET-GO!), eBioscience). For intracellular cytokine staining, 
splenocytes were restimulated in vitro with respective peptides for 6h and brefeldin A was 
added for the last 3h of incubation. Splenocytes were surface stained to identify CD8 T cells 
with CD3ε and CD8α, and intracellular stained for IFN-γ followed by analysis by flow 
cytometry. Controls were restimulated with PMA/ionomycin.  
Neutralization assay 
MACVGPC pseudotyped virus carrying the reporter gene luciferase were pre-incubated with 
experimental sera from mice for 45 min. and then added at 40x dilution to A549 cells for 48h. 
Luminescence was revealed by removing the cell medium and adding 100 μl/well of  Bright-
Glo™  (Promega). The luminescent signal was then measured with a TriStar LB 941 
luminometer (Berthold). Luciferase luminescence was normalized to wells infected with 
pseudotyped virus only and wells which saw no virus.  
CelluspotsTM 
CelluspotsTM slides were blocked with PBS-Tween 0.02% containing and 5% milk for 1h, 
followed by 2h incubation at room temperature with mice sera (1/200 dilution in PBS-Tween 
0.02% containing 5% milk). Slides were further washed 3 times 5 min. with PBS-Tween 
0.02% and incubated with an anti-mouse HRP-conjugated antibody (diluted 1/2000 in PBS-
Tween 0.02%, and 5% milk) for 1h. Finally slides were washed 3 times 5 min. with Tween 
0.02% containing and 5% milk. The epitopes were revealed by further incubation with HRP 
LiteAblot® chemiluminescent substrate (Euroclone) and transferred on an X-ray film. 
Detection of Abs binding to native MACVGP 
Sera from selected mice from each vaccination group were incubated for 1 hour at 4°C at 1/50 
dilution with MACGPC, DGE (dystroglycan HA-tagged, positive control) and pCAGGS 
(empty vector, negative control) transfected HEK 293 T cells. Cells were washed twice with 
PBS/1%FCS. Secondary antibody rabbit anti-mouse-phycoerythrin labeled was added for 45 
min at 4 °C. Cells were washed twice again and responses were measured by flow cytometry. 
  
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
 
  
106 
 REFERENCES 
 
1. EPFL (2011) Laboratory of Lymphatic and Cancer Bioengineering LLCB,  Biomaterials 
design for immunomodulation. 
2. Burri DJ, Palma JR, Kunz S, Pasquato A (2012) Envelope Glycoprotein of Arenaviruses. 
Viruses 4: 2162-2181. 
3. Kourtis IC, Hirosue S, de Titta A, Kontos S, Stegmann T, et al. (2013) Peripherally 
Administered Nanoparticles Target Monocytic Myeloid Cells, Secondary Lymphoid 
Organs and Tumors in Mice. PLoS ONE 8: e61646. 
4. Moraz M-L, Kunz S (2011) Pathogenesis of arenavirus hemorrhagic fevers. Expert Review 
of Anti-infective Therapy 9: 49-59. 
5. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, et al. (2007) Exploiting 
lymphatic transport and complement activation in nanoparticle vaccines. Nat 
Biotechnol 25: 1159-1164. 
6. Buchmeier MJ, de la Torre JC, Peters CJ (2007) Arenaviridae: the viruses and their 
replication. In: Knipe DL, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: 
Lippincott-Raven. pp. p. 1791-1828. 
7. Zapata J, Salvato M (2013) Arenavirus Variations Due to Host-Specific Adaptation. 
Viruses 5: 241-278. 
8. Emonet SF, de la Torre JC, Domingo E, Sevilla N (2009) Arenavirus genetic diversity and 
its biological implications. Infection, Genetics and Evolution 9: 417-429. 
9. de la Torre JC (2009) Molecular and cell biology of the prototypic arenavirus LCMV: 
implications for understanding and combating hemorrhagic fever arenaviruses. Ann N 
Y Acad Sci 1171 Suppl 1: E57-64. 
10. Rojek JM, Kunz S (2008) Cell entry by human pathogenic arenaviruses. Cell Microbiol 
10: 828-835. 
11. Cao W, Henry MD, Borrow P, Yamada H, Elder JH, et al. (1998) Identification of α-
Dystroglycan as a Receptor for Lymphocytic Choriomeningitis Virus and Lassa Fever 
Virus. Science 282: 2079-2081. 
12. Radoshitzky SR, Longobardi LE, Kuhn JH, Retterer C, Dong L, et al. (2011) Machupo 
Virus Glycoprotein Determinants for Human Transferrin Receptor 1 Binding and Cell 
Entry. PLoS ONE 6: e21398. 
13. Shimojima M, Stroher U, Ebihara H, Feldmann H, Kawaoka Y (2012) Identification of 
cell surface molecules involved in dystroglycan-independent lassa virus cell entry. J 
Virol 86: 2067-2078. 
14. Rojek JM, Sanchez AB, Nguyen NT, de la Torre JC, Kunz S (2008) Different 
mechanisms of cell entry by human-pathogenic Old World and New World 
arenaviruses. J Virol 82: 7677-7687. 
15. Pasqual G, Rojek JM, Masin M, Chatton JY, Kunz S (2011) Old world arenaviruses enter 
the host cell via the multivesicular body and depend on the endosomal sorting 
complex required for transport. PLoS Pathog 7: e1002232. 
16. Martinez MG, Cordo SM, Candurra NA (2007) Characterization of Junin arenavirus cell 
entry. J Gen Virol 88: 1776-1784. 
17. Perez M, de la Torre JC (2003) Characterization of the genomic promoter of the 
prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 77: 1184-1194. 
18. Baird NL, York J, Nunberg JH (2012) Arenavirus infection induces discrete cytosolic 
structures for RNA replication. J Virol 86: 11301-11310. 
19. Perez M, Craven RC, de la Torre JC (2003) The small RING finger protein Z drives 
arenavirus budding: implications for antiviral strategies. Proc Natl Acad Sci U S A 
100: 12978-12983. 
107 
 REFERENCES 
20. Strecker T, Eichler R, Meulen J, Weissenhorn W, Dieter Klenk H, et al. (2003) Lassa 
virus Z protein is a matrix protein and sufficient for the release of virus-like particles 
[corrected]. J Virol 77: 10700-10705. 
21. Urata S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J (2006) Cellular factors required for 
Lassa virus budding. J Virol 80: 4191-4195. 
22. Capul AA, Perez M, Burke E, Kunz S, Buchmeier MJ, et al. (2007) Arenavirus Z-
glycoprotein association requires Z myristoylation but not functional RING or late 
domains. J Virol 81: 9451-9460. 
23. McCormick JB, Fisher-Hoch SP (2002) Lassa fever. Curr Top Microbiol Immunol 262: 
75-109. 
24. Peters CJ (2002) Human infection with arenaviruses in the Americas. Current topics in 
microbiology and immunology 262: 65-74. 
25. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES (1987) A prospective study 
of the epidemiology and ecology of Lassa fever. J Infect Dis 155: 437-444. 
26. Weissenbacher MC, Laguens RP, Coto CE (1987) Argentine hemorrhagic fever. Curr Top 
Microbiol Immunol 134: 79-116. 
27. Yun NE, Walker DH (2012) Pathogenesis of Lassa Fever. Viruses 4: 2031-2048. 
28. Grant A, Seregin A, Huang C, Kolokoltsova O, Brasier A, et al. (2012) Junín Virus 
Pathogenesis and Virus Replication. Viruses 4: 2317-2339. 
29. Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot M-C, et al. (2004) Lassa Virus 
Infection of Human Dendritic Cells and Macrophages Is Productive but Fails to 
Activate Cells. The Journal of Immunology 172: 2861-2869. 
30. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic Cells Induce 
Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo. The 
Journal of Experimental Medicine 194: 769-780. 
31. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-
Specific Inhibition of Effector T Cell Function in Humans after Injection of Immature 
Dendritic Cells. The Journal of Experimental Medicine 193: 233-238. 
32. Pannetier D, Reynard S, Russier M, Journeaux A, Tordo N, et al. (2011) Human Dendritic 
Cells Infected with the Nonpathogenic Mopeia Virus Induce Stronger T-Cell 
Responses than Those Infected with Lassa Virus. J Virol 85: 8293-8306. 
33. Le Bon A, Tough DF (2002) Links between innate and adaptive immunity via type I 
interferon. Current Opinion in Immunology 14: 432-436. 
34. Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, et al. (2009) Early and strong 
immune responses are associated with control of viral replication and recovery in lassa 
virus-infected cynomolgus monkeys. J Virol 83: 5890-5903. 
35. Walker DH, McCormick JB, Johnson KM, Webb PA, Komba-Kono G, et al. (1982) 
Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol 107: 349-356. 
36. Harrison LH, Halsey NA, McKee KT, Jr., Peters CJ, Barrera Oro JG, et al. (1999) Clinical 
case definitions for Argentine hemorrhagic fever. Clin Infect Dis 28: 1091-1094. 
37. Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: progress and challenges. 
Nat Med 10: S110-121. 
38. Kunz S (2009) The role of the vascular endothelium in arenavirus haemorrhagic fevers. 
Thromb Haemost 102: 1024-1029. 
39. Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, et al. (2006) 
Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl 
J Med 354: 2235-2249. 
40. Palacios G, Druce J, Du L, Tran T, Birch C, et al. (2008) A new arenavirus in a cluster of 
fatal transplant-associated diseases. N Engl J Med 358: 991-998. 
108 
 REFERENCES 
41. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, et al. (1987) Clinical 
virology of Lassa fever in hospitalized patients. J Infect Dis 155: 456-464. 
42. Russier M, Pannetier D, Baize S (2012) Immune Responses and Lassa Virus Infection. 
Viruses 4: 2766-2785. 
43. Hayes M, Salvato M (2012) Arenavirus Evasion of Host Anti-Viral Responses. Viruses 4: 
2182-2196. 
44. Botten J, Sidney J, Mothé BR, Peters B, Sette A, et al. (2010) Coverage of Related 
Pathogenic Species by Multivalent and Cross-Protective Vaccine Design: 
Arenaviruses as a Model System. Microbiology and Molecular Biology Reviews 74: 
157-170. 
45. Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, et al. (2009) Early and Strong 
Immune Responses Are Associated with Control of Viral Replication and Recovery in 
Lassa Virus-Infected Cynomolgus Monkeys. Journal of Virology 83: 5890-5903. 
46. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa fever. 
Effective therapy with ribavirin. N Engl J Med 314: 20-26. 
47. Jahrling PB (1983) Protection of Lassa virus-infected guinea pigs with Lassa-immune 
plasma of guinea pig, primate, and human origin. J Med Virol 12: 93-102. 
48. Jahrling PB, Peters CJ (1984) Passive antibody therapy of Lassa fever in cynomolgus 
monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 
44: 528-533. 
49. Enria DA, Barrera Oro JG (2002) Junin virus vaccines. Curr Top Microbiol Immunol 263: 
239-261. 
50. Trombetta ES, Mellman I (2005) Cell biology of antigen processing in vitro and in vivo. 
Annu Rev Immunol 23: 975-1028. 
51. Burgdorf S, Kurts C (2008) Endocytosis mechanisms and the cell biology of antigen 
presentation. Curr Opin Immunol 20: 89-95. 
52. van Kooyk Y (2008) C-type lectins on dendritic cells: key modulators for the induction of 
immune responses. Biochem Soc Trans 36: 1478-1481. 
53. van Kooyk Y, Geijtenbeek TB (2003) DC-SIGN: escape mechanism for pathogens. Nat 
Rev Immunol 3: 697-709. 
54. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, et al. (2000) 
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-
infection of T cells. Cell 100: 587-597. 
55. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR (2002) DC-SIGN-
mediated internalization of HIV is required for trans-enhancement of T cell infection. 
Immunity 16: 135-144. 
56. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, et al. (2002) C-type lectins DC-
SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 76: 
6841-6844. 
57. Simmons G, Reeves JD, Grogan CC, Vandenberghe LH, Baribaud F, et al. (2003) DC-
SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages 
and endothelial cells. Virology 305: 115-123. 
58. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, et al. (2004) 
CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. 
Proc Natl Acad Sci U S A 101: 15748-15753. 
59. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, et al. (2003) 
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp 
Med 197: 823-829. 
60. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz O, Fieschi F, et al. (2003) Dendritic-
cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of 
109 
 REFERENCES 
human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4: 723-
728. 
61. Davis CW, Nguyen HY, Hanna SL, Sanchez MD, Doms RW, et al. (2006) West Nile 
virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and 
infection. J Virol 80: 1290-1301. 
62. Lozach PY, Kuhbacher A, Meier R, Mancini R, Bitto D, et al. (2011) DC-SIGN as a 
receptor for phleboviruses. Cell Host Microbe 10: 75-88. 
63. Parker WB (2005) Metabolism and antiviral activity of ribavirin. Virus Res 107: 165-171. 
64. Kilgore PE, Peters CJ, Mills JN, Rollin PE, Armstrong L, et al. (1995) Prospects for the 
control of Bolivian hemorrhagic fever. Emerg Infect Dis 1: 97-100. 
65. Andrei G, De Clercq E (1993) Molecular approaches for the treatment of hemorrhagic 
fever virus infections. Antiviral Res 22: 45-75. 
66. Andrei G, De Clercq E (1990) Inhibitory effect of selected antiviral compounds on 
arenavirus replication in vitro. Antiviral Res 14: 287-299. 
67. Candurra NA, Maskin L, Damonte EB (1996) Inhibition of arenavirus multiplication in 
vitro by phenotiazines. Antiviral Res 31: 149-158. 
68. Wachsman MB, Lopez EM, Ramirez JA, Galagovsky LR, Coto CE (2000) Antiviral 
effect of brassinosteroids against herpes virus and arenaviruses. Antivir Chem 
Chemother 11: 71-77. 
69. Cordo SM, Candurra NA, Damonte EB (1999) Myristic acid analogs are inhibitors of 
Junin virus replication. Microbes Infect 1: 609-614. 
70. Garcia CC, Candurra NA, Damonte EB (2000) Antiviral and virucidal activities against 
arenaviruses of zinc-finger active compounds. Antivir Chem Chemother 11: 231-237. 
71. Garcia CC, Djavani M, Topisirovic I, Borden KL, Salvato MS, et al. (2006) Arenavirus Z 
protein as an antiviral target: virus inactivation and protein oligomerization by zinc 
finger-reactive compounds. J Gen Virol 87: 1217-1228. 
72. Garcia CC, Topisirovic I, Djavani M, Borden KL, Damonte EB, et al. (2010) An antiviral 
disulfide compound blocks interaction between arenavirus Z protein and cellular 
promyelocytic leukemia protein. Biochem Biophys Res Commun 393: 625-630. 
73. Lee AM, Rojek JM, Gundersen A, Stroher U, Juteau JM, et al. (2008) Inhibition of 
cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. 
Virology 372: 107-117. 
74. Bolken TC, Laquerre S, Zhang Y, Bailey TR, Pevear DC, et al. (2006) Identification and 
characterization of potent small molecule inhibitor of hemorrhagic fever New World 
arenaviruses. Antiviral Res 69: 86-97. Epub 2005 Nov 2028. 
75. Lee AM, Rojek JM, Spiropoulou CF, Gundersen AT, Jin W, et al. (2008) Unique small 
molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem 283: 18734-
18742. 
76. Larson RA, Dai D, Hosack VT, Tan Y, Bolken TC, et al. (2008) Identification of a broad-
spectrum arenavirus entry inhibitor. J Virol 82: 10768-10775. 
77. Lenz O, ter Meulen J, Klenk HD, Seidah NG, Garten W (2001) The Lassa virus 
glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc 
Natl Acad Sci U S A 98: 12701-12705. 
78. Rojek JM, Lee AM, Nguyen N, Spiropoulou CF, Kunz S (2008) Site 1 protease is 
required for proteolytic processing of the glycoproteins of the South American 
hemorrhagic fever viruses Junin, Machupo, and Guanarito. J Virol 82: 6045-6051. 
79. Beyer WR, Popplau D, Garten W, von Laer D, Lenz O (2003) Endoproteolytic processing 
of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J 
Virol 77: 2866-2872. 
110 
 REFERENCES 
80. Kunz S, Edelmann KH, de la Torre JC, Gorney R, Oldstone MB (2003) Mechanisms for 
lymphocytic choriomeningitis virus glycoprotein cleavage, transport, and 
incorporation into virions. Virology 314: 168-178. 
81. Rojek JM, Pasqual G, Sanchez AB, Nguyen NT, de la Torre JC, et al. (2010) Targeting 
the proteolytic processing of the viral glycoprotein precursor is a promising novel 
antiviral strategy against arenaviruses. J Virol 84: 573-584. 
82. Maisa A, Stroher U, Klenk HD, Garten W, Strecker T (2009) Inhibition of Lassa Virus 
Glycoprotein Cleavage and Multicycle Replication by Site 1 Protease-Adapted 
alpha(1)-Antitrypsin Variants. PLoS Negl Trop Dis 3: e446. 
83. Pasquato A, Rochat C, Burri DJ, Pasqual G, de la Torre JC, et al. (2012) Evaluation of the 
anti-arenaviral activity of the subtilisin kexin isozyme-1/site-1 protease inhibitor PF-
429242. Virology 423: 14-22. 
84. Urata S, Yun N, Pasquato A, Paessler S, Kunz S, et al. (2011) Antiviral activity of a 
small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 
protease. J Virol 85: 795-803. 
85. Lukashevich I (2012) Advanced Vaccine Candidates for Lassa Fever. Viruses 4: 2514-
2557. 
86. Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, et al. (2010) A Multivalent 
Vaccination Strategy for the Prevention of Old World Arenavirus Infection in 
Humans. Journal of Virology 84: 9947-9956. 
87. McCormick JB, Mitchell SW, Kiley MP, Ruo S, Fisher-Hoch SP (1992) Inactivated Lassa 
virus elicits a non protective immune response in rhesus monkeys. Journal of Medical 
Virology 37: 1-7. 
88. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB (2000) Effective Vaccine for 
Lassa Fever. Journal of Virology 74: 6777-6783. 
89. Morrison HG, Bauer SP, Lange JV, Esposito JI, McCormick JB, et al. (1989) Protection 
of guinea pigs from lassa fever by vaccinia virus recombinants expressing the 
nucleoprotein or the envelope glycoproteins of lassa virus. Virology 171: 179-188. 
90. Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, et al. (2005) Development of 
a New Vaccine for the Prevention of Lassa Fever. PLoS Med 2: e183. 
91. Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion Jr R, Brasky K, et al. (2011) Yellow fever 
17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide 
protection against fatal disease in guinea pigs. Vaccine 29: 1248-1257. 
92. Bredenbeek PJ, Molenkamp R, Spaan WJM, Deubel V, Marianneau P, et al. (2006) A 
recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. 
Virology 345: 299-304. 
93. Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, et al. (2005) A Live 
Attenuated Vaccine for Lassa Fever Made by Reassortment of Lassa and Mopeia 
Viruses. Journal of Virology 79: 13934-13942. 
94. Carrion Jr R, Patterson JL, Johnson C, Gonzales M, Moreira CR, et al. (2007) A ML29 
reassortant virus protects guinea pigs against a distantly related Nigerian strain of 
Lassa virus and can provide sterilizing immunity. Vaccine 25: 4093-4102. 
95. Lukashevich IS, Carrion Jr R, Salvato MS, Mansfield K, Brasky K, et al. (2008) Safety, 
immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in 
small non-human primates. Vaccine 26: 5246-5254. 
96. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J (2001) Individual and Bivalent 
Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with 
Lassa and Ebola Viruses. Journal of Virology 75: 11677-11685. 
111 
 REFERENCES 
97. Branco L, Grove J, Geske F, Boisen M, Muncy I, et al. (2010) Lassa virus-like particles 
displaying all major immunological determinants as a vaccine candidate for Lassa 
hemorrhagic fever. Virology Journal 7: 279. 
98. Rodriguez-Carreno MP, Nelson MS, Botten J, Smith-Nixon K, Buchmeier MJ, et al. 
(2005) Evaluating the immunogenicity and protective efficacy of a DNA vaccine 
encoding Lassa virus nucleoprotein. Virology 335: 87-98. 
99. Djavani M, Yin C, Xia L, Lukashevich IS, Pauza CD, et al. (2000) Murine immune 
responses to mucosally delivered Salmonella expressing Lassa fever virus 
nucleoprotein. Vaccine 18: 1543-1554. 
100. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, et al. (2010) Preclinical and 
clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile 
and Japanese encephalitis viruses. Vaccine 28: 632-649. 
101. Maiztegui JI, McKee KT, Oro JGB, Harrison LH, Gibbs PH, et al. (1998) Protective 
Efficacy of a Live Attenuated Vaccine against Argentine Hemorrhagic Fever. Journal 
of Infectious Diseases 177: 277-283. 
102. Rehor A, Schmoekel H, Tirelli N, Hubbell JA (2008) Functionalization of polysulfide 
nanoparticles and their performance as circulating carriers. Biomaterials 29: 1958-
1966. 
103. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA (2006) In vivo targeting of 
dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control 
Release 112: 26-34. 
104. Hirosue S, Kourtis IC, van der Vlies AJ, Hubbell JA, Swartz MA (2010) Antigen 
delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide 
conjugated peptides: Cross-presentation and T cell activation. Vaccine 28: 7897-7906. 
105. Hajishengallis G, Lambris JD (2010) Crosstalk pathways between Toll-like receptors and 
the complement system. Trends Immunol 31: 154-163. 
106. Thomas SN, van der Vlies AJ, O’Neil CP, Reddy ST, Yu SS, et al. (2011) Engineering 
complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials 
32: 2194-2203. 
107. Carroll MC (2004) The complement system in regulation of adaptive immunity. Nat 
Immunol 5: 981-986. 
108. Carroll MC (2004) The complement system in B cell regulation. Mol Immunol 41: 141-
146. 
109. Stano A, van der Vlies AJ, Martino MM, Swartz MA, Hubbell JA, et al. (2011) PPS 
nanoparticles as versatile delivery system to induce systemic and broad mucosal 
immunity after intranasal administration. Vaccine 29: 804-812. 
110. Ballester M, Nembrini C, Dhar N, de Titta A, de Piano C, et al. (2011) Nanoparticle 
conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and 
CpG against tuberculosis. Vaccine 29: 6959-6966. 
111. Mintern JD, Bedoui S, Davey GM, Moffat JM, Doherty PC, et al. (2009) Transience of 
MHC Class I-restricted antigen presentation after influenza A virus infection. 
Proceedings of the National Academy of Sciences of the United States of America 
106: 6724-6729. 
112. Lukashevich IS (2012) Advanced vaccine candidates for Lassa fever. Viruses 4: 2514-
2557. 
113. Parren PW, Burton DR (2001) The antiviral activity of antibodies in vitro and in vivo. 
Adv Immunol 77: 195-262. 
114. Burton DR, Saphire EO, Parren PW (2001) A model for neutralization of viruses based 
on antibody coating of the virion surface. Curr Top Microbiol Immunol 260: 109-143. 
112 
 REFERENCES 
115. Leifer E, Gocke DJ, Bourne H (1970) Lassa fever, a new virus disease of man from West 
Africa. II. Report of a laboratory-acquired infection treated with plasma from a person 
recently recovered from the disease. Am J Trop Med Hyg 19: 677-679. 
116. Monath TP, Maher M, Casals J, Kissling RE, Cacciapuoti A (1974) Lassa fever in the 
Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological 
studies on selected hospital cases. Am J Trop Med Hyg 23: 1140-1149. 
117. Whitton JL (2002) Designing arenaviral vaccines. Curr Top Microbiol Immunol 263: 
221-238. 
118. Peters CJ (2002) Human infection with arenaviruses in the Americas. Curr Top 
Microbiol Immunol 262: 65-74. 
119. Enria DA, Briggiler AM, Sanchez Z (2008) Treatment of Argentine hemorrhagic fever. 
Antiviral Res 78: 132-139. 
120. Fisher-Hoch SP, McCormick JB (2004) Lassa fever vaccine. Expert Rev Vaccines 3: 
189-197. 
121. Parren PW, Burton DR (2001) The antiviral activity of antibodies in vitro and in vivo. 
Advances in immunology 77: 195-262. 
122. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) 
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. 
Nature reviews Microbiology 6: 143-155. 
123. Igonet S, Vaney MC, Vonhrein C, Bricogne G, Stura EA, et al. (2011) X-ray structure of 
the arenavirus glycoprotein GP2 in its postfusion hairpin conformation. Proc Natl 
Acad Sci U S A 108: 19967-19972. 
124. Bowden TA, Crispin M, Graham SC, Harvey DJ, Grimes JM, et al. (2009) Unusual 
molecular architecture of the machupo virus attachment glycoprotein. J Virol 83: 
8259-8265. 
125. Abraham J, Corbett KD, Farzan M, Choe H, Harrison SC (2010) Structural basis for 
receptor recognition by New World hemorrhagic fever arenaviruses. Nat Struct Mol 
Biol 17: 438-444. 
126. Sanchez A, Pifat DY, Kenyon RH, Peters CJ, McCormick JB, et al. (1989) Junin virus 
monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. J 
Gen Virol 70: 1125-1132. 
127. Borrow P, Oldstone MB (1992) Characterization of lymphocytic choriomeningitis virus-
binding protein(s): a candidate cellular receptor for the virus. J Virol 66: 7270-7281. 
128. Cresta B, Padula P, de Martinez Segovia M (1980) Biological properties of Junin virus 
proteins. I. Identification of the immunogenic glycoprotein. Intervirology 13: 284-288. 
129. van der Vlies AJ, O'Neil CP, Hasegawa U, Hammond N, Hubbell JA (2010) Synthesis of 
pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small 
molecules, peptides, and proteins. Bioconjug Chem 21: 653-662. 
130. Abraham J, Corbett KD, Farzan M, Choe H, Harrison SC (2010) Structural basis for 
receptor recognition by New World hemorrhagic fever arenaviruses. Nat Struct Mol 
Biol 17: 438-444. 
131. Rojek JM, Spiropoulou CF, Kunz S (2006) Characterization of the cellular receptors for 
the South American hemorrhagic fever viruses Junin, Guanarito, and Machupo. 
Virology 349: 476-491. Epub 2006 Mar 2030. 
132. Wu P, Shui W, Carlson BL, Hu N, Rabuka D, et al. (2009) Site-specific chemical 
modification of recombinant proteins produced in mammalian cells by using the 
genetically encoded aldehyde tag. Proceedings of the National Academy of Sciences 
106: 3000-3005. 
113 
 REFERENCES 
133. Rabuka D, Rush JS, deHart GW, Wu P, Bertozzi CR (2012) Site-specific chemical 
protein conjugation using genetically encoded aldehyde tags. Nat Protocols 7: 1052-
1067. 
134. Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: the 
two extremes of a wide spectrum. Nat Rev Immunol 6: 231-243. 
135. Zinkernagel RM (2002) Lymphocytic choriomeningitis virus and immunology. Curr Top 
Microbiol Immunol 263: 1-5. 
136. Liou LY, Walsh KB, Vartanian AR, Beltran-Valero de Bernabe D, Welch M, et al. 
(2010) Functional glycosylation of dystroglycan is crucial for thymocyte development 
in the mouse. PloS one 5: e9915. 
137. Cambi A, de Lange F, van Maarseveen NM, Nijhuis M, Joosten B, et al. (2004) 
Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic 
cells. J Cell Biol 164: 145-155. 
138. Quirin K, Eschli B, Scheu I, Poort L, Kartenbeck J, et al. (2008) Lymphocytic 
choriomeningitis virus uses a novel endocytic pathway for infectious entry via late 
endosomes. Virology 378: 21-33. 
139. Scutera S, Fraone T, Musso T, Cappello P, Rossi S, et al. (2009) Survival and migration 
of human dendritic cells are regulated by an IFN-alpha-inducible Axl/Gas6 pathway. J 
Immunol 183: 3004-3013. 
140. Rojek JM, Spiropoulou CF, Campbell KP, Kunz S (2007) Old World and clade C New 
World arenaviruses mimic the molecular mechanism of receptor recognition used by 
alpha-dystroglycan's host-derived ligands. J Virol 81: 5685-5695. 
141. Kanagawa M, Toda T (2006) The genetic and molecular basis of muscular dystrophy: 
roles of cell-matrix linkage in the pathogenesis. J Hum Genet 13: 13. 
142. Barresi R, Campbell KP (2006) Dystroglycan: from biosynthesis to pathogenesis of 
human disease. J Cell Sci 119: 199-207. 
143. Kanagawa M, Saito F, Kunz S, Yoshida-Moriguchi T, Barresi R, et al. (2004) Molecular 
recognition by LARGE is essential for expression of functional dystroglycan. Cell 
117: 953-964. 
144. Imperiali M, Thoma C, Pavoni E, Brancaccio A, Callewaert N, et al. (2005) O 
Mannosylation of alpha-dystroglycan is essential for lymphocytic choriomeningitis 
virus receptor function. J Virol 79: 14297-14308. 
145. Kunz S, Rojek JM, Kanagawa M, Spiropoulou CF, Barresi R, et al. (2005) 
Posttranslational modification of alpha-dystroglycan, the cellular receptor for 
arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J Virol 
79: 14282-14296. 
146. Michele DE, Barresi R, Kanagawa M, Saito F, Cohn RD, et al. (2002) Post-translational 
disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. 
Nature 418: 417-422. 
147. Barresi R, Michele DE, Kanagawa M, Harper HA, Dovicio SA, et al. (2004) LARGE 
can functionally bypass alpha-dystrolycan glycosylation defects in distinct congential 
muscular dystrophy. Nat Med 10: 696-703. 
148. Manya H, Chiba A, Yoshida A, Wang X, Chiba Y, et al. (2004) Demonstration of 
mammalian protein O-mannosyltransferase activity: Coexpression of POMT1 and 
POMT2 required for enzymatic activity. Proceedings of the National Academy of 
Sciences of the United States of America 101: 500-505. 
149. Yoshida A, Kobayashi K, Manya H, Taniguchi K, Kano H, et al. (2001) Muscular 
Dystrophy and Neuronal Migration Disorder Caused by Mutations in a 
Glycosyltransferase, POMGnT1. Developmental Cell 1: 717-724. 
114 
 REFERENCES 
150. Barresi R, Campbell KP (2006) Dystroglycan: from biosynthesis to pathogenesis of 
human disease. Journal of Cell Science 119: 199-207. 
151. Macal M, Lewis Gavin M, Kunz S, Flavell R, Harker James A, et al. (2012) 
Plasmacytoid Dendritic Cells Are Productively Infected and Activated through TLR-7 
Early after Arenavirus Infection. Cell Host & Microbe 11: 617-630. 
152. Dunn WA, Hubbard AL, Aronson NN, Jr. (1980) Low temperature selectively inhibits 
fusion between pinocytic vesicles and lysosomes during heterophagy of 125I-
asialofetuin by the perfused rat liver. J Biol Chem 255: 5971-5978. 
153. Doherty GJ, McMahon HT (2009) Mechanisms of endocytosis. Annu Rev Biochem 78: 
857-902. 
154. Mayor S, Pagano RE (2007) Pathways of clathrin-independent endocytosis. Nat Rev Mol 
Cell Biol 8: 603-612. 
155. Wang X, Huang L (2008) Identifying dynamic interactors of protein complexes by 
quantitative mass spectrometry. Mol Cell Proteomics 7: 46-57. 
156. Puig-Kroger A, Serrano-Gomez D, Caparros E, Dominguez-Soto A, Relloso M, et al. 
(2004) Regulated expression of the pathogen receptor dendritic cell-specific 
intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin in THP-1 human 
leukemic cells, monocytes, and macrophages. The Journal of biological chemistry 
279: 25680-25688. 
157. Radoshitzky SR, Abraham J, Spiropoulou CF, Kuhn JH, Nguyen D, et al. (2007) 
Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever 
arenaviruses. Nature 446: 92-96. Epub 2007 Feb 2007. 
158. Negrete OA, Levroney EL, Aguilar HC, Bertolotti-Ciarlet A, Nazarian R, et al. (2005) 
EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. 
Nature 436: 401-405. 
159. Frei AP, Jeon OY, Kilcher S, Moest H, Henning LM, et al. (2012) Direct identification 
of ligand-receptor interactions on living cells and tissues. Nat Biotechnol. 
160. Ballester M, Nembrini C, Dhar N, de Titta A, de Piano C, et al. (2011) Nanoparticle 
conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and 
CpG against tuberculosis. Vaccine 29: 6959-6966. 
161. Eddy GA, Wagner FS, Scott SK, Mahlandt BJ (1975) Protection of monkeys against 
Machupo virus by the passive administration of Bolivian haemorrhagic fever 
immunoglobulin (human origin). Bull World Health Organ 52: 723-727. 
162. Walker LM, Burton DR (2010) Rational antibody-based HIV-1 vaccine design: current 
approaches and future directions. Current opinion in immunology 22: 358-366. 
163. Kenyon RH, McKee KT, Jr., Zack PM, Rippy MK, Vogel AP, et al. (1992) Aerosol 
infection of rhesus macaques with Junin virus. Intervirology 33: 23-31. 
164. Choe H, Jemielity S, Abraham J, Radoshitzky SR, Farzan M (2011) Transferrin receptor 
1 in the zoonosis and pathogenesis of New World hemorrhagic fever arenaviruses. 
Curr Opin Microbiol 14: 476-482. 
165. Radoshitzky SR, Kuhn JH, Spiropoulou CF, Albarino CG, Nguyen DP, et al. (2008) 
Receptor determinants of zoonotic transmission of New World hemorrhagic fever 
arenaviruses. Proc Natl Acad Sci U S A 105: 2664-2669. 
166. Weissenbacher MC, Coto CE, Calello MA (1975) Cross-protection between Tacaribe 
complex viruses. Presence of neutralizing antibodies against Junin virus (Argentine 
hemorrhagic fever) in guinea pigs infected with Tacaribe virus. Intervirology 6: 42-49. 
167. Birmingham K, Kenyon G (2001) Lassa fever is unheralded problem in West Africa. Nat 
Med 7: 878. 
168. Richmond JK, Baglole DJ (2003) Lassa fever: epidemiology, clinical features, and social 
consequences. BMJ 327: 1271-1275. 
115 
 REFERENCES 
169. Jahrling PB, Peters CJ, Stephen EL (1984) Enhanced treatment of Lassa fever by 
immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 149: 
420-427. 
170. Eichler R, Lenz O, Garten W, Strecker T (2006) The role of single N-glycans in 
proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C. 
Virol J 3: 41. 
171. Yoshida-Moriguchi T, Yu L, Stalnaker SH, Davis S, Kunz S, et al. (2010) O-mannosyl 
phosphorylation of alpha-dystroglycan is required for laminin binding. Science 327: 
88-92. 
172. Oehen S, Junt T, Lopez-Macias C, Kramps TA (2000) Antiviral protection after DNA 
vaccination is short lived and not enhanced by CpG DNA. Immunology 99: 163-169. 
173. An LL, Rodriguez F, Harkins S, Zhang J, Whitton JL (2000) Quantitative and qualitative 
analyses of the immune responses induced by a multivalent minigene DNA vaccine. 
Vaccine 18: 2132-2141. 
174. Yokoyama M, Zhang J, Whitton JL (1995) DNA immunization confers protection 
against lethal lymphocytic choriomeningitis virus infection. Journal of virology 69: 
2684-2688. 
175. Hassett DE, Slifka MK, Zhang J, Whitton JL (2000) Direct ex vivo kinetic and 
phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization. 
Journal of virology 74: 8286-8291. 
176. Shedlock DJ, Talbott KT, Cress C, Ferraro B, Tuyishme S, et al. (2011) A highly 
optimized DNA vaccine confers complete protective immunity against high-dose 
lethal lymphocytic choriomeningitis virus challenge. Vaccine. 
177. EPFL (2011) Protein Expression Core Facility PECF. 
 
  
 
 
 
 
 
 
 
 
 
APPENDIX 
 
  
117 
APPENDIX 
 
ORIGINAL MANUSCRIPT: 
 
“Characterization of the cell entry of Lassa virus via the TAM receptor Axl”  
 
Marie-Laurence Moraz, Ana-Rita Goncalves, Antonella Pasquato, and Stefan Kunz* 
Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. 
 
 
* Corresponding author. Mailing address: Institute of Microbiology, University Hospital 
Center and University of Lausanne, Lausanne CH-1011, Switzerland. Phone: +41-21 314 
7743, Fax: +41-21 314 4060, E-mail: Stefan.Kunz@chuv.ch 
 
 
Manuscript in preparation 
  
118 
APPENDIX 
 
AUTHORS’ CONTRIBUTION: 
*Conceived and designed the experiments: Marie-Laurence Moraz, Antonella Pasquato, 
Stefan Kunz 
*Performed the experiments: Marie-Laurence Moraz, Ana-Rita Goncalves 
*Analyzed the data: Marie-Laurence Moraz, Ana-Rita Goncalves, Stefan Kunz 
*Wrote the paper: Marie-Laurence Moraz, Stefan Kunz 
  
119 
APPENDIX 
 
ABSTRACT 
The Old World arenavirus Lassa (LASV) is the causative agent of a severe hemorrhagic fever 
in humans causing several hundred thousand infections per year in Western Africa. The first 
cellular receptor discovered for LASV is dystroglycan (DG) a versatile receptor for proteins 
of the extracellular matrix (ECM). Recognition of DG by LASV critically depends on 
functional glycosylation of DG involving the glycosyltansferase LARGE, which occurs in a 
tissue-specific manner. Recent studies identified the TAM-family receptor tyrosine kinases 
Axl and Dtk as alternative cellular receptors for LASV in cells lacking functional DG.  Here 
we further characterized Axl-mediated cell entry of LASV in the context of productive 
arenavirus infection using a chimera of the prototypic arenavirus lymphocytic 
choriomeningitis virus (LCMV) expressing the LASV envelope glycoprotein (rLCMV-
LASVGP). In line with previous studies, we found that cell entry of rLCMV-LASVGP via 
Axl was less efficient when compared to functional DG. However, Axl-mediated productive 
infection with rLCMV-LASVGP showed kinetics similar to DG-dependent entry. Axl-
mediated cell entry of LASV involved a clathrin-independent pathway that critically 
depended on actin and dynamin, was sensitive to EIPA, but not to PAK inhibitors.  
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INTRODUCTION 
The Old World arenavirus Lassa (LASV) is the causative agent of a severe hemorrhagic 
fever with high mortality in humans (29). LASV is endemic in Western Africa from Senegal 
to Cameroon and causes several hundred thousand infections per year with thousands of 
deaths. Considering the number of people affected, the current lack of a licensed vaccine and 
the limited therapeutic options at hand, LASV represents a serious public health problem. 
LASV is an enveloped negative strand RNA virus with a non-lytic life cycle (5). The genome 
of LASV consists of two single-stranded RNA species, a large segment encoding the virus 
polymerase (L) and a small zinc finger motif protein (Z), and a small segment encoding the 
virus nucleoprotein (NP) and glycoprotein precursor (GPC). GPC is processed into GP1, 
implicated in receptor binding, and the transmembrane GP2, which contains the viral fusion 
machinery, allowing fusion of the viral and the cellular membrane during viral entry (37). 
The first cellular receptor discovered for LASV and the prototypic Old World Arenavirus 
arenavirus lymphocytic choriomeningitis virus (LCMV) is dystroglycan (DG) an ubiquitously 
expressed receptor for extracellular matrix (ECM) proteins (9, 41). Binding of LASV and 
LCMV to DG critically depends on the functional glycosylation of the α-DG subunit that 
critically depends on the glycosyltransferase LARGE (19). Upon binding to DG, LASV and 
LCMV enter the host cell via an endocytotic pathway that is independent of clathrin, caveolin, 
dynamin, and actin (47, 51, 52). Upon internalization, the virus is delivered to acidified 
endosomes via a pathway that is independent of the small GTPases Rab5 and Rab7, 
suggesting an unusual route of incoming vesicular trafficking (Fig. 2). Recent studies revealed 
that LASV passes through the multivesicular body (MVB), where it undergoes sorting into 
intraluminal vesicles (ILV) by hijacking the host cell’s endosomal sorting complex required 
for transport (ESCRT) machinery (42). Upon sorting into ILV, the virus is delivered to late 
endosomes, where fusion occurs at an unusually low pH (18).  Using an expression cloning 
approach, Shimojima and colleagues identified the C-type lectins DC-SIGN and LSECtin, as 
well as the Tyro3/Axl/Mer (TAM) receptor tyrosine kinases Axl and Tyro3(Dtk) as 
alternative LASV receptors (57). The data at hand convincingly show that Axl and Tyro-3 
enhance LASV binding to DG-deficeint cells and were able to mediate infection in a DG-
independent manner.  
Tyro-3, Axl, and Mer compose the TAM family of receptor tyrosine kinases (RTKs), 
whose extracellular domain is comprised of tandems of two immunoglobulin (Ig) domains 
and two fibronectin type II domains.  Tyro-3, Axl and Mer are expressed in a wide variety of 
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cell types, with overlapping but unique patterns. Among the TAM receptors implicated in 
LASV cell entry, Axl shows the widest expression pattern (38) and is found on  epithelial 
cells, platelets, endothelial cells, in the heart, liver, kidney, skeletal muscle, testis (1, 13, 36), 
and the brain (3). Tyro-3 is primarily expressed in the nervous system and is also detected in 
lung, kidney, retina and sexual organs, as well as hematopoietic cells (1, 21, 25, 26, 44). TAM 
receptors undergo interactions with serum protein S, and growth-arrest-specific protein 6 
(Gas6), and proteins of the tubby family (7, 23, 24). Gas6 serves as ligand for all three TAM 
receptors, albeit with different affinity: Axl > Tyro3/Dtk >> Mer.  Ligand binding induces 
homo- or hetero-dimerization of TAM receptors with consequent activation of their 
cytoplasmic tyrosine kinase domain. TAM-receptors are involved in many cellular functions, 
including chemotaxis (12), cell survival (22), the modulation of innate immunity (24, 55), and 
clearance of apoptotic debris (23). Apoptotic cells display the phospholipid 
phosphatidylserine (PS) that is recognized by Gas6 and ProS via their N-terminal gamma-
carboxylated glutamic acid (GLA) domain. Subsequent engagement of TAM receptors by the 
C-terminal domains of Gas6 and ProS results in the endocytosis of apoptotic cell debris.  
In the co-evolution with their hosts, viruses developed several strategies to hijack and 
manipulate cellular functions. Recent studies revealed that viruses are able to hijack the host’s 
apoptotic clearance machinery for cell entry (31, 32, 35). Enveloped viruses display PS at 
their surface, which can act as an “eat me” signal triggering endocytosis. This strategy of 
“apoptotic mimicry” to gain access to the host cell was initially described for vaccinia virus 
(32). Subsequent studies demonstrated that a variety of enveloped viruses expose PS and can 
hijack the Gas6/TAM system to enter the host cell (35), providing an entry mechanism that is 
not dependent on specific interaction between viral envelope proteins and cellular receptors, 
thus enlarging the tropisms of viruses. TAM kinases have been implicated in cell entry of the 
filoviruses Ebola and Marburg virus (58), as well as Dengue virus (30). Axl was shown to 
enhance uptake of Ebola virus via macropinocytosis (15) and cell entry via Axl did not 
involve a direct interaction with the viral glycoprotein (4). Mutagenesis of Axl highlighted the 
importance of a functional ligand-binding domain and signal transduction for Ebola virus 
entry (56), however, the exact underlying mechanism remains unclear.  
In the present study, we sought to characterize the unknown endocytotic pathway 
involved in Axl-mediated cell entry of LASV.  
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MATERIALS AND METHODS 
Cell lines and viruses 
HT-1080, HEK293H and A549 cells were cultured in DMEM, 10 % (vol/vol) FBS, 
supplemented with penicillin/streptomycin. The recombinant virus rLCMV-LASVGP and 
rLCMV-VSVG have been described (43, 52). Viruses were produced and titers determined as 
previously described (10). Recombinant vaccinia virus expressing GFP (VV-GFP) was kindly 
provided by Jason Mercer and produced as described (32). A recombinant Moloney murine 
leukemia virus expressing an Amphotropic envelope was generated as reported (54). 
Recombinant adenoviral vector (AdV)-Ad5-LARGE-enhanced green fluorescent protein 
(EGFP) and (AdV)-Ad5-EGFP have been described and were produced and titered as 
previously defined (2).  
 
Virus infection 
For virus infection, 5 x 104 HT-1080 cells per well were seeded in 96-well microtiter 
plates and cultured overnight. For infection of cells with rLCMV-LASVGP and rLCMV-
VSVG, seed stocks were diluted to the indicated MOI and added to cells for 1 hour at 37°C. 
After 1 hour of incubation, the inoculum was removed; cells were washed once with serum-
free medium and replaced with normal medium. To prevent secondary infection, 20 mM 
ammonium chloride (NH4Cl) was added to the cells 4 hours post-infection. Cells were fixed at 
16 hours post-infection and infected cells quantified by immunofluorescence assay (IFA) for 
LCMV NP using mAb 113 combined with fluorescence-labeled secondary antibodies (20). 
 
Antibodies and reagents 
Monoclonal antibody (mAb) 113 (anti-LCMVNP) and mAb clone 83.6 (anti-LCMVGP) 
have been previously described (6, 61). The mAb IIH6 anti-α-DG was used to detect 
functional DG (11). To detect the DG core protein, the mouse mAb anti-β-DG clone 56 from 
BD Biosciences was used (NJ, USA). TAM kinases were detected using the polyclonal goat 
anti-Axl Ab, anti-Dtk and anti-Mer PE-conjugated mouse mAbs from R&D Systems® 
(AF154, FAB859P, FAB8912P, MN, USA). DC-SIGN was detected using the mAb DCN46 
anti-CD209 (DC-SIGN)-PE purchased from BD Pharmingen. Mouse mAb anti-α-tubulin was 
purchased from Sigma-Aldrich (MO, USA). The rabbit polyclonal anti-Adenovirus Type 5 
was purchased from Abcam® (ab6982, UK) and directed against all capsid proteins. To detect 
Vaccinia virus (VV), an anti-A27L viral protein rabbit polyclonal antibody was used from 
LifeSpan BioSciences (Cat. No. LS-C19415, WA, USA). Horseradish peroxidase (HRP) 
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conjugated polyclonal rabbit secondary antibodies anti-goat and anti-mouse IgG were 
purchased from Dako (P0449, P0260, (Glostrup, Denmark). The HRP-conjugated polyclonal 
goat anti-mouse IgM antibody was purchased from Thermo Scientific (PA1-85999). 
Rhodamine Red-X-AffiniPure goat anti-mouse IgG from Jackson ImmunoResearch (EU) and 
Alexa Fluor 488 goat anti-mouse IgG2b were from Molecular Probes (A11017, Eugene, OR). 
Streptavidin HRP-conjugated secondary antibody was used to detect biotinylated annexin-V 
(ANX5) purchased from Thermo Fisher Scientific Inc. Dharmacon (Lafayette, CO). 
Cytochalasin B, jasplakinoline, latrunculin A, Phalloidin-FITC, chlorpromazine 
hydrochloride, dynasore hydrate, p21-activated kinase (PAK)-1 inhibitor 2,2’-dihydroxy-1, 
1’-dinaphthyldisulfide (IPA-3) and 5-(N-Ethyl-N-isopropyl) amiloride (EIPA) were 
purchased form Sigma-Aldrich. LIVE/DEAD® fixable dead cell stain kit was from Molecular 
probes® Invitrogen. The annexin-V-Biotin conjugated from Roche-applied-science (Cat. No. 
11 828 690 001) was used to detect the phosphatidylserine on purified viral particles. HT-
1080 cells transduced with lentiviral vectors were then selected using the Puromycin 
antibiotic from Calbiochem® (Merck Millipore, MA, USA). For all experiments, HT-1080 
cells were plated in poly-L-lysine-coated wells purchased from Sigma-Aldrich® (P8920). 
 
Lentivirus shRNA production and transduction of HT-1080 cells 
To deplete DG core protein in HT-1080 cells, lentiviral vectors expressing validated 
shRNA targeting human DG (sh-DG) (ID clone: TRCN0000056191, Thermo Scientific 
RHS3979-9623375) or a scrambled control shRNA (sh-sc) were generated following the 
manufacturers recommendations. Briefly, 3 x 106 HEK293T cells were cultured in 10-cm-
diameter dishes in serum-free 293 SFM II medium (Gibco™, Cat. No. 11686-029). At 24 
hours post-seeding, fresh medium was added to cells 4 hours before the transfection. CaCl2 
(250 mM CaCl2, ultrapure H2O) and HBS (50 mM Hepes, 1.5 mM Na2HPO4, 140 mM NaCl, 
ultrapure H2O) solutions were used to co-transfect the four required plasmids: pLP1 helper 
(gag/ pol), pLP2 helper (rev), pCAGGS/ VSVGP, with sh-DG 56191 (human pLKO.1) or 
with sh-sc (human pLKO.1) shRNA control. Transfected cells were incubated for16 hours at 
37°C, 5% CO2. After 16 hours, the transfection medium was replaced by fresh serum-free 293 
SFM II medium and cells incubated for circa 24 hours more at 37°C, 5% CO2. Circa 40 hours 
post-transfection, cell supernatants were collected and centrifuged for 5 min at 500 g to 
remove cellular debris. Each lentivirus was concentrated using the Amicon® Ultra-15 
Centrifugal Filter Devices by ultra-centrifugation according to the manufacturer’s instructions 
(Millipore, Ultracel® 100KREF. UFC910024). Then, 5 x 105 HT-1080 cells/well were seeded 
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in 6-well plate format and cultured for 24 hours at 37°C, 5% CO2. The day after, cell medium 
was replaced by classical medium supplemented with [6 µg/ml] Polybrene® in which 100 µl 
of each crude lentivirus stock was added. The cells were spinoculated at 2600 rpm for 3 hours 
at 23°C. Cells were then washed twice with supplemented classical medium to remover 
Polybrene®. The transduced cells were then incubated for 72 hours at 37°C, 5% CO2. After 
72 hours, cells were washed once with 1 x PBS and [2 µg/ml] puromycin selective medium 
added. After 48 hours, cell death was checked and the selective medium replaced each two 
days by fresh one during all the selective process. Depletion of DG was verified by Western-
blot detecting the β-DG core protein. 
 
Immunoblotting 
Proteins were separated by gel electrophoresis using 6% or 8% polyacrylamide gels and 
transferred to nitrocellulose. After blocking in 3% (wt/vol) skim milk in PBS, membranes 
were incubated with primary Abs used at 5-10 µg/ml in 3% (wt/vol) skim milk in PBS for 1 
hour at room temperature. After several washes in PBS, 0.1 % (wt/vol) Tween, secondary Abs 
coupled to HRP were applied 1:6000 in PBS, 0.1 % (wt/vol) Tween for 1 hour at room 
temperature. Blots were developed by enhanced chemiluminescence (ECL) using Super 
Signal West Pico ECL Substrate or TrueBlot® detection system (Pierce). 
 
Rescue of functional DG in HT-1080 cells 
Functional DG was rescued in HT-1080 cells by over-expression of LARGE using 
recombinant adenoviral vector (AdV)-Ad5-LARGE-EGFP and (AdV)-Ad5-EGFP as control 
(2). Briefly, 3 x 105 HT-1080 and A549 cells per well were seeded in poly-L lysine-coated 6-
well plate format and incubated for 24 hours at 37°C, 5% CO2. At 24 hours post-seeding, 
AdV-LARGE and AdV-EGFP vectors were added to cells at indicated MOI and incubated for 
4 hours at 37°C, 5% CO2. 4 hours post-transduction, inoculums were removed, cells washed 
with fresh normal medium and incubated overnight at 37°C, 5% CO2. Twenty-four hours 
post-transduction, transduced cells were re-seeded in 96-well plate format at 5x104 cells/well.  
At 48 hours post-transduction, cells were either infected with rLCMV-LASVGP at MOI = 1 
and infection quantified by detection of LCMV NP in IFA, or lysed to extract functional DG 
using Jacalin affinity purification as described (53). Lectin-bound proteins were then 
subjected to SDS-PAGE and Western-blotting using mAb IIH6 to functionally glycosylated 
α-DG (17) and mAb anti-β-DG clone 56 to β-DG core protein. 
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Flow cytometry analysis 
For extracellular staining with enzyme-free cell dissociation solution, resuspended in 
FACS buffer (1% (vol/vol) FCS, 0.1% (wt/vol) sodium azide, PBS), and plated in conical 96-
well plates, followed by one hour on ice with FACS buffer diluted with corresponding 
primary antibody. Cells were then washed twice in FACS buffer and labeled with secondary 
antibodies (as needed) for 1 hour on ice in the dark. After two wash-steps in 1% (vol/vol) FBS 
in PBS, cells were fixed with 1:10 CellFix® solution for 10 minutes at room temperature. 
Cells were washed twice with PBS, and fluorescence intensity assessed using a FACS Calibur 
flow cytometer (Becton Dickinson) using the CellQuest Pro® acquisition and analysis 
software. Intracellular FACS staining of LCMV NP antigen was performed as described (49). 
 
RNA interference (RNAi) 
RNA interference (RNAi) was performed using validated small interfering RNAs 
(siRNAs) ON-TARGETplus SMARTpool for Axl (L-003104-00-0005) and scrambled siRNA 
(D-001820-10-05) as control from Thermo Scientific Dharmacon (Lafayette, CO). Briefly, 3 
x 106 HT-1080 cells were reverse transfected with 0.72 µM siRNA using a10-cm-diameter 
dish and Lipofectamine RNAiMAX (Invitrogen, Paisley, United Kingdom) according to the 
manufacturer’s recommendation. Twenty-four hours after transfection, cells were replated in 
96-well plate format, and 48 hours post-transfection, cells were infected with rLCMV-
LASVGP (MOI = 0.1) and rLCMV-VSVG (MOI = 0.02) or mock infected or lysed to 
confirm by Western-blotting Axl knock-down using specific antibodies. To prevent secondary 
infection, 20 mM ammonium chloride (NH4Cl) was added to the cells 4 hours post-infection. 
Cells were fixed 16 hours post-infection and infected cells quantified by immunofluorescence 
assay (IFA) detection of LCMV NP using mAb 113 (anti- LCMVNP) and combined with 
fluorescence-labeled secondary antibody. 
 
Inhibitor studies in HT-1080 cells 
HT-1080 cells were seeded in round bottom 96-well plates (Costar) pretreated for 2 hours 
in the presence of chlorpromazine, or for 30 minutes in presence of the actin inhibitors 
cytochalasin B, latrunculin A, and jasplakinoline, dynasore, EIPA, and IPA-3 at the indicated 
concentrations at 37°C. Cells were then infected in the presence of inhibitors for 1 hour with 
rLCMV-LASVGP at 37°C. At 4 hours post-infection, 20 mM NH4Cl was added to prevent 
secondary infection. Infection was detected 16 hours post-infection by IFA as mentioned 
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above. The viability of drug-treated cells was determined by staining of single-cell 
preparations with Live and dead staining. 
 
Entry kinetics of rLCMV-LASVGP in HT-1080 cells 
The kinetics of rLCMV-LASVGP cell entry by NH4Cl treatment was performed as 
described (52). Briefly, 3x105 HEK293 and HT-1080 cells per well were seeded in 24-well 
plate format coated with poly-L-lysine and incubated for 24 hours. The day after, seeded cells 
were incubated on ice for 30 min and fresh ice cold medium containing rLCMV-LASVGP 
(MOI 3; 10) was added and cells incubated on ice for 1 hour to allow virus attachment. 
Unbound virus was removed by washing with cold medium. Pre-warmed complete medium 
was added and cells rapidly shifted to 37°C at 5% CO2. 20 mM NH4Cl was added at 0, 10, 20, 
30, 40, 50, 60, 75, 90, 120 and 240 min. After 16 hours, rLCMV-LASVGP infection was 
quantified by intracellular staining of the viral proteins by flow cytometry as described above. 
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RESULTS 
Axl mediates cell entry of rLCMV-LASVGP independently of DG 
LASV is a BSL4 pathogen and work with the live virus requires high containment 
laboratories. To circumvent the biosafety restrictions associated with live LASV, we used a 
recombinant LCMV expressing the LASV envelope GP (rLCMV-LASVGP) (52). Based on 
the close structural and genetic relationship between LASV and LCMV and the fact that 
receptor binding and entry of arenaviruses are mediated exclusively by the viral envelope, 
rLCMV-LASVGP represents a suitable BSL2 surrogate for studies on LASV cell entry in the 
context of productive arenavirus infection (42, 50, 52).  
Previous studies had shown that Axl can function as a cellular receptor for lentiviral 
pseudotypes of LASV in the human fibrosarcoma cell line HT-1080 (57). Consistent with 
earlier studies (57, 58), Western blot analysis revealed abundant Axl, but only low amounts of 
functionally glycosylated α-DG in HT-1080 cells, whereas HEK293-H cells expressed high 
amounts of functional DG, but lacked Axl (Fig. 1A, B). To exclude a possible contribution of 
residual functional DG to rLCMV-LASVGP entry into HT-1080 cells, we depleted the DG 
core protein by RNA interference (RNAi). For this purpose, HT-1080 cells were stably 
transduced with a lentival vector expressing a small hairpin (sh)RNA targeting DG or a 
scrambled control siRNA. Selected cells stable transfected with DG shRNA showed a 
reduction in DG expression of > 95%, as assessed in Western blot (Fig. 1C). DG-depleted and 
control HT-1080 were infected with rLCMV-LASVGP at low multiplicity (0.01). At 16 hours 
post infection, cells were fixed and infection detected by immunofluorescence assay (IFA). 
As shown in Fig. 1D, depletion of DG in HT-1080 cells did not affect infection of rLCMV-
LASVGP (Fig. 1B), indicating a negligible role for residual functional DG. 
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Figure 1. DG is dispensable for infection of rLCMV-LASVGP in HT-1080 cells. (A) Detection of Axl in 
HT-1080 cells. HT-1080, HeLa, and HEK293-H cells were lysed, total proteins separated by SDS-PAGE, and 
blotted to nitrocellulose. Blots were probed with a polyclonal rabbit antibody to Axl and an HRP-conjugated 
secondary antibody using enhanced chemiluminescence (ECL) for development. As a loading control, α-tubulin 
was detected. The positions of Axl and α-tubulin (Tub) are indicated.  (B) Detection of functional DG. HT-1080, 
HeLa, and HEK293-H cells (5 x 106 cells) were lysed and subjected to jacalin affinity purification as described 
(53). Lectin-bound proteins were eluated by boiling in reducing SDS-PAGE sample buffer and analyzed in 
Western blot (IB) using mAb IIH6 to functionally glycosylated α-DG (17) and mAb 8D5 to β-DG. Prolonged 
exposure time (exp) of blots for glycosylated α-DG revealed a weak, but specific band for HT-1080 cells 
(asterisk) indicating the presence of residual functional DG. The positions of glycosylated α-DG in HeLa and 
HEK293-H, as well as β-DG are indicated. (C) Depletion of DG core protein by RNAi. HT-1080 cells were 
transduced with a lentiviral vector expressing a shRNA targeting human DG (sh-DG) or a scrambled control 
shRNA that does not target any known human gene (sh-sc). After 48 hours of transfection, transduced cells were 
subjected to antibiotic selection with puromycin for a total of ten days. Resistant colonies were isolated and 
expanded. Depletion of DG by RNAi was validated by Western blot for β-DG. Shown are selected clones for 
HT-1080 cells expressing DG-specific shRNA (HT-1080-sh-DG), scrambled shRNA (HT-1080-sh-sc), and 
wild-type HT-1080 cells. Beta-DG and α-tubulin (loading control) were detected as in (B). Prolonged exposure 
of β-DG blots lead to the detection of an unspecific band of circa 50-55 kDa (*). The positions of β-DG and α-
tubulin are indicated. The efficiency of DG depletion was quantified by normalization of the β-DG signals with 
α-tubulin in densitometry. The rate of β-DG/α-tubulin (DG/Tu) in parental HT-1080 cells was set as 100. (D) 
Infection of DG-depleted HT-1080 cells with rLCMV-LASVGP. HT-1080-sh-DG cells (DG) and HT-1080-sh-
sc cells (Sc) were infected with rLCMV-LASVGP at multiplicity of 0.01. After 4 hours, 20 mM ammonium 
chloride was added to prevent secondary infection. At 16 hours post infection, cells were fixed and infection 
detected by intracellular staining of LCMV NP using mAb 113 combined with a Rhodamine-conjugated 
secondary antibody as described (42). Data are total numbers of infected foci per well (means + DG, n = 3).  
 
In line with published data, HT-1080 cells expressed only Axl, but lacked the candidate 
LASV receptors Dtk, DC-SIGN (Fig. 2A and B), and LSECtin (data not shown). Two 
consecutive transfections of HT-1080 cells with Axl-specific siRNA resulted in depletion of > 
95% of the protein after 72 hours (Fig. 2C). Axl-depleted and control cells treated with 
scrambled siRNA were infected with rLCMV-LASVGP and a recombinant LCMV 
expressing the G protein of vesicular stomatitis virus (rLCMV-VSVG) (43), which mediates 
infection in an Axl-independent manner (35). As expected, depletion of Axl markedly 
reduced infection with rLCMV-LASVGP, but not rLCMV-VSVG, confirming a crucial role 
of Axl in LASV entry into HT-1080 cells (Fig. 2D). To address the relative efficiency of Axl 
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and DG as cellular receptors for LASV, functional DG was rescued in HT-1080 cells by over-
expression of LARGE (Fig. 2E). Expression of functional DG greatly enhanced infection with 
rLCMV-LASVGP (Fig. 2F), confirming that DG acts as preferred receptor (57).  
 
 
Figure 2. Infection of HT-1080 cells with rLCMV-LASVGP is mediated by Axl. (A) Detection of the TAM 
receptors Axl, Mer, and Dtk in HT-1080 cells. Live non-permeabilized HT-1080 cells were stained with a 
polyclonal rabbit antibody to Axl, combined with a PE-conjugated secondary antibody in the cold. Dtk and Mer 
were detected with PE-conjugated mAb to Dtk and mAb to Mer, respectively. Cells were fixed and analyzed by 
flow cytometry in a FACSCalibur flow cytometer (Becton Dickinson) using the CellQuest Pro® acquisition and 
analysis software. Empty peaks: secondary antibody only, shaded peaks: primary and secondary antibody. (B) 
Detection of DC-SIGN in HT-1080 cells. Live non-permeabilized HT-1080 cells and human monocyte-derived 
dendritic cells (MDDC) were stained with mAb 120507 to DC-SIGN and a PE-conjugated secondary antibody. 
Cells were fixed and analyzed by flow cytometry as in (A). Empty peaks: secondary antibody only, shaded 
peaks: primary and secondary antibody. (C) Depletion of Axl by RNAi. HT-1080 cells were tranfected with Axl-
specific siRNA (siRNA Axl) and a scrambled control RNA (siRNA sc) by reverse transfection as described (42). 
After 24 hours, cells were subjected to a second round of transfection with the same siRNAs (forward 
transfection). At 72 hours after the first transfection, cells were lysed and Axl detected by Western blot as in 1A, 
using α-tubulin for normalization.  The efficiency of Axl depletion was assessed by normalization of the Axl 
signals with α-tubulin in densitometry and the rate of Axl/α-tubulin (Axl/Tu) in HT-1080 cells transfected with 
scrambled RNA set at 100. (D) Infection of Axl-depleted cells with rLCMV-LASVGP. HT-1080 cells 
transfected with siRNA to Axl (Axl) or scrambled siRNA (sc) were infected with rLCMV-LASVGP and 
rLCMV-VSVG at multiplicity of 0.01 and infection detected after 16 hours as in 1D. Data represent total 
numbers of infected foci per well (means + DG, n = 3). (E) Rescue of functional DG in HT-1080 cells. HT-1080 
cells were infected with adenoviral vectors expressing GFP (AdV-GFP) or LARGE (AdV-LARGE) at the 
indicated multiplicities of infection (MOI). After 48 hours, DG was extracted by jacalin affinity purification as in 
(B). Functionally glycosylated α-DG and β-DG were detected as in 1B. The broad band in cells transfected with 
AdV-LARGE at MOI = 100 corresponds to glycosylated α-DG. (F) Infection with rLCMV-LASVGP. HT-1080 
cells were infected with AdV-LARGE and AdV-GFP at MOI = 100 as in (E). After 48 hours, cells were infected 
with rLCMV-LASVGP at multiplicity of 1 and infection detected after 16 hours as in (D). Shown are 
percentages of infected cells (means + DG, n = 3).      
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Axl-mediated cell entry of rLCMV-LASVGP occurs rapidly 
In a next step, we compared the entry kinetics of rLCMV-LASVGP via Axl and DG. To 
assess how fast receptor-bound rLCMV-LASVGP trafficked to late endosomes, we assessed 
the time required for the viruses to become resistant to ammonium chloride a lysosomotropic 
agent that raises the endosomal pH rapidly and prevents low pH-dependent membrane fusion 
without causing overall cytotoxicity (39, 40). The virus was bound to HEK293H cells that 
express functional DG, but lack Axl, and HT-1080 cells in the cold, allowing receptor 
attachment without internalization. Unbound virus was removed and cells rapidly shifted to 
37°C to restore membrane mobility. Ammonium chloride was added at different time points 
post infection and kept throughout the experiment. Cells were fixed and infection assessed by 
IFA. In line with published data, DG-mediated infection allowed rLCMV-LASVGP to escape 
from late endosomes after circa 20 minutes (Fig. 3) (52). The kinetics of the infection of HT-
1080 cells mediated by Axl followed a similar kinetics with escape from the late endosome 
after only 15-20 minutes. In sum, the data confirm and extend published results by showing 
that Axl can serve as a cellular receptor in DG-deficient cells. While Axl seems significantly 
less efficient in mediating LASV cell entry when compared to DG, the two receptors mediate 
productive infection with similar kinetics.   
 
 
Figure 3. Entry kinetics of rLCMV-LASVGP in HEK293H and HT-1080 cells.  (A) Cells were incubated 
with rLCMV-LASVGP at multiplicity of 3 for one hour in the cold. Unbound virus was removed and cells 
shifted to 37 °C. At the indicated time points, 20 mM ammonium chloride was added and left throughout the 
experiment. After 16 hours cells were fixed and infection detected by IFA as in Fig. 1. The percentage of 
infected cells was plotted against time. Data are triplicates means + SEM. (B) Data from (A) normalized with the 
240 minutes time point set as 100%. 
 
Axl-dependent cell entry of rLCMV-LASVGP resembles macropinocytosis 
Next, we sought to characterize the Axl-mediated entry pathway for LASV using our 
rLCMV-LASVGP chimera in HT-1080 cells. To characterize the Axl-dependent LASV entry 
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pathway, we first perturbed clathrin-mediated endocytosis (CME) using chlorpromazine 
(CPZ), which prevents assembly of clathrin-coated pits at the plasma membrane. As control, 
we used a recombinant LCMV expressing the glycoprotein of vesicular stomatitis virus 
(VSV) that enters cells via CME (16).  Treatment of HT-1080 cells with up to 8 μM CPZ did 
not significantly affect infection with rLCMV-LASVGP, but diminished infection with 
rLCMV-VSVG in a dose-dependent manner (Fig. 4A). Next, we addressed the role of 
dynamin employing the dynamin inhibitor dynasore. As shown in Fig. 4B, infection of 
rLCMV-LASVGP in HT-1080 was blocked by dynasore in a dose-dependent manner, similar 
to rLCMV-VSVG, which depends on dynamin for cell entry (16). In contrast, infection of 
rLCMV-LASVGP in HEK293 cells was not inhibited by dynasore, suggesting a specific role 
of dynamin in LASV entry via Axl, but not DG.  
To address a possible role of actin in Axl-mediated LASV cell entry, HT-1080 and 
HEK293H cells were treated with cytochalasin B or latrunculin A, which disrupt actin fibers, 
as well as jasplakinolide, an actin-polymer stabilizing drug that blocks the dynamics of actin 
filaments. Staining of actin fibers in drug-treated HT-1080 cells with fluorescence-labeled 
phalloidin revealed the characteristic disruption of F-actin by cytochalasin B or latrunculin A, 
whereas jasplakinolide reduced phalloidin staining, as expected (Fig. 4C). Drug treatment did 
not affect cell viability as assessed by Cell titer Glo® assay (Fig. 4D). Perturbation of actin by 
all three inhibitors significantly reduced infection of rLCMV-LASVGP in HT-1080 cells, 
whereas DG-mediated infection in HEK293-H cells was unaffected.  
The marked actin- and dynamin-dependence of Axl-mediated LASV provided first 
hints towards a possible role of macropinocytosis. To address this possibility, HT-1080 cells 
were treated with ethylisopropyl amiloride (EIPA), an inhibitor of Na+/H+ exchangers (33). 
Pre-treatment with EIPA reduced infection with rLCMV-LASVGP, but did not affect 
infection with a recombinant Murine Mooney leukemia virus (MMLV) pseudotypes bearing 
an amphotropic envelope that mediated fusion at the cell membrane (Fig. 4F). Using the 
inhibitor IPA-3, we blocked PAK1, which plays a central role in macropinocytosis of some 
viruses (32). As shown in Fig. 4G, IPA-3 had no significant effects on infection with rLCMV-
LASVGP, but significantly reduced infection with vaccinia virus, in line with published data 
(32).  Although by no means comprehensive, our first characterization of Axl-dependent 
rLCMV-LASVGP entry revealed the involvement of a pathway that shares some 
characteristics of macropinocytosis (33, 34) and is strikingly different from DG-mediated 
entry (52).  
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Figure 4. Characterization of the Axl-associated cell entry pathway of rLCMV-LASVGP in HT-1080 cells. 
(A) Effect of CPZ on the infection of rLCMV-LASVGP. HT-1080 cells were treated with the indicated 
concentrations of CPZ or PBS only (0) for one hour, followed by infection with rLCMV-LASVGP or rLCMV-
VSVG at a multiplicity of 0.01. After 4 hours, 20 mM ammonium chloride were added to prevent secondary 
infection, and infected cells detected after 16 hours by IFA as in 1D (means + SEM, n = 3). (B) Blocking of 
infection of rLCMV-LASVGP with dynasore. HT-1080 and HEK293H cells were pre-treated with the indicated 
concentrations of dynasore or vehicle control (0), followed by infection with rLCMV-LASVGP (LASV) or 
rLCMV-VSVG (VSV). Infection was detected after 16 hours as in (A) (means + SEM, n = 3). (C) Treatment of 
HT-1080 cells with actin inhibitors. HT-1080 cells were treated with cytochalasin B (20 µM), latrunculin A (5 
µM), and jasplakinolide (1 µM) for 30 minutes. Cells were fixed and permeabilized. F-actin was stained with 
Rhodamine-conjugated phalloidin (red) and nuclei counter-stained with DAPI (blue) Please note the reduced 
phalloidin staining in cells treated with jasplakinolide due to a competition of the drug for the phalloidin binding 
site. Bar = 20 µm. (D) Cytotoxicity of actin inhibitors. HT-1080 cells were treated with 20 µM cytochalasin D 
(Cyto), 5 µM latrunculin A (Lat), and 1 µM jasplakinolide (Jas), or solvent control (Ctrl) for 4 hours, followed 
by a wash out and incubation for a total of 16 hours. Cell viability was assessed by Cell Titer Glo® assay 
according to the manufacturer’s recommendations. Data are triplicates + SD. (E) Axl-mediated infection of 
rLCMV-LASVGP in HT-1080 cells is actin-dependent. HT-1080 and HEK293-H cells were treated with 20 µM 
cytochalasin D (Cyto), 5 µM latrunculin A (Lat), and 1 µM jasplakinolide (Jas), or solvent control (Ctrl) for 30 
minutes, followed by infection with rLCMV-LASVGP. After 4 hours, drugs were washed out and fresh medium 
containing 20 mM ammonium chloride added. Infection was detected after a total of 16 hours post infection as in 
(A) (means + SEM, n = 3). (F) Inhibition of rLCMV-LASVGP infection in HT-1080 cells by EIPA. HT-1080 
cells were pre-treated with the indicated concentrations of EIPA or vehicle control (0) for 30 minutes, prior to 
infection with rLCMV-LASVGP as in (A) (means + SEM, n = 3). As a control, we employed a recombinant 
Moloney murine leukemia virus expressing an Amphotropic (Ampho) envelope and a GFP reporter in its 
genome generated in the Retro-XTM Universal Packaging System (Clontech) as described (54). Infection by the 
Ampho retrovirus was detected by direct fluorescence at 24 hours post infection. (G) Effect of the PAK1 
inhibitor IPA-3 on infection of rLCMV-LASVGP. HT-1080 cells were pre-treated with the indicated 
concentration of IPA-3 or vehicle control (0) for 30 minutes, followed by infection with rLCMV-LASVGP 
(LASV) or recombinant vaccinia virus expression GPF (VV) (32). Infection with rLCMV-LASVGP was 
assessed as in (A) and infection with VV by detection of the GFP reporter in direct fluorescence microscopy at 
12 hours post infection (means + SEM, n = 3).  
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DISCUSSION 
In line with previous studies (57), our results confirmed the TAM receptor Axl as an 
entry receptor for LASV in absence of DG. However, the molecular mechanisms of Axl 
recognition by LASV are largely unknown.  Recently, a general model for cell entry of 
enveloped viruses via TAM receptors has been proposed based on the concent of 
“apoptotic mimicry”.  According to this model, viral entry via Axl critically depends on 
phosphatidylserine (PS) of the viral envelope, which is bound by the serum proteins Gas6 
or protein S that provide a bridge to cellular TAM receptors  (35). Previous studies detected 
PS in the envelope of the Clade A New World arenavirus Pichinde (59), and studies in our 
laboratory revealed that virions of LCMV and rLCMV-LASVGP also display PS at their 
surface (Moraz et al., unpublished results). Current efforts in our laboratory investigate the 
exact role of virus-derived PS, Gas6, and protein S in Axl mediated cell entry of LASV and 
Old World arenaviruses in general. Alternatively, LASV GP may be able to directly bind to 
cellular Axl, a possibility we are likewise testing.  
Previous work on cell entry of the Old World arenaviruses, revealed that these viruses 
use an unusual pathway to invade the host cell. Upon DG binding, LASV is internalized via 
a cholesterol-dependent endocytic pathway that seems independent of classical regulatory 
proteins like clathrin, caveolin, and dynamin and apparently bypasses the classical Rab5-
dependent incoming pathways of vesicular trafficking, suggesting an unusual way of 
delivery to late endosomes (47, 51, 52, 60). Here we performed an initial characterization 
of the LASV entry pathway linked to Axl. We found that Axl-mediated cell entry of 
rLCMV-LASVGP was clathrin-independent, but critically depended on actin and dynamin. 
Combined with the exquisite sensitivity to EIPA, these initial findings suggest the 
involvement of a macropinocytosis-like pathway that has recently been implicated in cell 
entry of several viruses, including poxviruses and filoviruses (33, 34). Comparison of the 
entry kinetics of rLCMV-LASVGP via DG or Axl revealed similar rapid escape of the 
virus from the late endosome after less than 20 minutes.   Rescue of functional DG in HT-
1080 cells revealed much higher efficiency of cell entry of rLCMV-LASVGP when 
compared to Axl. This suggests that in cells co-expressing the two receptors, like e.g. 
epithelial or endothelial cells, LASV cell entry occurs predominantly via DG.  
A hallmark of LASV infection in most cell types is the inability of the infected host 
cell to induce a type I interferon (IFN) response. One reason for this is the ability of the 
arenavirus NP to counteract the activation of the IFN regulatory factor (IRF)-3 (27, 28) and 
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NF-κB (48). The NP contains a 3’-5’ exonuclease activity that is linked to its 
immunosuppressive activity (14, 46) and targets the non-canonical interferon regulatory 
factor-activating kinase IKKε (45). Since the viral NP act as an IFN antagonist in the 
cytoplasm, the suppression of IFN production by NP depends on productive viral infection 
with expression of sufficiently high levels of NP. During viral entry, the virus is located in 
extracellular space where NP cannot act as an IFN antagonist. It is thus possible that 
incoming arenaviruses could be detected by pathogen recognition receptors (PRRs) located 
in endosomal compartments, e.g. Toll-like receptors (TLRs). Upon DG binding, Old World 
arenaviruses are internalized via a pathway of endocytosis that bypasses the early 
endosome where PRRs like TLRs localize (52), possibly allowing the virus to evade innate 
detection. It will be of interest to investigate if LASV entry via Axl likewise allows the 
virus to evade innate detection of its entry via Axl results in innate detection with the 
consequent induction of IRF3 and NF-κB or not. 
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